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1 INTRODUCTION
1.1 Heat shock proteins (HSP) as activators of the immune system
Heat shock proteins (HSP) are highly conserved proteins constitutively expressed in
pro- and eukaryotic cells. Their intracellular synthesis is induced by a variety of
"stress stimuli" including heat shock, UV radiation, oxygen radicals, heavy metals,
cytostatic drugs, and viral or bacterial infections. In the cytosol HSP are involved in
folding/unfolding of proteins and nascent polypeptides, protection from protein-
denaturation and -aggregation, in protein transport processes across membranes,
and in antigen processing and presentation (DeNagel et al 1992, Hartl 1996). HSP
are known to function as activators of the adaptive and innate immune system.
Although the mechanism of release remains unclear, HSP have been found to be
secreted by stressed tumor cells (Barreto et al 2003). Extracellular localized HSP
either act as carrier molecules for the transport of immunogenic peptides to antigen
presenting cells (APC) (Tamura et al 1997, Schild et al 1999, Udono et al 1993), or
directly stimulate the innate immune system by the secretion of pro-inflammatory
cytokines (Asea et al 2000a, Asea et al 2000b). Our laboratory identified membrane-
bound Hsp70 as a recognition structure for the cytolytic attack mediated by natural
killer (NK) cells (Multhoff et al 1997).
1.1.1 HSP as peptide carriers
Tumor-derived peptides, chaperoned by members of the HSP70 (Hsp70, Hsc70) and
HSP90 (gp96) family (Tamura et al 1997, Schild et al 1999) can be taken up by APC
via HSP-specific receptors including α-2 macroglobulin receptor CD91 (Binder et al
2000 a, Binder et al 2000b, Basu et al 2001), B-cell receptor CD40 (Becker et al
2002), or TLR2/4 (Asea et al 2002), in the presence or absence of CD14 (Asea et al
2000a (Figure 1). Representation of HSP-chaperoned immunogenic peptides on
MHC class I molecules either through an endosomal or a TAP-proteasome-
dependent ER-Golgi route (Castellino et al 2000) elicits a CD8+ cytotoxic T cell
response (Udono et al 1993, Suto et al 1995) (Figure 1).
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Figure 1: HSP as peptide carriers. HSP-peptide complexes can be uptaken by antigen presenting
cells (APC) via HSP specific receptors including CD91, CD40, and TLR2/4 ± CD14. Tumor derived
peptides are represented on MHC class I either through a proteasome/TAP-dependent pathway or an
endosomal pathway. Presented peptides stimulate cytotoxic T cells.
The group of Srivastava developed a tumor vaccine approach based on this
mechanism (Janetzki et al 2000, Belli et al 2002). In this approach, gp96 or Hsp70
peptide complexes were isolated from tumors and used as a vaccine for the
stimulation of CD8+ T cells.
1.1.2 HSP as chaperokines
Beside their function as peptide-carriers extracellular localized HSP directly stimulate
the innate immune system. It has been shown that both peptide loaded and free
Hsp70 molecules are able to induce the secretion of proinflammatory cytokines
including IL-1β, IL-6, and TNF-α by APC (Asea et al 2000a, Asea et al 2000b). The
lipopolysaccharide (LPS) receptor CD14 together with members of the toll-like
receptor family, namely TLR2 and TLR4, are involved in the signal transduction
pathway resulting in cytokine release (Asea et al 2000a, Asea et al 2002). As shown
in Figure 2, binding of Hsp70 to cell surface receptors TLR2/4 results in an activation
of NF-κB and a rapid intracellular Ca2+ flux. Depending on the involvement of CD14
in binding of HSP either IL-1β, IL-6 and TNF-α, (Figure 2, left pathway) or TNF-α but
not IL-1β or IL-6 are released (Figure 2, right pathway) (Asea et al 2000a).
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Figure 2: HSP as chaperokines. Binding of Hsp70 to TLR2/4 on the cell surface of APC results in an
increase of intracellular calcium ions and activation of NF-κB. Depending whether CD14 is involved,
APC secrete TNF-α, IL-6, and IL-1β (left pathway) or TNF-α alone (right pathway).
In addition to Hsp70 extracellular Hsp60 also has been found to activate APC
through a CD14/TLR4 receptor pathway (Kol et al 2000, Ohashi et al 2000).
1.1.3 Hsp70 as an interacting partner for natural killer (NK) cells
In contrast to normal cells, tumor cells frequently express HSP on their plasma
membranes (Ferrarini et al 1992, Piselli et al 1995, Tamura et al 1993, Multhoff et al
1995 a, Altmeyer et al 1995, Shin et al 2003). The expression of the inducible 72 kDa
Hsp70 on the plasma membrane of tumor cells can be increased by physical (e.g.
heat, γ-irradiation) and chemical (e.g. cytostatic drugs, alkyllysophospholipids) stress
(Botzler et al 1996b, Botzler et al 1999, Rabinovich et al 2000, Feng et al 2001,
Gehrmann et al 2002, Gehrmann et al unpublished data). Our group demonstrated
that membrane-bound Hsp70 provides a tumor-selective target structure for the
cytolytic attack mediated by NK cells (Multhoff et al 1995b, Multhoff et al 1997,
Botzler et al 1996a). Furthermore, incubation of NK cells with recombinant Hsp70
and the C-terminal domain of Hsp70 (Hsp70-C) was found to stimulate proliferation
and cytolytic activity against Hsp70 membrane-positive tumor cells (Multhoff et al
1999). Since CD94 membrane expression was up-regulated on NK cells following
contact with Hsp70-protein (Multhoff et al 1999), an involvement of the C-type lectin
receptor in the interaction of NK cells with Hsp70 was assumed.
INTRODUCTION 12
1.2 Natural killer (NK) cells
Natural killer (NK) cells are large granular lymphocytes that comprise 5-20% of
peripheral blood mononuclear cells (PBMNC) (Trincheri 1989). In contrast to T cells,
NK cells do neither express the multimolecular CD3 complex nor α/β and γ/δ T cell
receptors (TCR). Almost all NK cells are positive for the neuronal adhesion molecule
CD56 mediating homo- and heterophilic cell adhesion (Lanier et al 1986, Lanier et al
1989). According to the cell surface density of CD56 two distinct NK cell subsets, the
CD56dim and CD56bright, could be separated (Figure 3) (Cooper et al 2001). The
majority of NK cells (90%) express low levels of CD56 (CD56dim) and high levels of
the low affinity FcγRIII (CD16) (Figure 3A). Only 10% of the NK cells are CD56bright
and CD16dim/neg (Figure 3B). The CD56dim cells contain more cytolytic granules
(granzymes and perforin) than the CD56bright NK cells and are potent mediators of
natural cytotoxicity, lymphokine activated killing (LAK) and antibody-dependent
cytotoxicity (ADCC) (Lanier et al 1986). Following stimulation with IL-2 or IL-12 a
drastically enhanced cytotoxicity is observed in the CD56bright NK cell population
(Nagler et al 1989, Ellis et al 1989, Robertson et al 1992). CD56dim NK cells lack a
strong cytokine response whereas the immunoregulatory CD56bright subsets secrete
high amounts of IFN-γ, TNF-α, TNF-β, GM-CSF and IL-10 (see Figure 3A) following
monokine activation (e.g. IL-15) (Fehniger et al 1999, Cooper et al 2002). Since
CD56bright NK cells constitutively express the high (IL-2Rαβγ) and intermediate (IL-
2Rβγ) affinity IL-2 receptor (Figure 3A), these cells can be expanded in vivo and in
vitro by stimulation with low doses (pM) of IL-2 (Caligiuri et al 1990 and Caligiuri et al
1993). In contrast, CD56dim cells expressing the intermediate (IL-2Rβγ) IL-2 receptor
(Figure 3B) show a weaker proliferative response against IL-2, even at high doses (1-
10 nM) (Caligiuri et al 1990, Baume et al 1992). With respect to NK cell receptors
(NKR), CD56bright NK cells show low or absent expression of killer cell
immunoglobulin (Ig) receptors (KIR) and immunoglobulin-like transcript (ILT) and a
high expression of CD94/NKG2 (Figure 3A). The CD56dim population could be
subdivided into a CD94/NKG2bright and a CD94/NKG2dim/- expressing subpopulation
(Nagler et al 1989, Voss et al 1998). CD56bright NK cells are believed to traffic to
secondary lymphoid organs as they constitutively express high levels of the adhesion
molecule L-selectin (CD62L) and the chemokine receptor CCR7 (Figure 3A). Both
molecules are not expressed on CD56dim NK cells, but instead they show high
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expression of the adhesion molecule PEN5/PSGL1 and the chemokine receptors
CXCR1 and CX3CR1 (Figure 3B) (Frey et al 1998, Campbell et al 2001).
Figure 3: NK subpopulations. (A) CD56bright/CD16low/- NK cells exhibit low antibody-dependent
cellular cytotoxicty (ADCC) and natural cytotoxicity, but high lymphokine-activated killer (LAK) activity.
They produce high levels of cytokines following stimulation with monokines. The expression of the C-
type lectin-receptor CD94/NKG2A is bright, whereas Ig-like receptors (KIR) are weakly expressed.
CD56bright NK cells express a number of cytokine and chemokine receptors including the high-affinity
IL-2 receptor (IL-2Rαβγ), c-kit, and CC-chemokine receptor 7 (CCR7). The adhesion molecule L-
selectin which is involved in trafficking to secondary lymph nodes (together with CCR7) is also highly
expressed by these cells. (B) In contrast, CD56dim/CD16bright NK cells are strong mediators of ADCC,
LAK, and natural cytotoxicty, but secrete only low amounts of cytokines. In contrast to the CD56bright
subpopulation these cells have high intracellular levels of cytotoxic granules. Also KIR are highly
expressed by the CD56dim subpopulation. CD56dim cells express different cytokine (IL-2Rβγ) and
chemokine (CXCR1 and CX3CR1) receptors than CD56bright ones. Instead of L-selectin CD56dim cells
highly express the adhesion molecule PEN5-P-selectin glycoprotein ligand-1 (PSGL-1). Figure 3 is
adapted from Cooper et al 2001 and 2002.
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1.2.1 NK cell receptors (NKR)
Function of NK cells is regulated by NK cell receptors (NKR). According to the
missing-self theory, NK cells preferentially recognize and kill target cells with
reduced, lost or altered self-MHC class I molecule expression (Ljunggren and Kärre
1990). Apart from MHC, tumor associated molecules present positive regulating
ligands for NK cells. Our laboratory identified membrane-bound Hsp70 as a target
recognition structure for NK cells (Multhoff et al 1997).
In humans the following major NKR-families have been identified (Table 1): killer cell
immunoglobulin (Ig) receptors (KIR), immunoglobulin-like transcripts (ILT), C-type
lectin receptors (Lanier 1998a, Borrego et al 2002), and natural cytotoxicity receptors
(NCR) (Pessino et al 1998, Vitale et al 1998, Cantoni et al 1999, Pende et al 1999). A
number of other cell surface molecules (e.g. 2B4) acting as co-receptors are also
involved in triggering of NK cell function (Table 1) (Tanguye et al 2000, Valiante and
Trinchieri 1993, Sivori et al 2000). 
1.2.1.1 Killer cell Ig receptors (KIR)
The killer cell Ig receptors (KIR, CD158) are characterized by two or more
extracellular localized immunoglobulin-like domains recognizing MHC class I allele
groups including predominantly those of the HLA-B and HLA-C family (Moretta et al
1993, Wagtmann et al 1995, Pende et al 1996, Andre et al 2001). KIR genes are
located on chromosome 19p13.4 and code for six activatory and six inhibitory
members and allelic variants (Selvakumar et al 1997, Wilson et al 1997). They are
single chain receptors with either two or three immunoglobulin-like domains (KIR2D
or KIR3D) and a long (KIR2DL and KIR3DL) or a short (KIR2DS and KIR3DS)
cytoplasmic tail. KIR with a long cytoplasmic domain contain one or two
immunoreceptor tyrosine-based inhibition motifs (ITIM) and generate an inhibitory
signal, whereas the short-tailed KIR have a positively charged amino acid in the
transmembrane domain that interacts with adaptor molecules with immunoreceptor
tyrosine-based activating motifs (ITAM) and generate an activatory signal (Biassoni
et al 1996, Colonna and Samaridis 1995).
After binding of HLA molecules to inhibitory KIR, the tyrosine of the ITIM motif
becomes phosphorylated by a member of the src kinase family (e.g. lck).
Phosphorylated ITIM binds to the SH2 (Src homology 2) domains of protein tyrosine
phosphatases SHP-1 and/or SHP-2, thereby releasing their catalytic site from
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autoinhibition. (Olcese et al 1996, Burshtyn et al 1996, Barford and Neel 1998,
Burshtyn and Long 1997). Two nonexclusive models are proposed for SHP-1
mediated inhibition: (i) SHP-1 inhibits NK cells by dephosphorylation of many
proteins within the activatory pathway (Binstadt et al 1996, Binstadt et al 1998). (ii) A
single key substrate that controls activation is targeted for dephosphorylation: e.g.
dephosphorylation of the guanine nucleotide exchange factor Vav1 by SHP-1 is
supposed to block activatory signals by inhibition of actin cytoskeleton
rearrangements (Stebbins et al 2003).
When HLA binds to an activatory receptor type, DAP-12 an adaptor molecule
becomes phosphorylated and binds to Syk/ZAP-70 (70 kDa, ζ-associated protein)
which activates NK cells (Chu et al 1998, Brumbaugh et al 1997, Negishi et al 1995).
Most inhibitory KIR have higher affinity for their HLA ligands than their activatory
counterparts (Vales-Gomez 1998).
1.2.1.2 Immunoglobulin-like transcripts (ILT)
ILT that are predominantly expressed by myeloid cells, dendritic cells and B cells,
also belong to the immunoglobulin-like superfamily (Colonna et al 1997, Cosman et
al 1997). ILT-2 (Table 1), which is expressed on some NK cells interacts directly with
a broad spectrum of classical and non-classical HLA molecules (Navarro et al 1999).
1.2.1.3 C-type lectin receptors
Most C-type lectin receptors are heterodimers consisting of CD94 (20-30 kDa)
covalently bound to members of the NKG2 family (43 kDa) (Figure 4) (Lanier et al
1994, Lazetic et al 1996). These receptors interact with non-classical HLA-E
molecules presenting peptides derived from signal sequences of HLA-A, HLA-B,
HLA-C and HLA-G in a TAP-dependent manner (Braud et al 1998, Borrego et al
1998, Ulbrecht et al 1998, Lee et al 1998, Brooks et al 1999). The CD94 and NKG2
genes are closely linked on chromosome 12p12.3-p13.1 in the NK receptor complex
(Sobanov et al 1999, Glienke et al 1998). CD94 is expressed by a single
nonpolymorphic gene and has only a short cytoplasmic tail of 7 amino acids (Chang
et al 1995). Therefore, CD94 alone is unable for signaling. Depending on its co-
receptor (Figure 4) the heterodimeric CD94 complex fulfills inhibitory or activatory
function: CD94/NKG2A and its splice variant NKG2B is an inhibitory receptor (Figure
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4, left side), whereas CD94/NKG2C, CD94/NKG2E, its splice variant NKG2H, and
CD94/NKG2F are activating receptors (Figure 4, middle) (Brooks et al 1997, Lanier
1998b). Similar to KIR with long cytoplasmic tails, the inhibitory receptors are
signaling through SHP-1/2 that mediate inhibitory signals (Figure 4, left), whereas
activatory receptors have a positively charged transmembrane domain that interacts
with DAP-12 and thus mediates activating signals through Syk family members
(Figure 4, middle). As shown for KIR, inhibitory receptors have a higher affinity to
their ligands (Llano et al 1998). Only a minority of NK cell clones expresses both
activating and inhibitory isoforms that recognize the same group of HLA alleles.
Figure 4: C-type lectin receptors. The C-type lectin receptors are disulfide-linked heterodimers of
CD94 and members of the NKG2 family (either the inhibitory NKG2A or the activatory NKG2C). They
recognize the nonclassical MHC class I molecule HLA-E. ITIM-containing NKG2A signals through
SHP-1/2 that mediate inhibitory signals, whereas NKG2C has a positively charged amino acid in the
transmembrane domain that interacts with DAP-12 and transduces activating signals through Syk
family members. The activatory receptor NKG2D forms homodimers and binds to the MHC-like ligands
MICA, MICB, and ULBP family. Through its positively charge in the transmembrane domain NKG2D
associates with the adaptor molecule DAP-10 that contains an YXNK motif to bind PI-3kinase (PI3K)
and sends activating signals through this alternative pathway. As the PI3K cascade is not inhibited by
SHP-1/2, NKG2D may be able to induce a dominant activation signal.
The activating receptor NKG2D also belongs to the C-type lectin family, but in
contrast to other NKG2 family members it forms only homodimers (Figure 4, right)
(Wu et al 1999). NKG2D is constitutively expressed on NK cells, γδ T cells and CD8+
T cells and interacts with the MHC class I chain-related (MIC) antigens, MICA and
MICB, and the UL16 binding proteins (ULBP) that are stress-inducible or induced by
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neoplastic transformation (Bauer et al 1999, Cosman et al 2001). The intracellular
domain of NKG2D does not contain any signaling motif and therefore signaling is
mediated through the adaptor molecule DAP-10 (Wu et al 1999). DAP-10 recruits
phosphatidylinositol (PI)-3 kinase after phosphorylation. A selection of important NK
cell receptors, their function and ligands are summarized in Table 1.
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Receptor Function Ligand specificity Chromosome
Ig-SF
a) KIR
  CD158a (p58.1)
     KIR2DL1
inhibitory HLA-Cw2, 4, 5, 6 19q13.4
  CD158h (p50.1)
     KIR2DS1
activatory HLA-Cw2, 4, 5, 6 19q13.4
  CD158b1/2
     (p58.2/3)
     KIR2DL2/3
inhibitory HLA-Cw1, 3, 7, 8 19q13.4
  CD158j/i (p50.2/3)
     KIR2DS2/4
activatory HLA-Cw1, 3, 7, 8 19q13.4
  CD158e1/2 (p70)
     KIR3DL1
     KIR3DS1  
inhibitory
activatory
HLA-Bw4 alleles 19q13.4
  CD158k (p140)
     KIR3DL2
inhibitory HLA-A3, 11 19q13.4
  CD158d (p49)
     KIR2DL4
inhibitory HLA-G, others 19q13.4
 
b) ILT
  CD85j 
     ILT-2/LIR-1
inhibitory HLA-G, various 19q13.42
C-type lectin
receptors
  CD94/NKG2A inhibitory HLA-E + leader peptides from
HLA-A, -B, -C, -G
12p12.3-13.1
  CD94/NKG2C activatory HLA-E + leader peptides from
HLA-A, -B, -C, -G
12p12.3-13.1
  NKG2D activatory MICA, MICB, H60, Rae1, ULBP
1, 2, 3
12p12.3-13.1
NCR
  NKp30 activatory unknown 6
  NKp44 activatory unknown 6
  NKp46 activatory unknown 19q13.4
Coreceptors
  CD244 (2B4) activatory GPI-anchored CD48 1q23.3
Table 1: NK Receptors.
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1.2.2 Mechanism of lysis mediated by NK cells
Cytotoxicity of NK cells is mediated by death receptor-mediated apoptosis including
Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) (Eischen et al 1997, Arase et al 1995, Kayagaki et al 1999, Screpanti et al
2001), or by exocytosis of cytotoxic granules (Trapani et al 1994). The cytotoxic
granules contain macromolecular complexes consisting of the proteoglycan serglycin
(SG), the serine protease granzyme B (grB), and perforin (PFN). In addition,
cytotoxic cells were also observed to secrete exclusively grB-SG complexes, PFN-
SG complexes, and monomeric PFN (Metkar et al 2002). The mechanism by which
granzyme B enters the target cells is poorly understood. Both, granzyme B uptake
via a perforin pore and a "poreless" mechanism (Figure 5) are discussed.
Figure 5: Mechanism by which granzyme B enters target cells. Effector cells including activated T
cells and NK cells release serglycin (SG) – granzyme B (grB) – perforin (PFN), SG-grB, SG-PFN
complexes. GrB enters the target cell via a perforin pore or a "poreless" mechanism mediated by the
mannose 6-phosphate receptor. The release of grB from the endosome is perforin-dependent. Inside
the target cell the serine protease grB induces apoptosis.
As illustrated in Figure 5 perforin polymerizes in the presence of Ca2+ and forms
pores in the target cell membrane. These lesions can be formed in viable cells in vitro
by addition of high concentrations of purified perforin. It was assumed that these
pores enable granzyme B to be taken up into the target cell. However, in vivo there is
no evidence for the stable transmembrane pore formation (Trapani and Smyth 2002).
Moreover, it has been shown that the uptake of granzyme B into target cells does not
necessarily require perforin. A receptor-mediated endocytosis for granzyme B was
hypothesized (Shi et al 1997, Trapani et al 1996, Pinkoski et al 1998, Froelich et al
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1996). In this "poreless" mechanism, the mannose 6-phosphate receptor (MPR) is
controversely discussed as an entry port for granzyme B (Pinkoski et al 1998,
Pinkoski et al 2002, Andrade et al 1998, Dressel et al 2003). However, the release of
granzyme B from the endosomes and thereby the induction of apoptosis is perforin-
dependent (Pinkoski et al 1998). Inside the target cell the serine protease granzyme
B cleaves peptide bonds at Asp residues and thereby induces both, caspase-
dependent and caspase-independent apoptosis (Figure 6) (Sarin et al 1997, Trapani
et al 1998, Beresford et al 1999).
Figure 6: Apoptotic pathways induced by granzyme B. Cytosolic granzyme B (grB) activates pro-
caspase 10 to its active form to initiate the caspase-dependent pathway. Caspase 10 then processes
caspase 3, which, in turn, activates the further "downstream" caspases. In addition to caspase 10,
granzyme B can directly process and activate caspase 3, 4, 5, 6, 7, and 9. In the caspase-
independent pathway BH3-interacting domain death agonist (BID) is an early target of granzyme B.
Truncated BID (tBID) disrupts the outer mitochondrial membrane which leads to the release of the pro-
apoptotic factors cytochromce c (crucial for activating pro-caspase 9), HtrA2/OMI (blocks inhibitors of
apoptosis), and endonuclease G (ENDOG, activates DNA damage). Released cytochrome c recruits
pro-caspase 9 to form the apoptosome by binding to apoptotic protease-activating factor 1 (APAF1). In
addition, granzyme B disrupts the mitochondrial transmembrane potential through an unknown
mechanism. It can directly cleave inhibitor of CAD (ICAD) to free caspase-activated DNase (CAD)
thus causing DNA fragmentation. Figure adapted from Froelich et al 1998 and Lieberman 2003.
In the caspase-dependent pathway (Figure 6), granzyme B is believed to initiate the
proteolytic cascade by activating caspase 10 (Muzio et al 1996). Caspase 10, in turn,
matures caspase 3 by cleaving the large and small subunits after Asp174. Activated
caspase 3, which is a point of convergence for multiple induction pathways, initiates
processing of caspase 7 and presumably other caspases. Additionally, granzyme B
is believed to process and activate directly caspase 3, 4, 5, 6, 7, and 9 (Figure 6)
(Froelich et al 1998). In contrast, the apoptotic pathways via Fas and TNF, which
activate caspase 8 and/or caspase 2 respectively, are linear.
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Another early target of granzyme B is BH3-interacting domain death agonist (BID)
that destroys the integrity of the mitochondrial outer membrane when it is cleaved
(Figure 6, Kuwana et al 2002). In addition to BID-mediated mitochondrial damage,
which involves the BCL-2-associated protein X (BAX) and BCL-2 antagonist/killer
(BAG) (Barry et al 2000, MacDonald et al 1999), granzyme B also directly disrupts
the mitochondrial transmembrane potential in a caspase- and BID-independent
manner (Alimonti et al 2001, MacDonald et al 1999). Disruption of the mitochondrial
transmembrane potential results in the release of pro-apoptotic molecules including
cytochrome c, HtrA2/OMI, and endonuclease G (ENDOG) from the intermembrane
space into the cytosol (Figure 6) (Kuwana et al 2002, Barry et al 2000, Heibein et al
2000, Sutton et al 2000, Alimonti et al 2001). Released cytochrome c binds to
apoptotic protease-activating factor (APAF) and thereby activates pro-caspase 9
(Figure 6). The homologue to the bacterial HSP Htr, HtrA2/OMI is a recently
identified serine protease that inhibits the inhibitor of apoptosis protein (IAP) and is
upregulated in response to heat shock. Endonuclease G, that is also released by the
action of granzyme-B-cleaved BID, can induce oligonucleosomal DNA damage (Li et
al 2001). Granzyme B can also activate the caspase-activated DNase (CAD) by
cleaving its inhibitor (Thomas et al 2000, Sharif-Askari et al 2001). Therefore,
granzyme B independently and directly activates at least two routes to DNA damage,
even when caspase activation is blocked. In addition to targeting mitochondria and
DNA degradation directly, granzyme B also directly cleaves several downstream
caspase substrates.
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1.3 Aims
1. Identification of the minimal NK cell stimulatory sequence of Hsp70
2. Characterization of the interaction of membrane-bound Hsp70 and NK cells
3. Definition of Hsp70-specific receptors on NK cells
4. Identification of the mechanism of lysis of Hsp70 membrane-positive tumor cells
by NK cells
Figure 7: Schematic illustration of the aims of my work.
1. The sequence of Hsp70 presented on the cell surface of tumor cells will be elucidated and tested
for its NK stimulatory capacity.
2. The interaction of NK cells with Hsp70 membrane-positive tumor cells will be characterized.
Receptors involved in this interaction will be identified.
3. The mechanism of kill of Hsp70 membrane-positive tumor cells by NK cells will be identified. 
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2 MATERIAL AND METHODS
2.1 Cell lines
All cell lines were screened regularly for mycoplasma contamination by an enzyme
immunoassay (Roche Diagnostics GmbH, Mannheim, Germany) detecting
Mycoplasma arginini, Mycoplasma hyorhinis, Mycoplasma laidlawii, and Mycoplasma
orale. Only mycoplasma-free cell lines were used.
2.1.1 Tumor cell lines
The human tumor sublines CX+ and CX- were derived by fluorescence activated cell
sorting (FACS) of CX-2 colon carcinoma cell line (TZB 61005, Tumorzentrum
Heidelberg, Germany) with 60% Hsp70 membrane-positive cells using the Hsp70-
specific monoclonal antibody cmHsp70.1 (Multhoff et al 1997) (multimmune GmbH,
Regensburg, Germany). Hsp70 stable high expressing CX+ (90% Hsp70 membrane-
positive cells) carcinoma cells differ significantly from Hsp70 stable low expressing
CX- (20% Hsp70 membrane-positive cells) carcinoma cells. CX+ and CX- cells were
kept in culture under exponential growth conditions by regular cell passages. Every
three days cells were transferred after short term (maximum: 1 min) trypsination
using trypsin/ethylene-diamine-tetra-acetic (EDTA) solution (PAN Biotech GmbH,
Aidenbach, Germany) and 0.5 x 106 cells were seeded in 5 ml RPMI-1640 medium
(Gibco, Eggenstein, Germany) supplemented with heat-inactivated 10% FCS
(Gibco), 1 mM sodium-pyruvate, 2 mM L-glutamine, 100 IU/ml penicillin, and 100
µg/ml streptomycin (all supplements were purchased from Life Technologies,
Rockville, CA) in T25 culture flasks at 37°C and 5% CO2.
The myelogenous cell line K562 was purchased from ATCC (CCL243, Rockville, MD)
and cultured in RPMI-1640-medium supplemented with heat inactivated FCS, 1 mM
sodium-pyruvate, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 µg/ml
streptomycin.
2.1.2 NK cell line YT
The IL-2 independent growing NK cell line YT (Yodoi et al 1985, ACC 434, DSMZ,
Heidelberg, Germany) was cultivated in RPMI-1640 medium supplemented with 10%
heat-inactivated FCS, 1 mM sodium-pyruvate, 2 mM L-glutamine, 100 IU/ml
penicillin, 100 µg/ml streptomycin ± 2 µg/ml of the 14-mer peptide TKD
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(TKDNNLLGRFELSG, Bachem, Bubendorf, Switzerland); doubling time was 50 h to
60 h at a low cell density of 0.1 x 106 cells/ml.
2.2 Primary cells
2.2.1 Peripheral blood mononuclear cells (PBMC)
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats (Red
Cross, Regensburg, Germany) or leukapheresis products (kindly provided by Clinical
Chemistry, University Hospital of Regensburg) of healthy human volunteers by Ficoll
density-gradient centrifugation. After two washing steps in RPMI-1640 medium
depletion of monocytes was performed overnight. Monocyte-depleted PBL (5 x
106/ml) were incubated for 3 – 4 days in RPMI-1640 medium supplemented with 10%
heat inactivated FCS, 1 mM sodium-pyruvate, 2 mM L-glutamine, 100 µg/ml
penicillin, 100 µg/ml streptomycin, 100 IU/ml IL-2 ± 2 µg/ml TKD.
2.2.2 NK cells
Primary human NK cells were generated from PBL either by plastic adhesion
following a modified protocol of Vujanovic (Vujanovic et al 1993) or by CD3-depletion
or CD94-positive selection using a standard Miltenyi separation method.
To generate plastic adherent NK cells, PBL were separated into non-adherent CD3+
T cells and cytokine-dependent, transient (12 – 24 h) plastic adherent CD3-
/CD16/56+ NK cell subpopulations after 12 h incubation in medium supplemented
with 100 IU/ml IL-2.
For CD3-depletion, 100 x 106 PBL/ml were incubated with 200 µl MACS CD3 Micro
Beads (Miltenyi Biotec, Bergisch Gladbach, Germany) for 15 min at 4°C. After
washing with bovine serum albumin containing cell sorting buffer (MACS buffer, 10 –
20 x of labeling volume), CD3-negative NK cells were separated using a LS/VS
column (Miltenyi Biotec, Bergisch Gladbach, Germany).
To obtain CD94-positive NK cells, PBL were separated by positive-selection using
biotinylated CD94 monoclonal antibody (Ancell Immunology Research Products,
Bayport, USA). Briefly 100 x 106 cells/ml were incubated with 5 µg biotin-conjugated
CD94 mAb for 30 min at 4° C. After extensive washing (10 – 20 x of labeling volume)
with MACS-buffer, cells (100 x 106/ml) were incubated with 200 µl MACS Anti-Biotin
Microbeads (Miltenyi Biotec, Bergisch Gladbach Germany) for 15 min at 4°C under
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gentle shaking. After washing, CD94-positive NK cells were separated using a LS/VS
column.
Sorted cells (2 x 106/ml) were incubated for 3 – 4 days in RPMI-1640 medium with
10% heat inactivated FCS, 1 mM sodium-pyruvate, 2 mM L-glutamine, 100 IU/ml
penicillin, 100 µg/ml streptomycin, 100 IU/ml IL-2 ± 2 µg/ml TKD.
2.3 Flow cytometry
The following antibodies either conjugated or unconjugated were used for FACS
analysis:
antibody (clone) isotype company
primary antibodies
IgG1 mouse Dianova, Hamburg, Germany
IgG1 rat Dianova, Hamburg, Germany
IgG1-FITC mouse BD Biosciences, Heidelberg, Germany
IgG1-PE mouse BD Biosciences, Heidelberg, Germany
IgG2a mouse Dianova, Hamburg, Germany
IgG2a-PE mouse BD Biosciences, Heidelberg, Germany
IgG2b-FITC mouse BD Biosciences, Heidelberg, Germany
IgM-PE mouse Dianova, Hamburg, Germany
CD3-FITC/
CD16/56-PE
mouse IgG1/
mouse IgG2a
BD Biosciences, Heidelberg, Germany
CD3-PE mouse IgG1 Dianova, Hamburg, Germany
CD6-PE mouse IgG1 BD Biosciences, Heidelberg, Germany
CD7 (8H8.1) mouse IgG2a Coulter Immunotech, Marseille,
France
CD8-PE (B9.11) mouse IgG1 Dianova, Hamburg, Germany
CD11b mouse IgG1 Coulter Immunotech, Marseille,
France
CD14-FITC mouse IgG2b Coulter Immunotech, Marseille,
France
CD16-FITC mouse IgG1 BD Biosciences, Heidelberg, Germany
CD54-FITC mouse IgG1 Coulter Immunotech, Marseille,
France
CD56-FITC (NCAM16.2) mouse IgG2b BD Biosciences, Heidelberg, Germany
CD57-PE (NC1) mouse IgM Coulter Immunotech, Marseille,
France
CD91 mouse IgG1 Progen Biotechnik, Heidelberg,
Germany
CD94-PE (HP-3D9) mouse IgG1 Ancell Immunology Research
Products, Bayport, USA
CD158a-PE mouse IgG1 Coulter Immunotech, Marseille,
France
CD158b-PE mouse IgG1 Coulter Immunotech, Marseille,
France
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granzyme B-PE (HC2) mouse IgG1 Hölzel Diagnostics, Cologne,
Germany
HLA-E (MEM-E/06) mouse IgG1 EXIBO, Prague, Czech Republic
HLA-G (87G) mouse IgG2a kindly provided by Dr. D. Geraghty,
Prague, Czech Republic
Hsp70-FITC (cmHsp70.1) mouse IgG1 multimmune GmbH, Regensburg,
Germany
Hsp70 (SPA810) mouse IgG1 Stressgen, Victoria, CA
MHC class I-PE (W6/32) mouse IgG2a Cymbus Biotechnology, Dianova,
Hamburg, Germany
MHC DR-PE (L243) mouse IgG2b Coulter Immunotech, Marseille,
France
MICA (IMA310-0-C100) mouse IgG1 Immatics Biotech, Tübingen, Germany
NKG2A (Z270) mouse IgG1 kindly provided by Dr. L. Moretta,
Milan, Italy
NKp30-PE (Z25) mouse IgG1 Beckman Coulter, Krefeld, Germany
NKp46-PE (BAB281) mouse IgG1 Beckman Coulter, Krefeld, Germany
p-glycoprotein mdr-1 gene-
product (UIC2)
mouse IgG2a Immunotech Coulter, Marseille,
France
TLR2 mouse IgG2a eBioscience, San Diego, USA
TLR4 mouse IgG2a eBioscience, San Diego, USA
TLR9 mouse IgG1 Biocarta Europe, Hamburg, Germany
Secondary antibodies
anti-mouse-FITC goat IgG, IgM DAKO, Glostrup, Denmark
anti-rat-FITC rabbit IgG1 Dianova, Hamburg, Germany
Table 2: Antibodies for FACS analysis
Briefly, 0.5 x 106 cells were incubated either with unconjugated antibody or
fluorescence-conjugated monoclonal antibody for 30 min at 4°C. After washing in
PBS conditioned with 2% (cell lines) or 10% (primary material) heat-inactivated FCS,
cells were analyzed directly by flow cytometry or incubated with a secondary antibody
for another 30 min at 4°C. Then the cells were analyzed on a FACS Calibur
instrument (BD Biosciences, Heidelberg, Germany). The percentage of positively-
stained cells was calculated as the number of specifically-stained, propidium-
iodide(PI)-negative, viable cells minus the number of cells stained with an isotype-
matched control.
For intracellular staining, 0.5 x 106 cells were fixed in 0.25% paraformaldehyde (PFA)
solution for 8 min and permeabilized in PBS containing 0.5% BSA and 0.1% saponin
(permeabilisation solution). Permeabilized cells were incubated with a granzyme B-
PE antibody or an isotype matched IgG1 control antibody at 4°C for 1 h in the dark.
Following washing with permeabilisation solution and PBS, cells were fixed in 1%
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paraformaldehyde solution and intracellular localized granzyme B was analyzed on a
FACS Calibur instrument.
2.4 Light and immunofluorescence microscopy
Cells were analyzed using a Zeiss Axiovert 25 microscope (Zeiss, Jena, Germany)
equipped with a 5 x objective. Pictures were taken with a Fuji FinePix S1 camera.
For fluorescence microscopy, labeled cells were fixed with 1% paraformaldehyde and
embedded in "Fluorescent Mounting Medium" (Neo-Mount, Merck, Darmstadt,
Germany) after cytospin. The samples were analyzed for transmission and
fluorescence microscopy using a Zeiss Axioscop 2 Scanning microscope (Zeiss)
equipped with a 40 x objective and standard filters (Filterset 10 for FITC- and Filterset
45 for PE-labeled cells). Multiplicative shading corrections were performed using the
sofware Axiovision (Zeiss) and photographs were taken using the Axiocam camera
(Zeiss).
2.5 Binding studies
2.5.1 FITC-labeling of Hsp70, BSA and TKD
1 mg/ml Hsp70 (Stressgen, Victoria, CA) and 1 mg/ml BSA (Sigma, St. Louis, USA)
were incubated overnight with fluoresceine-isothiocyanate (FITC) (Sigma, St. Louis,
USA) in 0.1 M sodium bicarbonate (pH 9.5) at 4°C. Unconjugated dye was removed
by passing the reaction mixture over a PD-10 desalting column (Sephadex G-25,
Amersham Bioscience, Uppsala, Sweden) equilibrated with PBS. Eluted fractions
containing FITC-labeled protein were pooled and stored at 4°C in the dark. The
number of FITC molecules bound per molecule protein was determined by measuring
the OD at 280 nm and 495 nm. It was calculated as 4.1 FITC molecules for Hsp70
protein and 4.4 FITC molecules for BSA. Before use the solutions of the FITC-labeled
proteins were centrifuged at 100,000 g in order to remove small particles.
FITC-labeled TKD was derived as a 94.3% pure, 2038.23 Da (C92H128N22O29S) FITC-
γ-Abu-TKDNNLLGRFELSG-OH lyophilized material (Bachem, Bubendorf,
Switzerland). The powder was diluted in sterile PBS at a stock concentration of 1
mg/ml. All experiments using FITC-labeled proteins and peptides were performed
with identical stock solutions within three month.
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2.5.2 Binding of BSA, Hsp70, and TKD to YT cells
Binding studies were performed with BSA-FITC, Hsp70-FITC and TKD-FITC.
Therefore 5 x 106 YT cells per ml PBS supplemented with 2% FCS were incubated
with 10, 25, 50 and 100 µg/ml BSA-FITC and Hsp70-FITC, and 0.2, 2.0, 4.0, and 8.0
µg/ml TKD-FITC for 45 min at 4°C. Binding was determined by flow cytometry.
Directly before flow cytometric analysis the cells were co-stained with propidium
iodide (PI). Only PI-negative viable cells were gated and analyzed on a FACS Calibur
instrument.
2.6 Granzyme B ELISA
Granzyme B released by NK cells during the stimulation period either with IL-2 (100
IU/ml) alone or IL-2 plus TKD (2 µg/ml) was quantified by standard ELISA technique.
Briefly, granzyme B antibody-coated (L-100-114, Hoelzel Diagnostics, Cologne,
Germany) 96 well plates (Corning Costar, USA) were incubated with 100 µl samples
or standard solutions at different concentrations in combination with the secondary
capture antibody (Hoelzel Diagnostics), for 2 h at room temperature. After two
washing steps, granzyme B was visualized by the addition of freshly prepared
avidin—horseradish peroxidase (Hoelzel Diagnostics) for 1 h and substrate solution
(Hoelzel Diagnostics) for another 25 min. Plates were counted on an ELISA reader at
450/650 nm.
2.7 3H thymidine uptake assay
The proliferation of NK and T cells after incubation with different Hsp70 derived
peptides and Hsp70 protein was determined in a standard 3H thymidine uptake assay
(Strong et al 1973). 5 x 104 viable cells per 100 µl were seeded in 96-well flat-bottom
microtiter plates in RPMI-1640 medium supplemented with 10% heat-inactivated
FCS, 1 mM sodium-pyruvate, 2 mM L-glutamine, 100 IU/ml penicillin, 100 µg/ml
penicillin, 100 µg/ml streptomycin, and 100 IU/ml IL-2. Different amounts of Hsp70
(10 and 200 µg/ml) and TKD derived peptides (0.02 – 8 µg/ml) were added. Cells
stimulated with IL-2 alone served as a negative control. After 48 h incubation at 37°C,
the cells were pulsed with 3H thymidine (0.5 µCi per well; Hartmann Analytic, Krefeld,
Germany). Following another 12 h incubation period at 37°C cells were harvested
onto a unifilter GF/96C well plate (Packard, GMI, Minnesota, USA) using the
Harvester Filtermate 196 (Packard). Finally, 50 µl Micro Scint-20 (Perkin Elmer,
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Boston, USA) were added per well and the total uptake was measured in a liquid
scintillation counter (Packard).
2.8 Cytotoxicity Assays
2.8.1 51Cr release assay
The cytolytic activity of effector cells was measured in a standard 51Cr radioisotope
assay (MacDonald et al 1974). Dilutions of the effector cells were incubated with
51Cr-labeled (100 µCi of Na51CrO4, Hartmann Analytic, Krefeld, Germany) tumor
target cells (3 x 103 cells per well) in duplicates at a final volume of 200 µl of RPMI-
1640 medium supplemented with 10% heat inactivated FCS at 37°C for 4 or 12 h in
96 well U-bottom plates. After the incubation period, supernatants (50 µl/well) were
collected and the radioactivity was counted in a γ-counter (Packard, GMI, Minnesota
USA). The percentage of specific lysis was determined according to the following
equation: [(experimental release – spontaneous release)/(maximal release –
spontaneous release)] x 100. The percentage of spontaneous release (supernatant
of tumor cells alone) was always less than 20% for each target cell.
The cytolytic activity was either blocked by incubation of tumor target cells with the
Hsp70 specific monoclonal antibody cmHsp70.1 (5 µg/1 x 106 cells, multimmune
GmbH, Regensburg, Germany) or by preincubation of NK cells with an antibody
directed against the C-type lectin receptor CD94 (5 µg/ml, HP-3B1, mouse IgG2a,
Coulter Immunotech, Marseille, France).
2.8.2 Granzyme B ELISPOT
In addition to the 51Cr release assay, the cytolytic activity of NK cells was measured
using a granzyme B ELISPOT assay (Rininsland et al 2000). Therefore, 96-well
ELISPOT plates were coated overnight at 4°C with 100 µl/well granzyme B capture
antibody (5 µg/ml, BD Biosciences, Heidelberg, Germany). Then, the plates were
blocked with RPMI-1640 medium containing 10% heat-inactivated FCS for 2 h at
room temperature. Tumor target cells (3 x 103 cells per well) and effector cells at
different effector to target cell (E:T) ratios were seeded in duplicates at a final volume
of 200 µl of RPMI-1640 medium supplemented with 10% FCS and incubated for 4 h
at 37°C and 5% CO2. After washing twice with deionized water and three times with
PBS supplemented with 0.05% Tween-20, 100 µl/well biotinylated anti-human
granzyme B antibody (2 µg/ml, BD Biosciences, Heidelberg, Germany) was added
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and the plate was incubated for 2 h at room temperature. Then, the plates were
washed three times with PBS supplemented with 0.05% Tween–20 and incubated
with 100 µl/well avidin-HRP (1:100, BD Biosciences, Heidelberg, Germany) at room
temperature for 1 h. After extensive washing with PBS supplemented with 0.05%
Tween-20 (four times) and PBS (two times) 100 µl 3-amino-9-ethyl-carbazoele (AEC)
substrate solution was added per well and plates were incubated for 25 min at room
temperature in the dark. Substrate reaction was stopped with deionized water and
after drying of the plates spots were counted automatically using the Bioreader-2000
(Biosys, Karpen, Germany).
2.9 Migration assay
Migration assays were performed in a transwell cell culture system (24 well plate,
Costar, Corning Incorporated, NY, USA) in triplicates. The upper and the lower
compartment were separated by a tissue culture polycarbonate membrane (polyvinyl-
pyrrolidone-free, Nucleopore, Pleasanton, CA), 6.5 mm in diameter, with a pore size
of 5 µm.
Figure 8: Principle of the migration assay. Target cells (for 48 h) or peptides are placed in the lower
compartment. 51Cr labeled PBL or CD94-positive NK cells are added in the upper compartment. After
a 4 h incubation period, the cell suspension in the lower compartment is harvested and radioactivity is
measured on a γ-counter.
0.1 x 106 tumor target cells (CX+/CX-), cell culture supernatants, and peptides were
placed in a total volume of 600 µl of RPMI-1640 medium supplemented with 10%
FCS in the lower compartment (Figure 8, left bottom). Then, 2 x 106 PBL or CD94-
positively sorted cells stimulated with TKD were labeled with sodium [51Cr]-chromate
(100 µCi, Hartmann Analytic, Braunschweig, Germany) for 2 h. After extensive
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washing 0.2 x 106 labeled cells were resuspendend in 100 µl RPMI-1640 medium
supplemented with 10% FCS and added carefully to the upper compartment (Figure
8, left top). Recombinant IL-15 (10 ng/ml, Promocell GmbH, Heidelberg, Germany)
served as a positive control for chemotaxis (Allavena et al 1997). After a 4 h
incubation period in an humidified incubator at 37°C and 5% CO2 (Figure 8, right), the
cell suspension in the lower compartment was harvested (50 µl cell suspension) and
radioactivity was measured on a γ-counter (Packard Instruments, GMI, Minnesota,
USA). The percentage of migrated cells was determined according to the following
equation: % specific migration = [(experimental value – spontaneous value) /
(maximum value – spontaneous value)] x 100.
2.10 Apoptosis assays
2.10.1 Annexin-V staining
For annexin-V staining cells (0.5 x 106) were washed twice in annexin buffer (10 mM
HEPES, 140 mM NaCl, 5 mM CaCl2, pH 7.4) and incubated with 100 µl Annexin-V-
Fluos labeling solution (Roche Diagnostics GmbH, Mannheim, Germany) for 15 min
at room temperature. After adding 400 µl annexin buffer, annexin positive cells were
measured on a FACS Calibur flow cytometer.
2.10.2 DAPI staining
Methanol/acetone fixed cells (0.1 x 106 cells/100 µl) were incubated with 0.5 µg/µl
4,6-diamino-2-phenylindol (DAPI; Roche Diagnostics GmbH, Mannheim, Germany) in
PBS/glycerol (3:1) for 15 min in the dark. Following washing in PBS the cells were
mounted with "Fluorescent Mounting Medium" (Neo-Mount, Merck, Darmstadt,
Germany) and analyzed for fluorescence using a Zeiss model Axioscop 2 scanning
microscope (Zeiss, Jena, Germany) equipped with a 40 x objective and standard
filters. Apoptosis was visualized with DAPI staining in 50 cells, each. Images were
treated by multiplicative shading corrections using the software Axiovision (Zeiss).
2.10.3 Cytochrome c release
Cytochrome c was determined using a quantitative immunoassay (Quantikine, R&D
Systems, Wiesbaden, Germany). Briefly, untreated, camptothecin (4 mg/ml), or
granzyme B (10 ng/ml)-treated cells (1.5 x 106/ml) were washed in PBS and treated
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with lysis buffer (R&D Systems, Wiesbaden, Germany) for 1 h at room temperature.
Following centrifugation at 1,000 x g for 15 min, supernatants were removed and 200
µl of a 1:100, 1:250, and a 1:500 dilution were used for a sandwich ELISA. Following
incubation with substrate solution in the dark for 30 min the reaction was stopped.
The optical density of each well was determined on an ELISA reader at 450 nm
(MWG Biotech AG, Ebersberg, Germany). The amount of cytochrome c was
determined according to a calibration curve.
2.11 Identification of human granzyme B
2.11.1 Membrane preparation
Membrane purification was performed by Dounce homogenization. Therefore, 1 x 109
cells were washed twice in 200 ml ice-cold PBS (500 g, 5 min, 4°C). After 10 min
incubation in 7.5 ml Dounce buffer (10 mM TrisCl, 0.5 mM MgCl2, pH 7.6) with
protease inhibitors (Complete Mini, EDTA-free, Roche Diagnostics GmbH,
Mannheim, Germany) at 4°C, the cells were stroked 30 times in a chilled Dounce
homogenizer on ice. Then 2.5 ml tonicity restoration buffer (10 mM TrisCl, 50 mM
MgCl2, pH 7.6) was added and the solution was centrifuged for 5 min at 500 g and
4°C. The supernatant was removed and centrifuged for 1 h at 100,000 g and 4°C.
The pellet containing membranes was resuspended in 5 ml lysis buffer (300 mM
NaCl, 50 mM TrisCl, pH 7.6) with protease inhibitors and solubilized 30-45 min by
frequent gentle vortexing. Finally, insoluble material was spun down (10,000 g, 15
min, 4°C) and the supernatant (plasma membrane proteins) was stored at -20° C
until used.
2.11.2 Affinity chromatography and immunoprecipitation
Bovine serum albumin (BSA, 1 mg/ml, Sigma, Munich, Germany), lyophilized,
recombinant human Hsp70-protein (1 mg/ml, StressGen, British Columbia, CA), and
Hsp70-peptide TKD (1 mg/ml, Bachem, Bubendorf, Switzerland) were incubated with
equilibrated AminoLink-agarose beads (2 ml, Pierce, Biotechnology Inc., Rockford,
USA) for 6 h, together with the reductant NaCNBH3, followed by removal of
uncoupled material and quenching non-reactive groups by extensive washing with 1
M Tris•HCl (pH 7.4). Binding capacity of BSA, Hsp70-protein, and Hsp70-peptide
TKD was greater than 95%.
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Figure 9: Affinity chromatography. TKD-conjugated columns are incubated with 10 mg cytoplasma
membranes (CM) of NK cells or K562 cells. After 1 h incubation non-bound proteins are eluted by
extensive washing. Bound proteins are eluted with 3 M sodium chloride.
As shown in Figure 9, 10 mg cytoplasma membranes of NK cells and the leukemic
non-NK cell line K562 were loaded onto BSA, Hsp70-protein, and Hsp70-peptide
TKD–conjugated columns for 1 h at room temperature. Columns were washed with
10 column volumes of 50 mM Tris buffer (pH 7.6). Bound proteins were eluted with 3
M sodium chloride in 50 mM Tris buffer in 5 fractions (1 ml). Each fraction was
subjected to a SDS-PAGE using a 10% polyacrylamide slab gel and transferred onto
polyvinylidene difluoride membranes.
2.11.3 Western-Blot analysis
Blots were blocked with 5% skim milk in PBS with 0.5% Tween 20 (Merck,
Darmstadt, Germany) at room temperature for 1 h. Membranes were incubated with
monoclonal antibody directed against granzyme B (2C5, IgG2a, BD Biosciences,
Heidelberg, Germany), for 5 h at 4°C. Afterwards, blots were washed with PBS/0.5%
Tween and incubated with a secondary mouse anti-IgG horseradish peroxidase
antibody (Dianova, Hamburg, Germany), for 1 h at 4°C. Proteins were detected using
the ECL detection kit (Amersham Biosciences Europe GmbH, Freiburg, Germany).
Autoradiographs were recorded on X-omat films (Kodak, Stuttgart, Germany).
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2.11.4 Protein identification by peptide mass fingerprinting (Collaboration with
W. Koelch)
A 32 kDa protein band was isolated by affinity chromatography on immobilized
Hsp70-protein or Hsp70-peptide TKD, which was excised from Coomassie Blue-
stained gels, digested with trypsin and desalted using reversed phase ZIP tips
(Millipore, Eschborn, Germany). The samples were embedded in 4-hydroxy-a-
cyanocinnamic acid and the peptide masses were determined with a Perseptive
Voyager DePro matrix-assisted laser desorption ionization-time of flight (MALDI-TOF)
mass spectrometer in reflective mode. A peaklist was compiled with the m/z software
(Proteometrics, Genomic Solutions, Ann Harbor, USA) and used for peak selection;
the resulting peptide mass fingerprint was used to search the non-redundant NCBI
protein data base using the Profound search engine (Proteometrics). Granzyme B
was identified with 100% probability and >95% confidence.
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3 RESULTS
Note: Since part of my work was published (see below), only the representative
results are shown in this chapter. For further results the publications comprised in the
appendix are cited. The appendix contains reprints of the following publications:
(i) Gross C, Hansch D, Gastpar R, Multhoff G. 2003a. Interaction of heat shock
protein 70 peptide with NK cells involves the NK receptor CD94. Biol Chem
384: 267-279.
(ii) Gross C, Koelch W, DeMaio A, Arispe N, Multhoff G. 2003b. Cell surface-
bound heat shock protein 70 (Hsp 70) mediates perforin-independent apoptosis
by specific binding and uptake of granzyme B. J Biol Chem 278: 41173-41181.
(iii) Gross C, Schmidt-Wolf IGH, Nagaraj S, Gastpar R, Ellwart J, Kunz-Schughart
L, Multhoff G. 2003c. Hsp70-reactivity is associated with increased cell surface
density of CD94/CD56 on primary NK cells. Cell Stress Chaperones 8: 348-360.
(iv) Gastpar R, Gross C, Rossbacher L, Ellwart J, Riegger J, Multhoff G. 2004. The
cell surface-localized Hsp70 epitope "TKD" induces migration and cytolytic
activity selectively in human natural killer (NK) cells. J Immunol 172: 972-980.
To examine the differences between Hsp70 membrane-positive and Hsp70
membrane-negative tumor cell lines, the colon carcinoma sublines CX+ (93% Hsp70
membrane-positive) and CX- (18% Hsp70 membrane-positive) and the pancreatic
carcinoma sublines Colo+ (73% Hsp70 membrane-positive) and Colo- (34% Hsp70
membrane-positive) were used. Similar results were obtained with both systems. In
this chapter only the results obtained in the CX+/CX- system are shown. Results
obtained in the Colo+/Colo- system are also shown in the publications of the
appendix and cited in the results part.
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3.1 The Hsp70 peptide TKD is a target structure for NK cells
Previous work demonstrated that membrane-bound Hsp70 serves as a target
structure for NK cells (Multhoff et al 1997). To identify the epitope of Hsp70 that
interacts with NK cells, deletion mutants were produced lacking either the C- or N-
terminal domain. It was shown, that similar to full-length Hsp70 C-terminal substrate
binding domain of Hsp70 (Hsp70-C, aa384-641, Figure 10) in combination with low
dose IL-2 (100 IU/ml) stimulates the proliferative capacity and cytotoxic activity of NK
cells (Botzler et al 1998, Multhoff et al 1999).
Figure 10: Hsp70, Hsp70-C, and TKD. Schematic illustration of Hsp70 protein, the C-terminal
substrate binding domain of Hsp70 (Hsp70-C, aa384-641), and the 14-mer peptide derived from the C-
terminal domain of Hsp70 (TKD, aa450-463). Underlined amino acids mark the 8-mer epitope that is
recognized by the Hsp70 specific antibody cmHsp70.1.
3.1.1 The 14-mer peptide TKD stimulates the proliferative capacity of NK cells
An Hsp70-specific monoclonal antibody (cmHsp70.1) detecting membrane-bound
Hsp70 on viable tumor cells was known to inhibit the immune response of NK cells
against Hsp70 membrane-positive tumor cells (Multhoff et al 1999). By peptide
scanning analyisis of the C-terminal domain of Hsp70 an 8-mer amino acid sequence
(NLLGRFEL, aa451-461, Figure 10) could be identified as the epitope of the Hsp70
specific antibody, detecting membrane-bound Hsp70 on the plasma membrane of
viable tumor cells (Multhoff et al 2001). Based on the primary sequence of Hsp70 and
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this 8-mer epitope the following peptides were synthesized and tested for their
capacity to stimulate NK cells (Table 3): the 8-mer antibody binding epitope (NLL), a
13-mer C-terminal-extended peptide (GIPP), a 14-mer N-terminal-extended peptide
(TKD), and a 12-mer N-terminal-extended peptide (TKD12). In addition, based on the
primary sequence of Hsp70, different homologous peptides derived from Hsp70hom
(88% sequence homology to Hsp70), the constitutive form Hsc70 (84% sequence
homology to Hsp70), and the Escherichia coli derived DnaK (50% sequence
homology to Hsp70), were synthesized (Table 3). One artificial 14-mer peptide
termed LKD exhibiting one amino acid exchange at position one (T to L) was also
tested for its stimulatory capacity on NK cells (Table 3).
Peptide Origin of protein aa Sequence
NLL
(8-mer)
Hsp70 454-461           NLLGRFEL
GIPP 
(13-mer)
Hsp70 454-466           NLLGRFELSGIPP
TKD 
(14-mer)
Hsp70 450-463 TKDNNLLGRFELSG
TKD12 
(12-mer)
Hsp70 450-461 TKDNNLLGRFEL
HOM 
(14-mer)
Hsp70hom 450-463 TKDNNLLGRFELTG
HSC70 
(14-mer)
Hsc70 450-463 TKDNNLLGKFELTG
DNAK 
(14-mer)
DnaK 447-460 AADNKSLGQFNLDG
LKD
(14-mer)
synthetic 450-463 LKDNNLLGRFELSG
Table 3: Amino acid (aa) sequences of peptides that were used for NK stimulation assays.
Name of the peptide, origin of protein, and amino acid position and sequence are shown. Hsp70hom,
the constitutive Hsc70, and the Escherichia coli derived DnaK are homologues of Hsp70. Bold
positions mark amino acids that are presumably involved in the interaction with NK cells. Underlined
positions mark amino acid exchanges compared to the primary sequence of Hsp70.
In a first set of experiments the 8-mer antibody binding epitope NLL, the 13-mer C-
terminal-extended peptide GIPP, and the 14-mer N-terminal extended peptide TKD
were tested for their capacity to stimulate the proliferation of NK cells in a 3H
thymidine assay.
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Figure 11: Comparison of the proliferative response of NK cells against Hsp70 derived
peptides. Plastic adherent NK cells were stimulated either with IL-2 (100 IU/ml) alone (ctrl) or with IL-2
plus peptides GIPP (13-mer), NLL (8-mer), and TKD (14-mer) at concentrations of 0.02, 0.2, 2, 4, and
8 µg/ml. NK cells were also stimulated with Hsp70 protein at concentrations of 10 and 200 µg/ml. The
proliferative response of NK cells was measured 66 h after peptide incubation and an 18 h incubation
period with 3H thymidine (0.5 µCi/ml). Values are given as the means of five independent experiments
± SD.
Therefore, plastic adherent NK cells were stimulated either with IL-2 (100 IU/ml)
alone, or with IL-2 plus peptides at different concentrations. Stimulation of NK cells
with low dose IL-2 plus rHsp70 served as a positive control. The concentration of 10
µg/ml has been defined as the optimal stimulatory dose for full length Hsp70
(Multhoff et al 1999). With respect to the molecular weight of the different peptides,
the concentration that is equivalent to 10 µg of Hsp70 protein (72 kDa) was
calculated as 0.2 µg/ml for all 13-mer and 14-mer peptides including GIPP (1452 Da)
and TKD (1563 Da) and as 0.1 µg/ml for NLL (942 Da). Therefore, all peptides were
tested in a concentration range of 0.02 to 8 µg/ml. As shown in Figure 11, neither the
8-mer peptide NLL nor the C-terminal-extended peptide GIPP were able to stimulate
the proliferative capacity of NK cells at any of the tested concentrations. Only the N-
terminal-extended 14-mer peptide TKD was able to stimulate the proliferative
capacity of NK cells similar to full-length Hsp70 in a concentration range of 0.2-2
µg/ml.
It was shown that Hsc70 and DnaK failed to stimulate NK cells (Multhoff et al 1999).
Furthermore, the homologue of Hsp70 (Hsp70hom) showed a weaker stimulatory
capacity compared to Hsp70. Therefore, the stimulatory capacity of the 14-mer
peptide TKD was compared to three 14-mer peptides based on the primary sequence
of these proteins (HSC70, HOM, DNAK, Table 3). The stimulatory capacity of the N-
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terminal extended 12-mer peptide (TKD12, Table 3), GIPP and NLL was also tested
in this experiment.
Figure 12: Comparison of the proliferative response of NK cells against different HSP70
derived peptides. Plastic adherent NK cells were stimulated either with IL-2 (100 IU/ml) alone or with
IL-2 plus peptides GIPP (13-mer), NLL (8-mer), TKD (14-mer), TKD12 (12-mer), HSC70 (14-mer),
HOM (14-mer), and DNAK (14-mer) at a concentration of 2 µg/ml. The proliferative response of NK
cells was measured 48 h after peptide incubation and an 18 h incubation period with 3H thymidine (0.5
µCi/ml). Values are given as the mean of two independent experiments ± SD.
As shown in Figure 12, only TKD plus low dose IL-2 was able to stimulate the
proliferative capacity of NK cells at a concentration of 2 µg/ml. In the absence of IL-2,
TKD exhibits no stimulatory activity towards NK cells.
3.1.2 The 14-mer peptide TKD stimulates the cytolytic activity of NK cells
Similar to full-length Hsp70, the 14-mer peptide TKD did not only stimulate the
proliferative capacity of NK cells, but also the cytolytic activity against Hsp70
membrane-positive tumor cells. Therefore, NK cells were stimulated with low dose IL-
2 (100 IU/ml) plus TKD (2 µg/ml) for 4 days and used as effector cells in a 4 h 51Cr
release assay. As target cells the Hsp70 high expressing (93% Hsp70 membrane-
positive) CX+ cells and the Hsp70 low expressing (18% Hsp70 membrane-positive)
CX- cells were used. These sublines were established from the colon carcinoma cell
line CX-2 (66% Hsp70 membrane-positive cells) by flow cytometric cell sorting using
the Hsp70-specific antibody cmHsp70.1. A phenotypic characterization of these
sublines shown in Table 4 revealed that they only differ with respect to their capacity
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to present Hsp70 on their cell membrane. All other cell surface markers tested
including HLA class I, adhesion molecules ICAM (CD54) and NCAM (CD56), and
MDR-1 were identically expressed by both sublines. HLA-E, the classical ligand for
the C-type lectin receptor CD94, and the stress inducible MICA, the ligand for
NKG2D, are weakly expressed by CX+/CX- cells.
specificity antibody clone positively stained cells [%]
CX+ CX- 
HLA class I W6/32 99 ± 1 99 ± 1
HLA DR L243 B8.12.2 8 ± 3 6 ± 2
HLA-G 87G 6 ± 2 5 ± 2
HLA-E MEM-E/06 11 ± 8 17 ± 3
MICA AMO1 4 ± 1 5 ± 0
Hsp70 cmHsp70.1 93 ± 3 18 ± 6
CD54 (ICAM) ICAM 69 ± 6 54 ± 5
CD106 (VCAM) VCAM 9 ± 3 10 ± 3
CD57 (HNK1) NC1 12 ± 4 14 ± 3
CD56 (NCAM) NCAM 16.2 19 ± 7 17 ± 4
MDR-1 p-gp UIC2 68 ± 8 64 ± 7
Table 4: Phenotypic characterization of Hsp70 membrane-positive CX+ and Hsp70 membrane-
negative CX- tumor target cells. Cells were stained with FITC- or PE-conjugated antibodies. Mean
values of at least three different experiments were shown.
As shown in Figure 13, TKD stimulated NK cells showed an enhanced lysis of Hsp70
membrane-positive CX+ cells compared to their Hsp70 membrane-negative
counterparts at different effector to target cell ratios. When CD94-sorted NK cells
were stimulated with the 14-mer peptide LKD exhibiting only one amino acid
exchange at position 1 (T to L) no increase in the lysis of CX+ cells could be
observed (right panel). Therefore, the 14-mer peptide TKD does not only enhance
the proliferative activity of NK cells but also the cytolytic activity against Hsp70
membrane-positive tumor cells at a concentration of 2 µg/ml which is equivalent to 10
µg/ml full-length Hsp70-protein.
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Figure 13: The 14-mer peptide TKD, but not the 14-mer peptide LKD, exhibiting one amino acid
exchange at position 1 (T to L) stimulates Hsp70-reactivity of NK cells against Hsp70
membrane-positive target cells. CD94 sorted NK cells were stimulated for 4 days with low dose IL-2
(100 IU/ml) plus either TKD (2 µg/ml) (left panel) or LKD (2 µg/ml) (right panel) and used as effector
cells at effector to target cell ratios ranging from 2/1 to 10/1 in a 4 h 51Cr release assay. Hsp70
membrane-positive CX+ cells (solid circles) and Hsp70 membrane-negative CX- cells (open circles)
were used as tumor target cells.  The spontaneous release for each tumor target cell was always less
than 20%.
In addition, the 14-mer peptide TKD enhances the secretion of the cytokines IFN-γ
and TNF-α similar to Hsp70 (Multhoff et al 1999). Furthermore, the secretion of
granzyme B was increased by stimulation of NK cells with low dose IL-2 plus TKD:
NK cells (2 x 106/ml) incubated for 4 days with IL-2 (100 IU/ml) alone secreted 10 ± 7
ng/ml granzyme B, whereas NK cells stimulated with IL-2 plus TKD secreted 42 ± 11
ng/ml granzyme B (data from three independent experiments).
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3.2 TKD stimulated NK cells migrate selectively towards Hsp70 membrane-
positive tumor cells and supernatants derived thereof
3.2.1 Hsp70 membrane-positive tumor cells are infiltrated by TKD stimulated
PBL
The 14-mer peptide TKD did not only enhance the cytotoxic activity of NK cells
against Hsp70 membrane-positive tumor cells but also induces migration of NK cells
towards them. A first hint that membrane-bound Hsp70 attracts NK cells was given
by the following experiment: TKD stimulated PBL were co-incubated with
exponentially growing Hsp70 membrane-positive CX+ and Hsp70 membrane-
negative CX- cells. After 24 h the morphology of the cells in the co-cultures and
controls (tumor cells alone) were analyzed by light microscopy (Figure 14).
Figure 14: Infiltration of Hsp70 membrane-positive tumor cell clusters by TKD activated PBL.
Hsp70 membrane-positive CX+ and Hsp70 membrane-negative CX- cells (0.1 x 106 cells/well) were
seeded in 96 well flat-bottom plates and grown for 48 h. Tumor cells were co-incubated either with
medium or with TKD stimulated PBL for another 24 h. Light microscopical analysis is shown for tumor
cells only (control, upper row) or tumor cells co-incubated with TKD activated PBL (+ PBL. lower row)
at a magnification of 50 x on a Zeiss Axiovert 25 microscope. Small inserts show a 2.5-fold
magnification of one representative cell cluster. The scale bar in the lower right panel indicates 100
µm.
Under control conditions both cell lines showed a similar morphology forming
adherent spheroidal cell clusters (Figure 14, control). If TKD activated effector cells
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were added, the Hsp70 membrane-positive CX+ cell clusters were infiltrated by PBL,
but not their Hsp70 membrane-negative counterparts (Figure 14, + PBL). Cell viability
of CX+ cells also appeared to be reduced. This finding was confirmed by the fact that
Hsp70 membrane-positive tumor cells are more susceptible to lysis mediated by TKD
stimulated NK cells, than Hsp70 membrane-negative tumor cells (Figure 13).
3.2.2 TKD stimulated PBL selectively migrate towards Hsp70 membrane-
positive tumor cells and supernatants derived thereof
Additional migration assays were performed using a transwell culture system. As
tumor target cells the Hsp70 membrane-positive CX+ and Hsp70 membrane-
negative CX- tumor cells were used. These cells were cultured in the lower
compartment for 48 h. TKD activated PBL were added to the upper compartment and
after a 4 h co-incubation period specific migration was measured. As shown in Figure
15A migration of TKD activated PBL towards Hsp70 plasma membrane-positive CX+
(11%) cells was higher than migration towards their negative counterparts (5%). As a
positive control the cytokine IL-15 (10 ng/ml) was used as an attractant. Comparable
to data published by Allavena et al (1997) migration towards IL-15 was 15% (data not
shown). It has been shown that co-incubation of IL-2 activated NK cells and K562
target cells results in effector-target cell conjugates that trigger chemokine secretion
and chemoattraction of other NK cells (Nieto et al 1998). To exclude chemoattraction
induced by direct cell-cell contact, cell-free supernatants derived from CX+ and CX-
tumor cells on day 2 were used. As demonstrated in Figure 15B left panel, TKD
activated PBL showed 12% migration towards supernatants derived from CX+ cells,
whereas only 3% of the PBL migrated towards supernatants derived from CX- cells.
This suggests that migration of TKD activated PBL might be induced by a soluble
factor that is produced selectively by Hsp70 membrane-positive tumor cells.
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Figure 15: TKD activated PBL selectively migrate towards Hsp70 membrane-positive tumor
cells and supernatants derived therof. Migration was analyzed in a transwell system with two
compartments separated by a polycarbonate membrane with a pore size of 5 µm. (A) In the lower
compartment CX+ and CX- tumor cells (0.2 x 106 cells/well) were grown for 48 h in 600 µl of RPMI-
1640 medium supplemented with 10% heat inactivated FCS. PBL stimulated with low dose IL-2 (100
IU/ml) plus TKD (2 µg/ml) for 4 days, were labeled with sodium 51chromate (100 µCi) and transferred
into the upper chamber of the transwell system. Following a 4 h co-incubation period radioactivity was
determined in PBL that migrated to the lower chamber. Specific migration was calculated as described
in Materials and Methods. Results are shown as the mean ± SD of at least five independent
experiments; statistically significant (student's τ-test) * p < 0.05. (B) In a next set of experiments 600 µl
of cell-free culture supernatant (SN) of CX+ and CX- tumor cells cultured for 48 h were administered in
the lower compartment. Following a 4 h co-incubation period with IL-2 and TKD stimulated PBL (left
panel) or IL-2 stimulated PBL (right panel), radioactivity was determined in the migrated cells of the
lower chamber. Specific migration was calculated as described above. Results are shown as the mean
± SD of at least five independent experiments; statistically significant (student's τ-test) * p < 0.05, ** p <
0.005.
Identical results were obtained with the pancreatic tumor system Colo+/Colo-
(Gastpar, Gross et al 2004, appendix iv). Similar to the CX+/CX- sublines the Hsp70
membrane-positive Colo+ (73% Hsp70 membrane-positive cells) subline and the
Hsp70 membrane-negative Colo- (34% Hsp70 membrane-positive cells) subline was
generated from the pancreas carcinoma cell line Colo357 (50% Hsp70 membrane-
positive cells) by flow cytometric cell sorting using the Hsp70 specific antibody
cmHsp70.1. In this system TKD activated PBL migrated towards Colo+ cells (10%)
and their supernatants (12%) whereas no migration against Colo- cells and their
supernatants was observed (6% and 6% respectively). It has to be mentioned that
stimulation of PBL with low dose IL-2 and TKD is a prerequisite for the induction of
the migratory capacity since PBL stimulated with IL-2 alone did not migrate at all
(Figure 15B, right panel).
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3.2.3 NK cells migrate and exhibit lytic activity against Hsp70 membrane-
positive tumor cells
A phenotypic analysis of the migrated cells revealed that selectively CD3-/CD16/56
NK cells but not CD3+ T cells were attracted by supernatants derived from Hsp70
membrane-positive tumor cells (Figure 16).
Figure 16: NK cells migrate towards and exhibit lytic activity against Hsp70 membrane-positive
tumor target cells. A 4 h migration assay was performed using TKD stimulated PBL against
supernatants of Hsp70 membrane-positive CX+ tumor cells to determine the phenotype and the lytic
activity of non-migrated and migrated cells in comparison to the initial PBL population. (A) Non
migrated PBL (middle panel), and migrated cells (right panel) were harvested and analyzed by
multiparameter flow cytometry using CD3-FITC and CD16/56-PE antibodies. The phenotype of each
cell population was compared to the initial PBL population (left panel) that had been stimulated with
TKD for 4 days. Numbers in the dot blot diagrams indicate percentage of positively stained cells for
each quadrant. Data of one representative result of three independent experiments is shown. (B)
Concomitantly, the cytolytic activity of the three effector cell populations (initial PBL, non-migrated
PBL, and migrated PBL) was tested in a standard 4 h 51Cr release assay. CX+ (solid circles) and CX-
(open circles) cells served as tumor target cells. Effector to target ratios ranged from 1/1 to 10/1. Mean
values of three independent experiments ± SD is shown.
As shown in Figure 16A the cells of the original population contained 34% CD3 T
cells, 11% CD3+/CD16/56+ NKT cells and 29% CD3-/CD16/56+ NK cells. The non-
migrated cells showed no significant differences in the percentage of CD3+ T cells
(36%) and CD3+/CD16/56+ NKT cells (7%), whereas a drastic decrease in CD3-
/CD16/56+ NK cells from 29% to 17% could be observed. Concomitantly, the CD3-
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/CD16/56+ increased significantly from 29% to 61% in the migrated cell population
and the amount of CD3+/CD16/56- T cells was reduced from 34% to 18%. Taken
together, these data indicate, that CD3-/CD16/56+ NK cells were specifically
attracted by Hsp70 membrane-positive tumor cells and supernatants derived thereof.
In addition, the migrated cell population showed a very strong lytic activity against
Hsp70 membrane-positive CX+ target cells (solid circles) and a weaker activity
against Hsp70 membrane-negative CX- target cells (open circles) (Figure 16B, right
panel), whereas non-migrated cells showed a very weak lytic activity against all
tumor target cells (Figure 16B, middle panel) indicating that CD3-/CD16/56+ NK cells
were selectively attracted by Hsp70 membrane-positive tumor cells and specifically
lyse them. Again, similar results were observed with the Colo+/Colo- system
(Gastpar, Gross et al 2004, appendix iv).
Since NK cells not only migrated towards Hsp70 membrane-positive tumor cells, but
also to supernatants derived thereof, a soluble factor was postulated that might be
released by Hsp70 membrane-positive tumor cells. This was proven by the fact that
both Hsp70 and TKD initiated migratory capacity in NK cells in a concentration-
dependent (1 – 5 µg/ml), highly selective and chemokine-independent manner
(Gastpar, Gross et al 2004, appendix iv). Taken together these results indicate that
Hsp70 as well as TKD stimulate cytolysis, proliferation and chemotaxis in CD3-
/CD16/56+ NK cells.
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3.3 Binding studies of Hsp70 and TKD to NK cells
3.3.1 Hsp70 and TKD bind to the cell surface of the NK cell line YT
In addition to their immunostimulatory capacity, the interaction of full-length Hsp70
and the 14-mer peptide TKD with NK cells was investigated by immunofluorescence
studies using the human NK cell line YT. Therefore, YT cells were treated with
Hsp70-FITC (50 µg/ml) and TKD-FITC (8 µg/ml) for 45 min at 4°C. An unrelated
protein, bovine serum albumin (BSA)-FITC (50 µg/ml), was used as a negative
control. After extensive washing, cells were analyzed by fluorescence microscopy at
a magnification of 500 x. As shown in Figure 17 both, Hsp70-FITC (Figure 17B) and
TKD-FITC (Figure 17C), bound to the cell surface of YT cells at 4° C whereas no
binding of BSA-FITC was observed at identical concentrations (Figure 17A).
Figure 17: Specific cell surface binding of FITC-labeled Hsp70 and TKD to YT cells at 4°C. YT
cells (5 x 106/ml) were treated with 50 µg/ml BSA-FITC (A), 50 µg/ml Hsp70-FITC (B), or 8 µg/ml TKD-
FITC (C) at 4°C for 45 min. After extensive washing, cells were fixed with 1% paraformaldehyde and
analyzed by fluorescence microscopy at a magnification of 500 x. The scale bar indicates 10 µm.
3.3.2 Binding of Hsp70 and TKD is concentration-dependent
To investigate whether cell surface binding of Hsp70-FITC is concentration-
dependent, YT cells were incubated for 45 min with 10, 25, and 50 µg/ml Hsp70-
FITC at 4°C. These concentrations have been defined as optimal for the stimulation
of naive NK cells (Multhoff et al 1999). Identical concentrations of BSA-FITC were
used as a control. Binding of Hsp70-FITC and BSA-FITC was analyzed by flow
cytometry (Figure 18). The solid line represents binding of Hsp70-FITC (left panel)
and BSA-FITC (right panel); a dashed line shows autofluorescence. Hsp70-FITC was
bound specifically to YT cells at all concentrations (Figure 18, left panel): a
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concentration of 10 µg/ml Hsp70-FITC resulted in 8% binding, 25 µg/ml in 29%
binding, and 50 µg/ml in 71% binding. At 10 µg/ml and 25 µg/ml, the control protein
BSA-FITC (Figure 18, right panel) was not bound by YT cells (2% and 4% binding,
respectively); at a concentration of 50 µg/ml, binding of BSA-FITC was still
significantly weaker (27% binding) as compared to Hsp70-FITC (71% binding).
Concentrations above 50 µg/ml resulted in a non-specific binding of Hsp70-FITC and
BSA-FITC (data not shown). Therefore, binding of full-length Hsp70 is dose
dependent in a concentration range of 10 to 50 µg/ml.
Figure 18: Hsp70 binding is concentration dependent. Concentration-dependent binding was
determined by incubation of 5 x 106/ml YT cells with 10 µg/ml, 25 µg/ml, or 50 µg/ml of Hsp70-FITC
(left panel), or BSA-FITC (right panel) at 4°C for 45 min. After extensive washing viable, PI-negative
cells were analyzed by fluorescence analysis. Intensity of surface fluorescence (x-axis) was plotted
against cell counts. The dashed line represents the autofluorescence; the solid line represents Hsp70
or BSA positively stained cells. Hsp70 or BSA binding is indicated in percent in the upper right corner
of each graph, as the difference in the amount of positively stained cells minus autofluorescence-
stained cells. Data of one representative result of at least three independent experiments is shown.
In addition to full-length Hsp70 protein concentration-dependent binding of TKD-FITC
was investigated. Therefore, YT cells were incubated with TKD-FITC at
concentrations ranging between 0.2 µg/ml and 8 µg/ml. The non-NK cell line K562
was used as a negative control. As shown in the left panel of Figure 19 specific
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binding of TKD-FITC was observed at peptide concentrations of 2.0 µg/ml (12%
binding), 4.0 µg/ml (19% binding), and 8.0 µg/ml (40% binding). An incubation of
K562 cells with identical peptide concentrations revealed no significant binding of
TKD-FITC. At a concentration of 8.0 µg/ml, the binding of TKD-FITC to YT cells as
compared to K562 cells was still increased by 10-fold; 4% binding compared to 40%
respectively. Concentrations above 8.0 µg/ml resulted in a non-specific interaction of
TKD to both cell types.
Figure 19: TKD binding is concentration dependent. TKD-FITC binding to YT (left panel) and the
non-NK cell line K562 (right panel) is illustrated. Identical cell numbers of viable YT and K562 cells (5 x
106/ml each) were incubated with 0.2, 2.0, 4.0, or 8.0 µg/ml TKD-FITC as described in Figure 17. Data
of one representative result of at least three independent experiments is shown.
In summary, a dose-dependent specific binding of both full-length Hsp70 (10 µg/ml –
50 µg/ml) and TKD (2 µg/ml – 8 µg/ml) but not of unrelated proteins was observed at
4°C. Interestingly, these concentration ranges also have been defined as optimal for
stimulation of NK cell function including cytotoxicity, migration, and proliferation
(Multhoff et al 1999, chapter 3.1).
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3.3.3 Binding of Hsp70-FITC can be inhibited by free Hsp70
In order to show that Hsp70 binding is not only concentration-dependent but also
highly specific, competition assays were performed using either unlabeled Hsp70-
protein or an unrelated protein (glutathione-S-transferase, GST) in 20-fold excess
(Figure 20). The binding of Hsp70-FITC (33% binding, Figure 20, left) was completely
suppressed upon addition of a 20-fold excess of unlabeled Hsp70 (0% binding,
Figure 20, middle), whereas an excess of unlabeled GST (20 x GST) only weakly
competed for the Hsp70 binding site on YT cells (20% binding, Figure 20, right).
Figure 20: Hsp70 protein binding to YT cells is specific. Specificity of Hsp70 binding was
measured by competition assays. YT cells (5 x 106/ml) were incubated with 20 µg/ml Hsp70-FITC,
either alone or together with a 20-fold excess of unlabeled Hsp70 protein or unlabeled glutathione S-
transferase (GST), at 4°C for 45 min. Data of one representative result of at least three independent
experiments is shown.
These data indicate that binding of Hsp70/TKD to NK cells was concentration
dependent and specific. These data led me to speculate about an Hsp70/TKD
specific receptor.
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3.4 The C-type lectin receptor CD94 is involved in Hsp70/TKD-NK cell
interaction
3.4.1 CD94 is commonly expressed by YT cells and Hsp70-reactive NK cells
To characterize the molecular nature of the receptor responsible for Hsp70/TKD-NK
cell interaction the NK cell line YT was used. A phenotypic characterization of YT
cells revealed that none of the previously described HSP-receptors on APC including
CD91 (Binder et al 2000a, Binder et al 200b, Basu et al 2001), TLR2, TLR4, and
CD14 (Asea et al 2000a, Asea et al 2002) was present on the cell membrane of YT
cells (Table5).
Antibody Specificity Positively stained cells
[%]
+/-
YT cell marker
W6/32 HLA class I 98.9 ± 0.2 +
CD7 gp40, FcµR, YT positive ctrl T cell
marker
93.3 ± 0.7 +
CD3 gp20-50, TcR associated complex 1.4 ± 0.2 -
CD6 gp100, thymocytes 0.0 ± 0.0 -
CD8 gp32, cytotoxic, suppressor T 0.0 ± 0.0 -
NK cell marker
CD11b gp165, C3biR 0.4 ± 0.7 -
CD16 gp50-80, FcγR 2.8 ± 3.7 -
CD56 gp180, N-CAM 1.5 ± 0.9 -
CD57 p110, HNK1 0.0 ± 0.0 -
CD161 gp60, C-type lectin, KAR 0.0 ± 0.0 -
CD158a p58.1, p50.1, Ig-SFR, KIR/KAR 0.0 ± 0.0 -
CD158b p58.2, p50.2, IG-SFR, KIR, KAR 0.0 ± 0.0 -
CD94 gp43, C-type lectin R, KIR/KAR 20-45.8 ± 6.0 +
HSP receptors on APC
CD91 p600, α2-macroglobulin receptor 1.8 ± 0.7 -
CD14 gp55, LPS receptor 0.0 ± 0.0 -
TLR2 Toll-like receptor 2 1.0 ± 0.8 -
TLR4 Toll-like receptor 4 0.1 ± 0.1 -
Table 5: Phenotypic characterization of the NK cell line YT. IL-2 independent YT cells were
cultured at cell densities ranging from 0.1 – 0.8 x 106 cells/ml (doubling time: 40-50 h). The data
represent mean values of at least three independent experiments. Cell surface markers, commonly
expressed by YT cells and Hsp70-reactive NK cells, are indicated in bold.
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A comparison of YT cells and Hsp70-reactive primary NK cells demonstrated that
only the C-type lectin receptor CD94 was commonly expressed by both cell types
(Table 5).
3.4.2 The expression of CD94 is upregulated after stimulation of NK cells with
Hsp70/TKD
As previously shown, CD94 was found to be upregulated after stimulation of naive
NK cells with low dose IL-2 (100 IU/ml) plus full-length Hsp70 (Multhoff et al 1999).
Similar to full-length Hsp70 the 14-mer peptide TKD revealed also an upregulated
CD94 expression. As shown in Table 6, after stimulation with either low dose IL-2 or
IL-2 plus TKD, peripheral blood mononuclear cells (PBMNC) derived from 25
different human volunteers revealed no significant differences in the amount of CD3
positive T cells. An incubation with IL-2 plus TKD resulted in a slight increase in the
amount of CD56 and CD94 positive NK cells from 14.4 to 18.0 and from 13.5 to 17.4,
respectively. With respect to the mean fluorescence intensity (mfi) significant
changes were observed: after incubation with IL-2 plus TKD, the mfi of CD16
dropped from 873 to 583. In contrast, the mfi of the NK markers CD56 and CD94
increased from 534 to 981 and from 284 to 606, respectively.
Percentage of positively stained cells ± SD [%] (mfi)
Antibody Unstimulated (d0) IL-2 (d4) IL-2 + TKD (d4)
CD3 71.9 ± 6.5 (200) 71.2 ± 4.6 (199) 70.0 ± 7.7 (205)
CD16 12.3 ± 7.8 (873) 13.2 ± 8.2 (821) 12.6 ± 7.1 (583)*
CD56 14.4 ± 7.8 (534) 12.8 ± 4.1 (715)* 18.0 ± 5.2 (981)*
CD94 13.5 ± 5.5 (284) 14.0 ± 5.3 (377)* 17.4 ± 4.3 (606)*
Table 6: Phenotypic characterization of unstimulated, IL-2 stimulated or IL-2 plus TKD
stimulated PBMNC. Unstimulated PBMNC on d0 were compared by fluorescence analysis with
PBMNC incubated for 4 days with either 100 IU/ml IL-2 alone, or IL-2 plus 2 µg/ml TKD. The cells
were stained with the following mAb directed against T and NK cell-specific markers: CD3, CD16,
CD56, and CD94. Flow cytometric analysis was performed using propidium iodide negative, viable
cells of 25 different human volunteers. *significant difference in mean fluorescence intensity (mfi).
Similar results were obtained by stimulation of NK cells with low dose IL-2 plus TKD
(Gross et al 2003c, appendix iii). Other cell surface receptors including the NCR
NKp30 and NKp46 remained unaffected (Gross et al 2003c, appendix iii).
Furthermore, a positive correlation of a high CD94 cell surface density and an
RESULTS 53
increased binding of Hsp70 was detected using the NK cell line YT (Gross et al
2003a, appendix i).
3.4.3 CD94 expression correlates with Hsp70-reactivity
With respect to the Hsp70-reactivity an increased cell surface density of CD94 on NK
cells could be associated with an increased cytolytic activity against Hsp70
membrane-positive tumor cells. To confirm this finding, PBMNC were separated in a
CD94high (CD94+++) and CD94low (CD94++) expressing NK cell subpopulation by
flow cytometric cell sorting using a CD94 specific antibody (Figure 21). Both
subpopulations were stimulated separately with low dose IL-2 and TKD for 4 days
and used as effector cells in a 51Cr cytotoxicity assay. As shown in Figure 21, lysis of
Hsp70 membrane-positive tumor cells mediated by the CD94high cell population (solid
diamonds) was stronger compared to the CD94low subpopulation (open diamonds).
Figure 21: Comparative cytolytic activity of CD94high (+++) and CD94low (++) expressing NK
cells. Peripheral blood mononuclear cells (PBMNC) were separated in CD94high (+++) and CD94low
(++) expressing NK cells by flow cytometric cell sorting. Both subpopulations were stimulated with low
dose IL-2 (100 IU/ml) and TKD (2 µg/ml) for 4 days and used as effector cells in a 4 h 51Cr cytotoxicity
assay. MHC class I- and Hsp70-positive CX-2 tumor cells were used as target cells. The spontaneous
release for each target cell was less than 20%. Effector to target cell ratios were only 0.5/1, 1/1, and
2/1.
3.4.4 CD94 specific antibody blocks binding of Hsp70 and lysis of Hsp70
membrane-positive tumor cells
An involvement of CD94 in Hsp70 interaction was further confirmed by the fact, that
both, binding of Hsp70 to YT cells (Figure 22) and lysis of Hsp70 membrane-positive
tumor cells (Figure 23) could be abrogated by a CD94 specific antibody.
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As shown in Figure 22, 51% of the YT cells were found to be CD94-positive (upper
row). Following incubation with 20 µg/ml Hsp70-FITC 59% of the cells did bind Hsp70
(lower row, left panel). By preincubation of YT cells with 5 µg/ml CD94 antibody
Hsp70-FITC binding could be abrogated (16% binding, lower row, middle panel),
whereas preincubation with 5 µg/ml CD7 antibody only weakly competed for the
Hsp70 binding site on YT cells (38% binding, lower row, right panel).
Figure 22: Blocking of Hsp70-FITC binding with a CD94 antibody. YT cells, either untreated (left
panel) or after preincubation with CD94 mAb (HP-3B1, 5 µg/ml, middle panel) or CD7 mAb (5 µg/ml,
right panel) for 30 min, were incubated with 20 µg/ml Hsp70-FITC at 4° C for 45 min. After extensive
washing with PBS supplemented with 2% heat inactivated FCS viable, PI negative cells were analyzed
by flow cytometry. The percentage of CD94-positive YT cells was 51%. The dashed line represents
the autofluorescence; the solid line represents Hsp70 positively-stained cells. Specific Hsp70 protein
binding is indicated in percent in the upper right corner of each graph. One representative data of
three independent experiments is shown.
Furthermore, it could be shown that the CD94 specific antibody not only blocks
binding of Hsp70 to NK cells but also inhibits the cytotoxicity of NK cells against
Hsp70 membrane-positive tumor cells. This was demonstrated in a 51Cr release
assay (Figure 23). As target cells the Hsp70 membrane-positive CX+ and Hsp70
membrane-negative CX-cells were used. TKD stimulated CD3-depleted NK cells
were used as effector cells.
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Figure 23: Blocking of lysis of Hsp70-positive tumor cells with a CD94 antibody. Hsp70
membrane-positive CX+ cells (circles) and Hsp70 membrane-negative CX- cells (triangles) were used
as tumor target cells in a 4 h 51Cr-release assay. The spontaneous release for each tumor target cell
was always less than 20%. TKD stimulated CD3-depleted NK cells (4 days) either untreated (filled
circles or triangles) or preincubated for 30 min with CD94 mAb (HP-3B1, 5 µg/ml) (open circles) were
used as effector cells at different effector to target cell ratios ranging form 2/1 to 20/1. One
representative data of three independent experiments is shown.
As illustrated in Figure 23, Hsp70 membrane-positive CX+ tumor cells (solid circles)
were lysed significantly better as compared to their Hsp70 membrane-negative
counterparts (solid triangles). Lysis of the Hsp70 membrane-positive CX+ cells could
be decreased by preincubation of NK cells with an antibody directed against CD94
(open circles), whereas lysis of Hsp70 membrane-negative CX- cells was not
affected by this antibody (data not shown). Multhoff et al have shown, that neither
anti-CD57 antibody, nor HLA class I specific antibody have any inhibitory effect on
the lysis of CX+ and CX- cells (Multhoff et al 1999).
In summary, it could be shown that (i) following incubation of NK cells with
Hsp70/TKD, the expression of CD94 was upregulated, (ii) binding of Hsp70 to NK
cells correlates with CD94 cell surface expression and could be abrogated by an
CD94 specific antibody, and (iii) Hsp70 reactivity of NK cells correlated with CD94
cell surface expression and could be abrogated by an CD94 specific antibody. Taken
together these data indicated that the C-type lectin receptor CD94 might be involved
in the interaction of NK cells with Hsp70 membrane-positive tumor cells.
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3.5 Mechanism of lysis of Hsp70 membrane-positive tumor cells
3.5.1 Human granzyme B interacts with Hsp70 and TKD
Although the preceding observations indicated that the 14-mer peptide TKD functions
as a target recognition structure for NK cells, the mechanism how NK cells lyse
Hsp70 membrane-positive tumor target cells remained to be elucidated. To answer
this question, affinity chromatography was performed using sepharose columns
coupled either with Hsp70 or TKD. Carrier or BSA-conjugated columns were used as
controls. These columns were incubated with cell lysates of the NK cell line YT for 1
h. In addition cell lysates of the non-NK cell line K562 were used as a negative
control. After extensive washing bound proteins were eluted in five fractions (F1 – F5)
with 3 M sodium chloride. The eluted fractions were separated by SDS-PAGE and
visualized by silver staining. A dominant 32 kDa protein band was observed in
fractions two (F2) and three (F3) of YT cell eluates obtained from Hsp70 and TKD
columns (Figure 24A). This band was not detected in eluates of carrier (data not
shown) or BSA-conjugated columns nor in material eluted from the TKD affinity
columns loaded with K562 cell lysates (Figure 24A). Additionally the 32 kDa protein
band derived from F3 of the TKD-conjugated column was excised from a SDS-PAGE
stained with Coomassie Blue and digested with trypsin (Figure 24B). The resulting
peptides were analyzed by matrix-assisted laser desorption ionization time-of-flight
mass peptide fingerprinting (MALDI-TOF) in collaboration with the laboratory of W.
Koelch. Sequences of the tryptic peptides exhibited 100% homology with granzyme B
(Figure 24B). The identity of the 32 kDa protein as granzyme B was further confirmed
by Western blot analysis using a specific antibody (2C5) against granzyme B.
Fractions of YT cell lysates on Hsp70 and TKD columns revealed the presence of a
granzyme B protein band by Western blotting (Figure 24C). However, no granzyme B
was detected in the eluted fraction of Hsp70 and TKD affinity columns loaded with
K562 cell lysates (Figure 24). Intracellular flow cytometry using a PE-conjugated
granzyme B antibody (HC2-PE) showed positive staining for cytoplasmic granzyme B
in YT cells, but not in K562 cells (Gross et al 2003b, appendix ii). In summary, these
data indicate that granzyme B interacts with Hsp70 and TKD.
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Figure 24A, B: Identification of granzyme B as an interacting partner for Hsp70 and TKD. (A)
Hsp70, BSA, and TKD columns were incubated either with cell lysates of the NK cell line YT or the
non-NK cell line K562. Bound proteins were eluted from the columns in 5 fractions (F1 - F5), and
resolved on SDS-PAGE. Following silver staining, eluates of YT cells derived from Hsp70 and TKD
columns revealed a dominant 32 kDa protein band in fractions two (F2) and three (F3). No 32 kDa
protein band was detectable in YT eluates derived from BSA columns and in K562 eluates derived
from TKD columns. The position of the 32 kDa band is indicated with an arrowhead. (B) The tryptic
peptides of the Coomassie Blue-stained 32 kDa band of fraction 3 (F3), derived from the TKD column,
correspond to human granzyme B. The probability of identification was 100% and the estimated Z-
score was 1.89 corresponding to >95% confidence. 
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Figure 24C: Identification of granzyme B as an interacting partner for Hsp70 and TKD. (C)
Corresponding Western blot analysis of YT and K562 cell eluates (F3) following incubation with Hsp70
and TKD columns. The blot was autoradiographed and the localization of granzyme B was visualized
by immunostaining with the granzyme B specific monoclonal antibody 2C5. Eluates of YT cells (left),
but not of K562 cells (right) revealed a 32 kDa granzyme B protein band.
3.5.2 Granzyme B binds specific to the cell surface of Hsp70 membrane-
positive tumor cells and is taken up at 37°C
The preceding findings resulted in the following working hypothesis: if a tumor cell
expresses Hsp70 on the cell surface, granzyme B might bind to it and might be taken
up. In the case of an Hsp70-negative tumor cell no binding and uptake of granzyme
B should be detected. This hypothesis was proven using the CX+ and CX- tumor
system. Both cell types were incubated with perforin-free purified granzyme B at 4°C
and at 37°C. Binding and uptake was shown by fluorescence microscopy (Figure
25A) and FACS analysis (Figure 25B), using an antibody directed against granzyme
B (HC2-PE). Compared to untreated tumor cells (Figure 25A, control), granzyme B
was bound to the cell surface of Hsp70 membrane-positive CX+ cells at 4°C (Figure
25A, grB 4°C). After a temperature shift to 37°C granzyme B was taken up by the
Hsp70 membrane-positive tumor cells (Figure 25A, grB 37°C). In contrast, Hsp70
membrane-negative CX- cells neither exhibited any granzyme B cell surface binding
at  4°C nor uptake at 37°C (data not shown). Furthermore, it could be shown that
granzyme B was selectively taken up by Hsp70 membrane-positive tumor cells in a
concentration-dependent manner, but not by their Hsp70 membrane-negative
counterparts (Figure 25B). Therefore, Hsp70 membrane-positive CX+ cells and
Hsp70 membrane-negative CX- cells were treated with different amounts of perforin-
free, purified granzyme B (1 µg/ml, 2 µg/ml, and 4 µg/ml). A concentration-dependent
uptake of granzyme B was detected in Hsp70 membrane-positive CX+ cells after
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incubation with 2 and 4 µg/ml granzyme B, but not in their Hsp70 membrane-
negative counterparts.
Figure 25: Specific cell surface binding and uptake of granzyme B (grB) by Hsp70 membrane-
positive tumor cells. (A) Comparative binding of granzyme B (2 µg/ml) to the cell surface of CX+
tumor cells at 4°C, and uptake into the cytosol after a temperature shift to 37°C for 30 min, using the
PE-conjugated granzyme B-specific monoclonal antibody HC2-PE. Light microscopy (first row);
immunofluorescence of cells without granzyme B (control, second row); immunofluorescence of cells
after addition of granzyme B (grB, third row). One representative fluorescence microscopy of three
showing identical results is shown; magnification 400 x. (B) Intracellular flow cytometry of
permeabilized CX+/CX- (n = 2) tumor cells using granzyme B-specific monoclonal antibody HC2-PE
before (dashed line) and after (solid line) incubation of the tumor cells with 1, 2, and 4 µg/ml granzyme
B at 37°C for 30 min. Only CX+ but not CX- cells showed a dose-dependent shift of the granzyme B
peak to the right, indicating uptake of extracellularly offered granzyme B. Scale bar represents 10 µm.
Identical results were obtained using the pancreatic carcinoma sublines Colo+ and
Colo- (Gross et al 2003b, appendix ii). In summary, these data indicated specific
binding and internalization of granzyme B in Hsp70 membrane-positive tumor cells. 
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3.5.3 Granzyme B causes apoptosis selectively in Hsp70 membrane-positive
tumor cells
After internalization the serine protease granzyme B cleaves procaspases into their
activated form, and thereby induces programmed cell death (apoptosis) by promoting
DNA fragmentation. Furthermore, granzyme B is involved in the release of
cytochrome c from the mitochondria into the cytosol (Berke 1995, Froelich et al 1999,
Shresta et al 1999). Since granzyme B was specifically taken up by Hsp70
membrane-positive tumor cells, only these cells should become apoptotic after
treatment with granzyme B. Using three independent apoptosis assays (annexin V-
FITC staining, nuclear DNA fragmentation and mitochondria cytochrome c release), it
could be demonstrated that granzyme B caused apoptosis specifically in Hsp70
membrane-positive tumor cells, but not in their Hsp70 membrane-negative
counterparts.
In a first set of experiments Hsp70 membrane-positive CX+/Colo+ and Hsp70
membrane-negative CX-/Colo- cells were incubated with 10 ng/ml enzymatically
active granzyme B for 4, 12 and 24 h. The topoisomerase inhibitor camptothecin
(cam, 4 µg/ml) was used as a positive control reagent for the induction of apoptosis.
After a 4 h incubation period, neither camptothecin nor granzyme B initiated
apoptosis in any of the tested tumor cells. 
Figure 26: Isolated granzyme B (grB) induces apoptosis selectively in Hsp70 membrane-
positive tumor cells (annexin-V staining). Percentage of annexin-V positive and propidium iodide-
negative CX+ (left) and CX- (right) tumor cells, either untreated (black bars), or following incubation
either with camptothecin (4 µg/ml; light gray bars) or granzyme B (10 ng/ml; dark gray bars) for 12 and
24 h. The data represent the mean of four independent experiments ± SD. * marks granzyme B values
significantly different from control (p < 0.005).
After a 12 and 24 h incubation period with camptothecin significant apoptosis was
observed in all tumor sublines (Figure 26). If the tumor sublines were incubated with
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physiological relevant concentrations of granzyme B, the amount of annexin-V
positive cells was increased in Hsp70 membrane-positive CX+/Colo+ cells, but not in
their Hsp70 membrane-negative counterparts after 12 h and even more pronounced
after 24 h. Figure 26 shows the results of the CX+/CX- system. For the Colo+/Colo-
system see Gross et al 2003b, appendix ii.
In line with the annexin-V staining, both CX+ and CX- cells exhibited a typical positive
DAPI staining pattern, as a sign for DNA fragmentation, following treatment with
camptothecin, as compared with untreated controls (Figure 27).
Figure 27: Isolated granzyme B (grB) induces apoptosis selectively in Hsp70 membrane-
positive tumor cells (DAPI staining). Untreated (control), camptothecin (4 µg/ml; cam), or granzyme
B (10 ng/ml; grB) treated CX+ and CX- tumor cells (24 h) were stained with DAPI. Considerable
nuclear DNA fragmentation was observed in all tumor sublines following incubation with camptothecin
(middle panel). After incubation with granzyme B only CX+ tumor cells exhibited nuclear DNA
fragmentation (lower panel, left). No signs of apoptosis were observed in CX- tumor cells following
incubation with granzyme B (lower panel, right). Scale bar represents 10 µm.
DNA fragmentation was observed selectively in Hsp70 membrane-positive CX+
tumor cells, 24 h post-treatment with granzyme B, whereas no DNA fragmentation
was detected in their Hsp70 membrane-negative counterparts (Figure 27). Identical
results were observed in the Colo+/Colo- system (Gross et al 2003b, appendix ii).
Cytochrome c release was measured following incubation of CX+ and CX- cells with
granzyme B and camptothecin (Table 7). After 24 h incubation with granzyme B,
cytochrome c concentration was increased 1.8-fold (0.382 mg/ml versus 0.690
mg/ml) in CX+ cells, whereas no increase after treatment with granzyme B was
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observed in CX- cells (0.452 versus 0.425 mg/ml). An incubation with camptothecin
(4 µg/ml) for 24 h resulted in a comparable, 1.5-fold increase in cytochrome c
concentrations in both CX+ and CX- tumor cells.
Cytochrome c [mg/ml]Cells
Control Camptothecin Granzyme B
-fold increase
CX+ 0.382 ± 0.02 0.555 ± 0.04* 0.690 ± 0.08*
1.0 1.5 1.8
CX- 0.452 ± 0.02 0.672 ± 0.02* 0.425 ± 0.075
1.0 1.5 0.9
Table 7: Isolated granzyme B (grB) induces apoptosis selectively in Hsp70 membrane-positive
tumor cells (cytochrome c release). Quantitative determination of human cytochrome c in CX+ and
CX- tumor cells either untreated (control), or following incubation with camptothecin (4 µg/ml) or
granzyme B (10 ng/ml), for 24 h. The data represent the mean of four independent experiments ± SD;
* values significantly different from control (p < 0.05).
Taken together, these results indicate that following binding and selective uptake, via
membrane-bound Hsp70, granzyme B initiates apoptosis in a perforin-independent
manner. 
3.5.4 Granzyme B released by TKD activated NK cells mediates apoptosis in
Hsp70 membrane-positive tumor cells
To test the physiological relevance of these findings the intracellular levels of
granzyme B in NK cells were measured before (d0) and after treatment with TKD
(d3). It was shown, that intracellular levels of granzyme B were upregulated in NK
cells 1.4-fold following stimulation with TKD plus low dose IL-2. Concomitantly, lysis
of Hsp70 membrane-positive CX+ cells was elevated 1.5-fold in TKD stimulated NK
cells compared to naive NK cells (Figure 28, left panel). Lysis of Hsp70 membrane-
negative CX- cells remained unaffected (Figure 28, right panel). Furthermore, the
increased cytolytic activity of TKD-stimulated NK cells against Hsp70 membrane-
positive CX+ cells could be inhibited by Hsp70-specific antibody (cmHsp70.1) down
to the level of lysis of Hsp70 membrane-negative tumor cells (1.7-fold inhibition,
Figure 28, left), indicating that Hsp70 serves as an entry port for granzyme B.
Identical results could be obtained in the Colo+/Colo- system (Gross et al 2003b,
appendix ii).
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Figure 28: Selective kill of Hsp70 membrane-positive tumor cells, mediated by NK cells, is
blockable by Hsp70-specific monoclonal antibody and correlates with granzyme B secretion.
Killing of CX+ (left panel) and CX- (right panel) tumor target cells by naive, unstimulated (NK d0, open
circles), and TKD stimulated NK cells (NK d3, filled circles and filled triangles) was quantified in 12 h
51Cr release assays. Intracellular granzyme B levels in naive NK cells (NK d0) versus TKD-stimulated
NK cells (NK d3) increased 1.4-fold; concomitantly lysis of CX+ cells was elevated 1.5-fold at different
effector to target ratios. Lysis of CX- tumor cells remained unaffected. Furthermore, the increased
cytolytic activity of TKD-stimulated NK cells (NK d3) against CX- tumor cells was inhibited by the
Hsp70 specific antibody cmHsp70.1 (Hsp70 mAb,) down to the level of lysis of Hsp70 membrane-
negative tumor cells (1.7-fold inhibition, filled triangles). Cytotoxicity was determined at E:T ratios
ranging form 2/1 to 20/1. Spontaneous release of each target cell was below 10%. The data represent
the mean of three independent experiments ± SD.
Apart from this observation, Hsp70 membrane-positive tumor target cells stimulated
the production and release of granzyme B in primary NK cells. This was shown by an
ELISPOT assay measuring the release of granzyme B in a co-incubation of either
unstimulated (NK d0) or TKD-stimulated NK cells with CX+/CX- and Colo+/Colo-
tumor target cells. Co-incubation of tumor cells with unstimulated NK cells (NK d0)
always resulted in very low granzyme B release, independent of the tumor target cell
line and the effector to target cell (E:T) ratio. In controls, the number of spots was
always less than 20. After a 3 day stimulation period with TKD (NK d3) followed by a
4 h co-incubation time with tumor cells, granzyme B release was significantly up-
regulated. At an E:T ratio of 5:1, the following numbers of granzyme B spots were
determined: CX+: 260 ± 20; CX-: 165 ± 6; Colo+: 137 ± 55, Colo-: 66 ± 8.
Concomitantly, Hsp70 membrane-positive tumor target cells (CX+/Colo+) were lysed
significantly better as compared to their negative counterparts (Figure 28). In
summary these data suggested a dual role for Hsp70 and TKD in the immune
response against cancer: On the one hand it stimulates the cytolytic activity of NK
cells by an increased production of the pro-apoptotic enzyme granzyme B, on the
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other hand it facilitated uptake of granzyme B selectively into Hsp70 membrane-
positive tumor target cells.
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4 DISCUSSION
4.1 The 14-mer peptide TKD serves as a target structure for NK cells
Tumor cells frequently express Hsp70, the major stress-inducible member of the
HSP70 family, on their plasma membranes (Tamura et al 1993, Multhoff et al 1995 a,
Farkas et al 2003, Kleinjung et al 2003). These tumor cells are more susceptible for
the lysis mediated by NK cells. Furthermore, it could be shown that 3 to 4 days
stimulation of NK cells with Hsp70 (10 µg/ml) and low dose IL-2 (100 IU/ml)
enhanced the proliferative and cytolytic activity of NK cells (Multhoff et al 1999). It
could be demonstrated that similar to full-length Hsp70 and the C-terminal domain of
Hsp70 (Hsp70-C, aa384-641, Botzler et al 1998), the 14-mer peptide TKD
(TKDNNLLGRFELSG, aa450-463) stimulated the proliferative capacity and cytolytic
activity of NK cells. TKD is an N-terminal extended peptide of the 8-mer binding
epitope of the Hsp70 specific antibody cmHsp70.1. This antibody detects cell
surface-bound Hsp70 on viable tumor cells (Multhoff et al 1995) and inhibits NK cell
mediated lysis of Hsp70 membrane-positive tumor cells (chapter 3.5.4, Figure 28).
Other Hsp70 specific antibodies directed against the N-terminal ATPase domain or
epitopes in the C-terminal domain different from NLLGRFEL (aa454-461) neither detect
membrane-bound Hsp70 on viable tumor cells nor block the cytolytic function of NK
cells (Botzler et al 1998). Therefore, one might speculate that the 8-mer is exposed to
the extracellular milieu or that other Hsp70 epitopes are hidden and thus not
accessible to antibodies.
Since the 8-mer peptide NLL, the C-terminal extended 13-mer peptide GIPP and the
12-mer N-terminal extended peptide TKD12 failed to stimulate NK cells the 14-mer
peptide TKD represents the minimal stimulatory sequence for NK cells. Comparison
of TKD with other 14-mer peptides for example the sequence of Hsp70hom (88%
homology to Hsp70, HOM, TKDNNLLGRFELTG, 1 aa exchange at postion 462), the
constitutively expressed highly homologous Hsc70 (84% homology, HSC70,
TKDNNLLGKFELTG, 2 aa exchanges at position 458 and 462), and the E. coli
derived Hsp70 homologue DnaK (50% homology, DNAK, AADNKSLGQFNLDG, 7 aa
exchanges at position 450, 451, 454, 455, 458, 460, and 462) revealed that the TKD
region is quite variable (Altschul et al 1999). Functionally already one aa exchange at
position 450 (T to L, LKD, LKDNNLLGRFELTG) or at position 462 (S to T, HOM) is
sufficient to inhibit the immunostimulatory activity of this peptide.
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Stimulation of NK cells with TKD is concentration dependent. The optimal stimulatory
dose of TKD is 0.2 – 2.0 µg/ml. This concentration is equivalent to 10 – 100 µg/ml
full-length Hsp70 that is also known to stimulate NK cells. Concentrations above the
optimal dose 2 µg/ml TKD or 200 µg/ml Hsp70 protein, respectively, failed to
stimulate NK cells. These findings lead to the hypothesis that Hsp70/TKD NK cell
interaction is saturable and thus might be receptor mediated.
Stimulation of NK cells with low dose IL-2 plus TKD does not only enhance the
proliferative and cytolytic activity of NK cells, but also its migratory capacity. Only
Hsp70 membrane-positve tumor cells showed chemotactic properties. In
coincubation and migration assays, TKD stimulated PBL selectively infiltrated Hsp70
membrane-positive tumor cells, but not their Hsp70 membrane-negative
counterparts. Since supernatants derived from Hsp70 membrane-positive tumor cells
did also enhance migration a soluble factor was assumed. It was shown that TKD
stimulated PBL only migrated towards supernatants derived from Hsp70 membrane-
positive tumor cells but not to that of Hsp70 membrane-negative counterparts.
Phenotypical analysis of the migrated and non-migrated cell population showed that
mainly CD3-/CD16/56+ NK cells, but not CD3+ T cells migrated towards these
supernatants. In addition, the migrated cell population also showed an enhanced
cytotoxicity against Hsp70 membrane-positive tumor cells. Recent data demonstrated
that Hsp70 can be released by tumor cells (Barreto et al 2003, Broquet et al 2003).
Here, it could be shown that TKD stimulated NK cells migrated towards full-length
Hsp70 and TKD in a concentration (1 – 5 µg/ml) dependent manner. Chemokinesis
or random cell mobility was excluded, since NK cells only migrated in a positive
gradient.
Migration towards TKD is highly selective, because TKD related peptides with 2
(HSC70) and 7 aa exchanges (DNAK) failed to stimulate migration (Gastpar, Gross
et al 2004). It is important to note that TKD stimulation is a prerequisite for induction
of migration, since NK cells stimulated with IL-2 alone did not show any migratory
capacity towards Hsp70 membrane-positive tumor cells.
It has been shown that IL-2 activated NK cells can induce regression of established
lung and liver tumors (Schwarz et al 1989, Vujanovic et al 1995, Whiteside et al
1989, Yasmura et al 1994). However, the antitumor effect is often limited, because
primary tumors and metastases are not efficiently infiltrated by effector cells.
Stimulation of NK cells with the 14-mer peptide TKD plus low dose IL-2 might
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enhance both, the migratory capacity and cytolytic activity of NK cells and thus might
provide an innovative basis for the development of a cellular immunotherapy.
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4.2 The C-type lectin receptor CD94 is involved in NK-Hsp70 interaction
The 14-mer peptide TKD was identified as the minimal NK stimulatory sequence of
Hsp70. Activation of NK cells via TKD is concentration dependent (0.2 – 2.0 µg/ml)
and specific. The same could be shown for interaction of Hsp70/TKD with the NK cell
line YT. Using FITC labeled full-length Hsp70 protein and TKD it could be
demonstrated that cell surface binding is specific and saturable and therefore might
be receptor mediated: (i) binding of Hsp70-FITC could be abrogated by 20 x excess
of free Hsp70 but not of an unrelated protein (GST) and (ii) Hsp70-FITC and TKD-
FITC bound specifically to the cell surface of YT cells in a concentration dependent
manner (10 – 50 µg/ml and 2 – 8 µg/ml respectively). These concentrations also
have been found to stimulate NK cell function (chapter 4.1, Multhoff et al 1999,
Hantschel et al 2000). Concentrations above 50 µg/ml (Hsp70) or 8 µg/ml (TKD)
resulted in non-specific binding. These observations differed from published data
(Basu et al 2001), demonstrating a receptor-mediated, specific binding of Hsp90,
gp96, Hsc70 and Hsp70 to CD11b-positive macrophages at concentrations of 200
µg/ml. Therefore, it was assumed that interaction of NK cells with Hsp70 is mediated
by receptors different from that expressed by APC. This hypothesis was further
confirmed by the fact that NK cells interact specifically with Hsp70/TKD, whereas
Hsp70hom/HOM, Hsc70/HSC70, and DnaK/DNAK failed to stimulate NK cell activity
(Multhoff et al 1999). In contrast APC have been found to interact with several HSP,
including Hsc70, Hsp70, Hsp90, gp96, and Hsp60 (Kol et al 2000, Ohashi et al 2000,
Habich et al 2002). Furthermore, a phenotypical analysis of the Hsp70 specific NK
cell line YT revealed that none of the recently described HSP-receptors including
CD91 (Binder et al 2000 a, Basu et al 2001), TLR2, TLR4, and CD14 (Asea et al
2000 a, Asea et al 2002) were expressed on the cell surface of YT cells. A
comparison of YT cells with Hsp70 reactive NK cells, showed that only C-type lectin
receptor CD94 (Lanier et al 1994, Lazetic et al 1996), which was described to interact
with HLA-E molecules, presenting leader peptides of MHC class I molecules
including HLA-A, HLA-B, HLA-C, and HLA-G (Braud et al 1998, Borrego et al 1998,
Ulbrecht et al 1998, Lee et al 1998, Brooks et al 1999), was commonly expressed by
both cell types. An increased CD94 expression was observed when NK cells were
stimulated either with full-length Hsp70 protein (10 µg/ml) or the 14-mer peptide TKD
(2 µg/ml) in combination with low dose IL-2. Furthermore, it could be shown that
binding of Hsp70 and Hsp70-reactivity correlates with CD94 membrane-expression
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on NK cells. In addition, a CD94 specific antibody suppressed both, binding of Hsp70
to YT cells and cytolytic activity of NK cells against Hsp70 membrane-positive tumor
cells. However, CD94 alone is unlikely to be responsible for the interaction with
Hsp70/TKD for several reasons: (i) CD94 as a homodimer is unable to mediate cell
signaling and (ii) transiently CD94 transfected COS cells did not exhibit significant
Hsp70 or TKD binding (data not shown). Although these data support the idea that
CD94 is involved in the interaction of NK cells with Hsp70/TKD, the co-receptor of
CD94 that mediates signaling has not been defined. CD94 is known to form
heterodimers with members of the NKG2 family. Depending if its partner molecule
contains an ITIM or ITAM motif the heterodimeric CD94 complex fullfills inhibitory or
activatory function. Since binding of Hsp70/TKD activates NK cells it is likely that the
co-receptor of CD94 is a member of the NKG2 family that contains an ITAM motif.
This includes NKG2C, NKG2E and its splice variant NKG2H, and NKG2F (Brooks et
al 1997, Lanier 1998b). The activating receptor NKG2D can be excluded, since
NKG2D forms homodimers.
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4.3 Membrane-bound Hsp70 mediates perforin-independent apoptosis by
specific binding an uptake of granzme B
Although it was shown that the 14-mer peptide TKD functions as a target recognition
structure for NK cells, the mechanism how NK cells lyse Hsp70 membrane-positive
tumor cells remained to be elucidated. In the cytoplasm, Hsp70 binds hydrophobic
residues of denaturated polypeptides and co-chaperones via the substrate binding
pocket, localized in the C-terminus in an ATP-dependent manner (Hartl et al 2002,
Hartl et al 1996, Rüdiger et al 1997, Demand et al 1998). To identify molecules that
are involved in the interaction of NK cells with Hsp70 membrane-positive tumor cells
affinity chromatography was performed with cell lysates from the NK cell line YT. To
characterize interacting partners specific for membrane-bound Hsp70, an affinity
column coupled with recombinant Hsp70 or TKD. TKD was used since this sequence
is believed to be exposed on the cytoplasma membrane. A dominant 32 kDa protein
was eluted from Hsp70 and TKD columns incubated with NK cell lysates. This protein
was neither detected using control columns (uncoupled, BSA-conjugated, or GST-
conjugated) or cell lysates of a non-NK cell line. The serine protease granzyme B
was identified as the interacting partner for Hsp70 and TKD by matrix-assisted laser
desorption ionization time-of-flight mass peptide fingerprinting (MALDI-TOF) and by
Western Blot analysis. This observation is confirmed by the finding that Hsp70 and
Hsp27 binds to granzyme-immobilized sepharose columns (Beresfold et al 1998).
Granzyme B is an important pro-apoptotic enzyme produced by activated T cells and
also by NK cells. One mechanism of NK cell-mediated killing involves exocytosis of
cytotoxic granules containing serglycin, serine proteases and perforin (Trapani et al
1994, Metkar et al 2002). Granzyme B is believed to enter target cells by endocytosis
via the mannose 6-phosphat receptor. However, the release of grB from the
endosome into the cytosol is perforin-dependent (Pinkoski et al 1998, Pinkoski et al
2002, Andrade et al 1998). The group of A. De Maio has shown that Hsc70 forms a
functionally stable ATP-dependent cation channel in acidic phospholipid membranes
(Arispe and De Maio 2000, Arispe et al 2002). In collaboration with A. De Maio, it was
shown that Hsp70 also forms ion channels in the cell surface of Hsp70 membrane-
positive CX+ tumor cells; no channel formation was observed in Hsp70 membrane-
negative CX- tumor cells. Together with the fact, that granzyme B binds specifically to
Hsp70/TKD the following working hypothesis could be postulated: if a tumor cell
expresses Hsp70 on its cell surface granzyme B might bind to it and is possibly taken
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up by this tumor cell. In the case of an Hsp70-negative tumor cell no binding and
uptake of granzyme B should be observed. This hypothesis was proven using the
CX+/CX- and Colo+/Colo- system. It was shown that granzyme B selectively bound
to the cell surface of Hsp70 membrane-positive tumor cells (CX+/Colo+) and was
internalized by them after a temperature shift from 4°C to 37°C (Figure 29).
Figure 29: Granzyme B causes apoptosis selectively in Hsp70 membrane-positive tumor cells.
Granzyme B binds to the cell surface of Hsp70 membrane-positive tumor cells via the extracellularly
exposed 14-mer peptide TKD. It is internalized in Hsp70 membrane-positive tumor cells which
undergo apoptosis. In the case of Hsp70 membrane-negative tumor cells, granzyme B remains
outside of the cell and cannot induce apoptosis.
After internalization the serine protease granzyme B induces both caspase-
dependent and –independent apoptosis by promoting DNA fragmentation (Froelich et
al 1998, Beresfold et al 1999, Thomas et al 2000, Sharif-Askari et al 2001, Figure 6
Introduction). Moreover granzyme B causes the release of pro-apoptotic molecules
(e.g. cytochrome c) by disruption of the mitochondrial transmembrane potential
(Alimonti et al 2001, MacDonald et al 1999, Kuwana et al 2002, Figure 6
Introduction). Since granzyme B was specifically taken up by Hsp70 membrane-
positive tumor cells, only these cells should selectively undergo apoptosis after
treatment with granzyme B. Using three idependent apoptosis assays detecting
membrane changes (Annexin V staining), nuclear DNA fragmentation (DAPI
staining), and mitochondrial disintegrity (cytochrome c release), it could be
demonstrated that physiological relevant concentrations of granzyme B (Spaneny-
Dekking et al 1998) caused apoptosis perforin-independent and specifically in Hsp70
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membrane-positive CX+/Colo+ cells, but not in their Hsp70 membrane-negative
counterparts (CX-/Colo-) (Figure 29). These differences were not obtained with the
alkaloid camptothecin, which inhibits DNA topoisomerase by stabilizing the cleavable
complex and thereby causing apoptosis. This indicates that initiation of apoptosis by
granzyme B and camptothecin involves different routes. Variable intracellular Hsp70
levels could be excluded since tumor sublines with differential Hsp70 membrane-
expression express similar amounts of intracellular Hsp70 even under stress
(Multhoff et al 1997). Moreover, binding and uptake of granzyme B via extracellular
exposed TKD might be a critical step for induction of apoptosis. This hypothesis is
supported by the fact that cytolytic activity of NK cells against Hsp70 membrane-
positive tumor cells could be reduced by the Hsp70 specific antibody cmHsp70.1 that
binds to TKD. It is possible that this antibody prevents tumor cells from apoptosis by
blocking specific binding and uptake of granzyme B. Taken together these data
showed a new perforin-independent pathway for the induction of apoptosis by
granzyme B (Figure 30).
Figure 30: Perforin-dependent/-independent pathway. Effector cells including activated T cells and
NK cells release serglycin (SG) – granzyme B (grB) –perforin (PFN), SG-grB, and SG-PFN
complexes. In the perforin-dependent pathway grB is endocytosed by the target cell via the mannose
6-phosphat receptor. The release of grB into the cytosol is perforin-dependent. In the perforin-
independent pathway grB enters the target cell via membrane-bound Hsp70. Inside the target cell the
serine protease granzyme B induces apoptosis
Apart from the observation that Hsp70 serves as an entry port for granzyme B into
Hsp70 membrane-positive tumor target cells, Hsp70 and TKD stimulate the
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production and release of granzyme B in primary NK cells. Therefore, cell surface
expression of Hsp70 does not only enhance sensitivity of tumor target cells to
apoptotic cell death but also induces NK cell activation. In contrast to in vitro applied
granzyme B, activated NK cells also kill Hsp70 membrane-negative tumor cells to a
certain extent. Since this weak lysis was not blockable with the Hsp70 specific
antibody cmHsp70.1, another pathway for killing of Hsp70 membrane-negative tumor
cells is hypothesized. Furthermore, NK cells lysed Hsp70 membrane-positive tumor
target cells more efficiently as compared to in vitro provided granzyme B. This could
be explained by the fact that killing mediated by NK cells include physical cell-to-cell
contact which is likely to result in high local granzyme B concentrations at the tumor
cells. Since these concentrations cannot be quantified experimentally, the in vitro
apoptosis assays were performed with granzyme B concentrations similar to those
found in human serum (Spaeny-Dekking et al 1998). These concentrations are
propably different from those secreted by NK cells and therefore have different
efficacy. However, the relative release of granzyme B from NK cells after tumor target
cell contact could be determined by ELISPOT analysis. A correlation between the
cytotoxic response of activated NK cells against Hsp70 membrane-positive tumor
cells with the relative release of granzyme B by these cells could be observed. These
findings were supported by the fact that increasing amounts of in vitro provided
granzyme B are still selectively taken up by Hsp70 membrane-positive tumor cells.
In summary these data suggested a dual role for Hsp70 and TKD in the immune
response against cancer: On the one hand NK cells are stimulated to produce and
deliver granzyme B on the other hand it facilitated uptake of granzyme B selectively
into Hsp70 membrane-positive tumor target cells.
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5 SUMMARY
A broad variety of tumor cells express Hsp70 on their cell surface. These tumor cells
are more sensitive to the lysis mediated by NK cells. Here, it was shown that the
14mer peptide TKD (TKDNNLLGRFELSG, aa450-463 derived from the C-terminus of
Hsp70 is the minimal sequence of Hsp70 that has the capacity to activate NK cells.
NK cells incubated with low dose IL-2 (100 IU/ml) plus TKD (2 µg/ml) showed an
enhanced proliferative capacity and an enhanced cytolytic activity and migratory
capacity against Hsp70 membrane-positive tumor cells. Furthermore, secretion of the
cytokines IFN-γ and TNF-α was enhanced. TKD stimulated NK cells also showed
enhanced intracellular levels of the serine protease granzyme B. Since binding of full-
length Hsp70 protein and TKD to NK cells was specific and concentration-dependent,
an involvement of a Hsp70 specific receptor was hypothesized. It was shown that the
C-type lectine receptor CD94 is involved in Hsp70/TKD-NK cell interaction: (i) CD94
was upregulated in NK cells after incubation with Hsp70/TKD; (ii) binding of Hsp70
correlated with CD94 expression on NK cells; (ii) binding of Hsp70 could be inhibited
by a CD94 specific antibody; (iii) Hsp70 reactivity correlated with CD94 expression on
NK cells; and (iv) Hsp70 reactivity of NK cells could be inhibited by a CD94 specific
antibody. Finally the mechanism how NK cell lyse Hsp70 membrane-positive tumor
cells could be elucidated. It was shown that the serine protease granzyme B binds to
Hsp70/TKD on the cell surface of Hsp70 membrane-positive tumor cells and is
specifically taken up by these cells. As demonstrated by different apoptosis assays
(annexin V staining, cytochrome c release, and DAPI staining) granzyme B causes
apoptosis specifically in Hsp70 membrane-positive tumor cells, but not in their Hsp70
membrane-negative counterparts.
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maturation result in increased HSP levels (Lindquist and
Craig, 1988; DeNagel and Pierce, 1992). The major role of
intracellular-residing HSP is protecting cells against
lethal damage induced by stress, and support of the fold-
ing and transport processes of newly produced polypep-
tides and abberant proteins (Hartl, 1996). Recently, extra-
cellular-localized and membrane-bound HSPs have been
found to be important in eliciting immune responses. Up-
take of HSP (gp96, Hsp90, Hsp70, and calreticulin) pep-
tide complexes by antigen-presenting cells (APC) via the
α2-macroglobulin receptor CD91 and presentation by
MHC class I molecules (Arnold-Schild et al., 1999; Binder
et al., 2000a,b; Sondermann et al., 2000; Basu et al.,
2001) elicits an antigen-specific CD8+ T cell response
(Schild et al., 1999; Wells and Malkovsky, 2000; Binder
et al., 2001). Binding of extracellular HSP70 to mono-
cytes stimulates the secretion of pro-inflammatory cyto-
kines, including IL-1β, IL-6 and TNF-α, through a CD14-
associated pathway that is dependent on intracellular
calcium and on the activation of NF-κB (Asea et al.,
2000a). For this ‘chaperokine effect’, HSP70-chaperoned
peptides are not required (Asea et al., 2000b). Our group
demonstrated that membrane-bound Hsp70 renders tu-
mor cells more sensitive to the cytolytic activity of tran-
siently plastic adherent natural killer (NK) cells (Vujanovic
et al., 1995; Multhoff et al., 1995b, 1997; Hantschel et al.,
2000). By sequencing of the Hsp70 antibody epitope of
clone C92F3B1 (Reineke et al., 1996), which is known to
inhibit the cytolytic NK activity against Hsp70-positive tu-
mor cells, a 14-mer peptide TKDNNLLGRFELSG (TKD)
could be identified as the minimal Hsp70-NK cell inter-
acting peptide (Multhoff et al., 2001). Incubation of puri-
fied NK cells, either with full-length Hsp70 protein, with
the C-terminal domain of Hsp70 (Hsp70C), or with the
Hsp70 peptide at a concentration of 10 µg/ml Hsp70 pro-
tein or 2 µg/ml Hsp70 peptide, resulted in a comparable
stimulation of the cytolytic function of NK cells against
Hsp70-positive tumor target cells (Multhoff et al., 1999,
2001). In contrast, related HSP70 members, including the
constitutively-expressed Hsc70 (84% homology to
Hsp70) and DnaK, the E. coli-derived Hsp70 (50% ho-
mology to Hsp70), did not affect NK cell activity (Botzler
et al., 1998). Since saturation and specificity are typical
attributes for a receptor-ligand interaction we speculate
about the existence of Hsp70-specific receptors on NK
cells. Functionally, experimental evidence exists that the
C-type lectin KIR/KAR receptor CD94 is involved in the
interaction of NK cells with Hsp70 protein for several rea-
sons: (i) following incubation of purified NK cells with
Hsp70 protein and the Hsp70 peptide, CD94 expression
is up-regulated; (ii) the cytolytic activity of NK cells
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Full-length Hsp70 protein (Hsp70) and the C-terminal
domain of Hsp70 (Hsp70C) both stimulate the cytolyt-
ic activity of naive natural killer (NK) cells against
Hsp70-positive tumor target cells. Here, we describe
the characterization of Hsp70-NK cell interaction
with binding studies using the human NK cell line YT.
Binding of recombinant Hsp70 protein (Hsp70) and
the C-terminal domain of Hsp70 (Hsp70C) to YT cells
is demonstrated by immunofluorescence studies. A
phenotypic characterization revealed that none of the
recently described HSP-receptors (2-macroglobulin
receptor CD91, Toll-like receptors 2, 4, 9, CD14) are
expressed on YT cells. Only the C-type lectin receptor
CD94 is commonly expressed by YT cells and Hsp70
reactive NK cells. A correlation of the cell density-de-
pendent, variable CD94 expression and the binding
capacity of Hsp70 was detected. Furthermore, Hsp70
binding could be completely abrogated by preincuba-
tion of YT cells with a CD94-specific antibody. Com-
petition assays using either unlabeled Hsp70 protein
or an unrelated protein (GST) in 20-fold excess and
binding studies with escalating doses of Hsp70 pro-
tein provide evidence for a specific and concentra-
tion-dependent interaction of Hsp70 with YT cells.
In addition to Hsp70 and Hsp70C, a 14-mer Hsp70
peptide termed TKD is known to exhibit comparable
stimulatory properties on NK cells. Similar to full-
length Hsp70 protein (10 µg/ml– 50 µg/ml), a specific
binding of this peptide to YT cells was observed at 4°C,
at equivalent concentrations (2.0 µg/ml– 8.0 µg/ml).
Following a 30 min incubation period at 37°C, mem-
brane-bound Hsp70 protein and Hsp70 peptide TKD
were completely taken up into the cytoplasm. 
Key words: Binding studies /Hsp70 protein /
Hsp70 peptide /NK cell receptor CD94.
Introduction
Heat shock proteins (HSP) are highly conserved proteins
that inhabit nearly all subcellular compartments. Environ-
mental stress as well as differentiation, proliferation and
Interaction of Heat Shock Protein 70 Peptide with
NK Cells Involves the NK Receptor CD94
against Hsp70-positive tumor target cells is selectively
reduced by the addition of anti-CD94 antibody; other NK-
specific antibodies did not influence NK-mediated killing
(Multhoff et al., 1999).
Here the involvement of CD94 as a putative receptor
for Hsp70 is analyzed using the IL-2-independent, hu-
man NK cell line YT (Yodoi et al., 1985; Drexler and Mat-
suo, 2000). The Hsp70-YT cell interaction is investigated
in binding studies using either unconjugated or FITC-la-
beled full-length Hsp70 protein, the C-terminal domain of
Hsp70 (Hsp70C), and Hsp70 peptide TKD.
Results
Binding of Full-Length Hsp70 Protein (Hsp70) 
and the C-Terminal Domain of Hsp70 (Hsp70C) to
YT Cells
Previously, we observed that incubation of naive human
NK cells with full-length Hsp70 protein enhances the
cytolytic activity against Hsp70-positive tumor cells. This
stimulatory activity was concentration dependent
(10 µg/ml– 100 µg/ml) and restricted to Hsp70, the major
stress-inducible member of the HSP70 group. Other re-
lated members of this family, including Hsc70 (84% ho-
mology to Hsp70) or DnaK (50% homology to Hsp70),
did not stimulate NK cell activity (Multhoff et al., 1999). In
a first experiment, we wanted to know whether full-length
Hsp70 protein binds to the human NK cell line YT. Fol-
lowing incubation of YT cells with 50 µg/ml unlabeled
Hsp70 protein at 4°C, binding was measured by indirect
flow cytometry, using the Hsp70-specific monoclonal an-
tibody (mAb) SPA810. The epitope of SPA810 is localized
within the C-terminal domain of Hsp70 (Botzler et al.,
1998), but differs from that of the Hsp70-specific Ab
clone C92F3B1 (Multhoff et al., 2001). Only the latter mAb
inhibits the cytolytic activity of NK cells against Hsp70-
positive tumor target cells in antibody blocking studies
(Multhoff et al., 1995a,b). We assumed that the epitope of
clone C92F3B1 might be involved in the Hsp70-NK cell
interaction and therefore not be detectable in binding as-
says. As shown in Figure 1, a significantly increased
mean fluorescence value of the Hsp70 peak was ob-
served with the mAb SPA810, but not with the mAb clone
C92F3B1 (data not shown). As negative controls, YT cells
that had not been incubated with Hsp70 protein were
stained with the Hsp70-specific mAb SPA810 and sec-
ondary Ab (mAb ctrl, dashed line). In addition, Hsp70 pro-
tein-incubated YT cells were stained with an isotype-
matched control Ab and a secondary Ab (isotype ctrl,
dotted line).
Our previous data indicate that part of the C-terminal
substrate binding domain, and not the N-terminal ATP-
ase domain of Hsp70, is exposed to the extracellular mi-
lieu if expressed on the cell surface of Hsp70-positive tu-
mor cells (Botzler et al., 1998). Therefore, we asked the
question whether the C-terminal domain Hsp70C also
binds to YT cells. For these binding studies the fusion
protein Hsp70C-GST, consisting of the C-terminal do-
main of human Hsp70 (Hsp70C, aa 384 – 563) and glu-
tathione S-transferase (GST), was used. As shown in Fig-
ure 2A, the mean fluorescence value of the indirect
Hsp70-staining using the mAb SPA810, as compared to
the mAb SPA810 control of untreated YT cells (mAb ctrl,
dashed line), or the isotype-matched control of Hsp70C-
GST-treated YT cells (isotype control, dotted line), shifted
to the right. A similar staining pattern was obtained with a
GST-specific mAb (Figure 2B). As controls, either the
GST mAb (mAb ctrl) was incubated with untreated YT
cells, or Hsp70C-GST treated YT cells were incubated
with an isotype-matched control antibody (isotype ctrl).
As shown in Figure 2C, GST alone at an equivalent con-
centration did not bind to YT cells non-specifically. In
summary, these data indicate by indirect immunofluores-
cence studies that the NK cell line YT binds full-length
Hsp70 protein and the C-terminal domain Hsp70C fused
to GST; no binding of GST alone was observed. 
Phenotypic Characterization of YT Cells
Since naive NK cells have been found to interact with
Hsp70 proteins in a concentration-dependent manner,
we hypothesize that the NK cell line YT, similar to anti-
gen-presenting cells (APC), might express Hsp70-spe-
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Fig. 1 Hsp70 Protein Binding to YT Cells as Determined by In-
direct Immuno-Flow Cytometry.
YT cells (5×106/ml) were incubated with 50 µg/ml Hsp70 protein
at 4°C for 45 min. Binding of Hsp70 was measured by indirect
flow cytometry using Hsp70-specific mAb SPA810. This anti-
body detects an epitope within the C-terminal substrate binding
domain of Hsp70 that differs from that of the blocking Hsp70 an-
tibody, clone C92F3B1. Intensity of surface fluorescence (x-axis)
was plotted against cell counts. The dotted line represents the
isotype-matched control (isotype ctrl) of YT cells incubated with
Hsp70 protein; the dashed line represents the SPA810 mAb con-
trol (mAb ctrl) of YT cells that had not been incubated with Hsp70
protein; the solid line represents Hsp70 positively-stained cells.
Only viable PI-negative cells were used for the analysis. The data
show one representative experiment out of five. 
cific receptors on the cell surface. In an effort to identify
this putative Hsp70 receptor, a phenotypic characteriza-
tion was performed (Table 1). In addition to common YT
cell markers, T and newly defined NK cell-specific Killer
cell inhibitory/activating, Ig-like, superfamily receptors
(KIR) and C-type lectin receptors were tested (Braud
et al., 1998; Lanier et al., 1998; Lanier, 2000; Vales-
Gomez et al., 2000), as well as HSP receptors that had
been identified on APC (Binder et al., 2000a; Asea et al.,
2000a; Ohashi et al., 2000). As a positive control the
MHC class I expression was determined using the anti-
body W6/32. In line with published data (Drexler and
Matsuo, 2000), YT cells were found to be positive for the
pluripotent stem cell and leukemic marker CD7 (FcµR).
As an NK cell line, they lack expression of classical T cell
markers including CD3, CD6 and CD8. Several NK cell-
specific markers, including CD11b, CD16 (Lanier et al.,
1988), CD56, CD57, the immunoglobulins KIR p 58.1, p
58.2 (Moretta et al., 1995; Long, 1999) and the activating
C-type lectin receptor CD161 (Lanier et al., 1994) were
also not present on YT cells. Only CD94 is commonly
expressed by YT cells and Hsp70-reactive NK cells.
However, the expression levels of CD94 varied; a nega-
tive correlation was found with an increased cell density
of YT cells.
As mentioned earlier, several receptors, including the
α2-macroglobulin receptor CD91, the LPS receptor CD14,
and the Toll-like receptors TLR 2, 4, and 9, have been dis-
cussed as potential HSP receptors on APC that mediate
HSP binding and/or signal transduction (Asea et al.,
2000a,b; Binder et al., 2000a; Ohashi et al., 2000; Habich
et al., 2002). To understand their involvement in the inter-
action of NK cells with Hsp70, their membrane expression
was measured on YT cells. As summarized in Table 1, nei-
ther the α2-macroglobulin receptor CD91, which was
identified as a common receptor for gp96, Hsp90 and
Hsp70 on APC (Binder et al., 2000b; Basu et al., 2001), nor
one of the the Toll-like receptors (TLR 2, 4, 9) alone, or in
combination with CD14 (Asea et al., 2000a; Kol et al.,
2000), were found to be expressed on YT cells. 
CD94 Is Involved in the Binding of Hsp70-FITC to
YT Cells
Based on previous results with naive human NK cells, ex-
perimental evidence exists that the C-type lectin receptor
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Fig. 2 Binding of the Fusion Protein Hsp70C-GST to YT Cells
Is Detectable by Indirect Flow Cytometry Using Anti-Hsp70 and
Anti-GST mAb.
YT cells (5×106/ml) were incubated with 10 µg/ml of the fusion
protein consisting of the C-terminal domain of Hsp70 (Hsp70C)
and glutathione S-transferase (GST), or with the same amount of
GST (10 µg/ml), at 4°C for 45 min. Protein binding was measured
indirectly using either the Hsp70-specific mAb SPA810 (A) or the
GST-specific mAb (B and C). Intensity of surface fluorescence
(x-axis) was plotted against cell counts. The dotted line repre-
sents the isotype-matched control (isotype ctrl) of YT cells incu-
bated with Hsp70 protein; the dashed line represents the
SPA810 (A) or GST (B and C) mAb controls (mAb ctrl) of YT cells
that had not been incubated with Hsp70 protein; the solid line
represents either Hsp70 (A) or GST (B and C) positively stained
cells. Only viable PI-negative cells were used for the analysis.
The data represent one representative experiment out of three.
CD94 might be involved in the interaction with Hsp70: (i)
following incubation of isolated, pure NK cells with
Hsp70 protein or Hsp70C, the expression of CD94 was
up-regulated (Multhoff et al., 1999). (ii) The cytolytic activ-
ity of NK cells could be up-regulated by a 4-day incuba-
tion period with Hsp70 protein (Multhoff et al., 1999;
Hantschel et al., 2000). (iii) Antibody blocking studies us-
ing a CD94-specific antibody on the effector cells re-
duced the cytolytic response of NK cells against Hsp70-
positive tumor target cells specifically (Multhoff et al.,
1999). (iv) CD94 is commonly expressed on Hsp70-reac-
tive NK cells and the NK cell line YT (Table 1). Therefore,
there was a special interest in studying the role of CD94
as a potential receptor for the interaction with Hsp70. 
By flow cytometry we have shown a negative correla-
tion of cell density and CD94 expression on YT cells (Fig-
ure 3A). At elevated cell densities (0.8×106 cells/ml) the
CD94 expression was much weaker as compared to low
cell densities (0.1×106 cells/ml). If the cells were diluted in
fresh medium on day 0, day 2, day 4 and day 6, the per-
centage of CD94-positive cells increased from 13% to
23%. Concomitantly, the percentage of Hsp70C-GST
binding as determined by indirect immunofluorescence
studies increased from 12% to 42% (Figure 3A). These
data provide evidence that CD94 might be involved in the
interaction of YT cells with Hsp70.
To further support this hypothesis, antibody blocking
studies were performed. In these experiments Hsp70
binding was not only demonstrated by indirect flow cy-
tometry but also by direct means using FITC-labeled
Hsp70 protein. As shown in Figure 3B, 41% of the YT
cells were positively stained with the CD94 antibody. Fol-
lowing incubation with 20 µg/ml Hsp70-FITC for 45 min,
binding was found on 33% of the cells. This Hsp70-FITC
binding could be abrogated by preincubation of YT cells
with 5 µg/ml CD94 antibody; following antibody incuba-
tion only 6% Hsp70-FITC binding was detected (Fig-
ure 3B). As a control, a CD7-specific antibody was used
for blocking; this antibody did not affect Hsp70-FITC
binding (data not shown). 
Binding of Full-Length Hsp70 Protein to YT Cells Is
Specific and Concentration-Dependent
Specificity of Hsp70-FITC binding to CD94-positive YT
cells was confirmed by competition assays. Hsp70-FITC
binding (20 µg/ml) at a CD94 expression level of 41% was
33%. Upon addition of a 20-fold excess of unlabeled
Hsp70 (20x Hsp70), binding of Hsp70-FITC was com-
pletely suppressed (0% binding), whereas the identical
amount of unlabeled GST (20x GST) only weakly com-
peted for the Hsp70 binding site on YT cells. As shown in
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Table 1 Phenotypical Analysis of the NK Cell Line YT.
Antibody Specificity Positively stained cells (%) +/–
YT cell marker
W6/32 MHC class I 98.9±0.2 +
CD7 gp40, FcµR, YT positive ctrl T cell marker 93.3±0.7 +
CD3 gp20 – 50, TcR associated complex 1.4±0.2 –
CD6 gp100, thymocytes 0.0±0.0 –
CD8 gp32, cytotoxic, suppressor T 0.0±0.0 –
NK cell marker
CD11b gp165, C3biR 0.4±0.7 –
CD16 gp50 – 80, FcγR 2.8±3.7 –
CD56 gp180, N-CAM 1.5±0.9 –
CD57 p110, HNK1 0.0±0.0 –
CD161 gp60, C-type lectin, KAR 0.0±0.0 –
CD158a p58.1, p50.1, Ig-SFR, KIR/KAR 0.0±0.0 –
CD158b p58.2, p50.2, Ig-SFR, KIR/KAR 0.0± 0.0 –
CD94 gp43, C-type lectin R, KIR/KAR 20 – 45.8±6.0 +
HSP receptors on APC
CD91 p600, α2-macroglobulin receptor 1.8±0.7 –
CD14 gp55, LPS receptor 0.0±0.0 –
TLR 2 Toll-like receptor 2 1.0±0.8 –
TLR 4 Toll-like receptor 4 0.1±0.2 –
TLR 9 Toll-like receptor 9 2.9±0.2 –
IL-2 independent YT cells were cultured at cell densities ranging from 0.1 – 0.8×106 cells/ml (doubling
time: 40 – 50 h). The data represent mean values of at least three independent experiments. Cell sur-
face markers, commonly expressed by YT cells and Hsp70-reactive NK cells, are indicated in bold. A
negative correlation of the CD94 expression and increased cell densities was observed. Abbrevia-
tions: APC, antigen presenting cells; ctrl, control; gp, glycoprotein; LPS, lipopolysaccharide; MHC,
major histocompatibility complex; p, protein; R, receptor; TcR, T cell receptor.
Figure 4A, Hsp70-FITC binding was still 20% if a 20-fold
excess of unlabeled GST was applied together with
Hsp70-FITC. The data represent one experiment out of
three demonstrating identical results. To determine the
concentration range of specific Hsp70 binding, YT cells
were incubated with Hsp70-FITC at concentrations rang-
ing from 10 µg/ml to 50 µg/ml (Figure 4B). These concen-
trations have been defined as optimal for the stimulation
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Fig. 3 Hsp70 Protein Binding Is Associated with CD94 Cell Surface Expression on YT Cells.
CD94 expression was measured concomitant with Hsp70C-GST binding using a mAb directed against GST (A). YT cells were cultivat-
ed for seven days at decreasing cell densities (0.8, 0.4, 0.2, 0.1×106/ml). The CD94 expression increased with decreasing cell densities.
On days 1, 3, 5, and 7 YT cells were incubated with Hsp70C-GST fusion protein as described in Figure 2. 
Hsp70 binding was also determined directly using FITC-labeled Hsp70 protein (Hsp70-FITC; B). YT cells, either untreated (left panel) or
after preincubation with CD94 mAb (5 µg/ml) for 30 min (right panel), were incubated with 20 µg/ml Hsp70-FITC (B) at 4°C for 45 min. Fol-
lowing incubation cells were extensively washed with PBS and fixed in 1% PFA solution. The percentage of CD94-positive YT cells was
41%. The fluorescence pattern was analyzed by flow cytometry. The dashed line represents the autofluorescence; the solid line repre-
sents Hsp70 positively-stained cells. Specific Hsp70 protein binding is indicated in percent in the upper right corner of each graph.
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of naive NK cells (Multhoff et al., 1999). As negative con-
trols, bovine serum albumin (BSA-FITC) and glutathione
S-transferase (GST-FITC) were chosen and used at
identical concentration ranges. All proteins had been
conjugated to FITC with a comparable coupling efficien-
cy: for Hsp70-FITC it was calculated as 4.1, for BSA-
FITC as 4.4 and for GST-FITC as 4.5. YT cells were incu-
bated with 10, 25, and 50 µg/ml Hsp70-FITC, BSA-FITC,
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Fig. 4 Hsp70 Protein Binding to YT Cells Is Specific and Concentration-Dependent.
Specificity of Hsp70 binding was measured by competition assays (A). YT cells (5×106/ml) were incubated with 20 µg/ml Hsp70-FITC,
either alone or together with a 20-fold excess of unlabeled Hsp70 protein or unlabeled glutathione S-transferase (GST), at 4°C for
45 min. 41% of the YT cells were positively stained with CD94. 
Concentration-dependent binding was determined by incubation of YT cells with different amounts of Hsp70-FITC or BSA-FITC (B). YT
cells were incubated with 10, 25, or 50 µg/ml Hsp70-FITC (left), or BSA-FITC (right) as described in Figure 3.
Fig. 5 Specific and Concentration-Dependent Binding of Hsp70 Peptide TKD to YT Cells Is Associated with CD94 Expression.
The upper row shows flow cytometric analysis of the CD94 expression on the cell lines YT (21%) and K562 (0%). Below, TKD-FITC bind-
ing to YT (left) and to K562 cells (right) is illustrated. Identical cell numbers of viable YT and K562 cells (5×106/ml each) were incubated
with the following concentrations of TKD-FITC: 0.2, 2.0, 4.0, and 8.0 µg/ml for 45 min at 4°C. Only viable, PI-negative YT and K562 cells
were analyzed. Intensity of surface fluorescence (x-axis) was plotted against cell counts. The dashed line represents the autofluores-
cence; the solid line represents Hsp70 peptide positively stained cells. Specific peptide binding is indicated in percent in the upper right
corner of each graph, as the difference in the amount of positively stained cells minus autofluorescence-stained cells. 
and GST-FITC for 45 min. In order to avoid endocytosis
the whole incubation procedure was performed at 4°C.
As shown in Figure 4A, YT cells used in this experiment
exhibit CD94 expression on 44% of the cells. Specific
binding to YT cells was observed at all protein concen-
trations, a concentration of 10 µg/ml Hsp70-FITC result-
ed in 8% binding, 25 µg/ml in 29% binding, and 50 µg/ml
in 71% binding. At 10 µg/ml and 25 µg/ml, the negative
control protein BSA-FITC was not bound to YT cells (2%
and 4% binding, respectively); at a concentration of
50 µg/ml, binding of BSA-FITC was still significantly
weaker (27% binding) as compared to Hsp70-FITC (71%
binding). The solid line represents binding of Hsp70-FITC
in the left panel and of BSA-FITC in the right panel; auto-
fluorescence is shown by a dashed line. GST-FITC, as an
additional negative control protein, did not bind to YT
cells at a concentration of 50 µg/ml (data not shown).
However, concentrations above 50 µg/ml result in a non-
specific binding of all FITC-labeled proteins with YT cells
(data not shown). Regarding these results, we conclude
that a specific binding of Hsp70-FITC is detectable with-
in a concentration range of 10 µg/ml to 50 µg/ml. 
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Fig. 6 Specific Cell Surface Binding of FITC-Labeled Hsp70 Protein and Hsp70 Peptide TKD at 4°C (A, B, C), and Uptake Following
Incubation at 37°C (D, E, F) by YT Cells. 
Binding at 4°C: autofluorescence of untreated YT cells (A) incubated at 4°C for 45 min is shown in (A). YT cells were incubated either
with 50 µg/ml Hsp70-FITC (B) or 8.0 µg/ml TKD-FITC (C) at 4°C for 45 min, as described in the legend to Figure 5, fixed with 1%
paraformaldehyde and then analyzed for fluorescence microscopy at a magnification of 50×. 
Uptake at 37°C: YT cells were treated with BSA-FITC (50 µg/ml), Hsp70-FITC (50 µg/ml) and TKD-FITC (8 µg/ml), as described above
and then incubated at 37°C for 30 min, following extensive washing. After fixation in 1% paraformaldehyde, cells were analyzed for
transmission microscopy (middle row). The corresponding fluorescence microscopy (lower row) of YT cells incubated with BSA-FITC
(background fluorescence) is shown in (D), with Hsp70-FITC in (E), and with TKD-FITC in (F); magnification 50×.
Specific Binding of Hsp70 Peptide TKD to YT Cells
In addition to full-length Hsp70, a 14-mer Hsp70 peptide
localized in the C-terminal substrate binding domain of
Hsp70 (aa 450 – 463; TKDNNLLGRFELSG) has been
found to possess stimulatory properties on NK cells
(Multhoff et al., 2001). Therefore, we were interested in
examining whether the FITC-conjugated Hsp70 peptide
TKD also binds to YT cells in a concentration-dependent
manner. According to previous data the concentration
range was chosen between 0.2 µg/ml and 8.0 µg/ml
Hsp70 peptide. The CD94 expression on YT cells that
had been used for this binding study was 21% (Figure 5,
upper graph). As shown in the lower graph of Figure 5,
specific binding of TKD-FITC to the NK cell line YT was
observed at peptide concentrations of 2.0 µg/ml (12%
binding), 4.0 µg/ml (19% binding) and 8.0 µg/ml (40%
binding). An incubation of the CD94 negative control cell
line, K562, with identical peptide concentrations revealed
no significant binding of TKD-FITC. At a concentration of
8.0 µg/ml, the binding of TKD-FITC to YT cells as com-
pared to K562 cells was still increased by 10-fold; 4%
binding compared to 40%, respectively. Concentrations
above 8.0 µg/ml result in a non-specific interaction of the
Hsp70 peptide TKD to both cell types. Similar results
were seen with other CD94-negative cells (Küppner et al.,
2001). Binding studies using an irrelevant FITC-labeled
14-mer control peptide (PAASIDRSTKPPLL) revealed no
specific binding to YT cells (data not shown).
With respect to our Hsp70 protein and Hsp70 peptide
binding studies, we propose that specific binding of
Hsp70 protein to YT cells is found at concentrations of
10 µg/ml to 50 µg/ml and of Hsp70 peptide at equivalent
concentrations of 2.0 µg/ml to 8.0 µg/ml. These data
support previous work, which indicated that within these
concentration ranges both Hsp70 protein and Hsp70
peptide increase the cytolytic activity of naive NK cells
(Multhoff et al., 1999, 2001).
Binding and Uptake of Hsp70-FITC as Compared to
Hsp70 Peptide (TKD) by YT Cells
The binding of FITC-labeled Hsp70 protein (Hsp70-FITC)
and Hsp70 peptide TKD (TKD-FITC) was demonstrated
by indirect and direct flow cytometry, and could be con-
firmed by fluorescence microscopy. As compared to au-
tofluorescence (Figure 6A), YT cells incubated either with
50 µg/ml FITC-labled Hsp70 protein (B, Hsp70-FITC) or
with 8.0 µg/ml Hsp70 peptide (C, TKD-FITC) at 4°C for
45 min, exhibit a ring-shaped fluorescence (Figure 6, up-
per row). These data clearly indicate a typical cell surface
binding of Hsp70 protein and Hsp70 peptide TKD to the
NK cell line YT. In a second set of experiments, YT cells
were incubated with BSA-FITC (Figure 6D, 50 µg/ml),
Hsp70-FITC (E, 50 µg/ml) and Hsp70 peptide TKD-FITC
(F, 8 µg/ml), as described above. Following binding of
Hsp70 protein and peptide to YT cells at 4°C, the cells
were washed in order to remove non-specifically bound
FITC-labeled material. Then, viable cells were incubated
at the physiological temperature of 37°C for another
30 min. Following fixation, fluorescence microscopy was
performed. In the middle row of Figure 6, light mi-
croscopy of the protein- and peptide-treated, fixed YT
cells is illustrated. As shown in the corresponding fluo-
rescence microscopy (Figure 6, lower row), the ring-
shaped cell surface staining profoundly changes. As
compared to transmission microscopy, all cells that had
been pre-incubated either with Hsp70-FITC (E) or
TKD-FITC (F) exhibited a cytoplasmic staining pattern.
As a control, YT cells were incubated with BSA-FITC
(50 µg/ml) under identical conditions. Neither at 4°C nor
following incubation at 37°C was any staining observed
(D). These data provide evidence that Hsp70-FITC (E)
and TKD-FITC (F) have been selectively internalized from
the cell surface into the cytoplasm within 30 min.
Kinetic studies revealed that under physiological con-
ditions, already after 10 min 50% of the YT cells internal-
ized FITC-labeled Hsp70 from the cell surface (data not
shown). Regarding these results, we speculate that
Hsp70 protein and Hsp70 peptide uptake is a tempera-
ture-dependent, rapid process.
Discussion
Previously, we have shown that membrane-bound Hsp70
renders tumor cells more sensitive to the cytolytic activi-
ty of transiently plastic adherent, CD94-positive human
NK cells. This finding has been verified in several tumor
cell types including carcinomas, sarcomas and leukemia
(Multhoff et al., 1995a; Botzler et al., 1996; Multhoff,
1997; Hantschel et al., 2000). Within an autologous hu-
man colon carcinoma cell system, CX+ and CX-, which
differ only with respect to the Hsp70 cell surface expres-
sion pattern, the role of Hsp70 as the recognition site for
NK cells was determined (Multhoff et al., 1997). The effi-
ciency of human NK cells to eradicate Hsp70-positive
tumors could be confirmed in vivo in a xenograft
SCID/beige tumor mouse model (Multhoff et al., 2000). A
14-mer sequence, TKDNNLLGRFELSG (aa 450 – 463), in
the C-terminal substrate binding domain of Hsp70 could
be identified as a target recognition site for NK cells by
sequencing the epitope of the Hsp70-specific antibody
clone C92F3B1 (Welch and Suhan, 1986) that abrogates
NK-mediated lysis against Hsp70-positive tumor target
cells (Multhoff et al., 2001). This sequence has been
found to be unique for human Hsp70. Furthermore, it has
been demonstrated that incubation of purified, naive NK
cells with either full-length Hsp70 protein, the C-terminal
domain of Hsp70 (aa 384 – 563), or with the 14-mer
Hsp70 peptide TKD, induces comparative immunostimu-
latory effects (Multhoff et al., 1999).
Although the functional role of Hsp70 protein and
Hsp70 peptide on NK cells is clear, the molecular basis
for the interaction of Hsp70 protein, Hsp70C-terminus or
Hsp70 peptide remains to be elucidated. Since the avail-
ability of purified naive NK cells is limited, the leukemic
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NK cell line YT was used for binding studies. Our data
provide evidence for a specific and saturable interaction
of either unlabeled or FITC-conjugated Hsp70, Hsp70C
and Hsp70 peptide TKD with YT cells. For Hsp70 and
Hsp70C-GST fusion protein a specific binding to YT cells
was seen within a concentration range of 10 µg/ml to
50 µg/ml and for Hsp70 peptide TKD within a concentra-
tion range of 2.0 µg/ml to 8.0 µg/ml. These concentra-
tions have been found to stimulate NK cell function
(Multhoff et al., 1999, 2001; Hantschel et al., 2000).
Therefore, we propose that YT cells provide a reliable
model system to study Hsp70-NK interaction. Hsp70
protein concentrations above 50 µg/ml and Hsp70 pep-
tide concentrations above 8.0 µg/ml result in a non-spe-
cific interaction with different cell types. At these high
concentrations, Hsp70 is bound non-specifically also by
non-NK cells. These findings differ from published data
(Basu et al., 2001), which demonstrated a receptor-medi-
ated, specific binding of Hsp90, gp96, Hsc70 and Hsp70
to CD11b-positive macrophages at concentrations up to
200 µg/ml. With respect to these observations and due to
the fact that, compared to APC, NK cells fulfill different
immunological functions, we speculate that NK cells
might use other Hsp70 receptors that require different
concentrations. Several receptors, including CD91
(Binder et al., 2000b; Basu et al., 2001) and members of
the Toll-like receptor family, either alone or in a receptor-
complex with CD14 (Kol et al., 2000; Pfeiffer et al., 2001),
are presently discussed as putative HSP60, HSP70 and
HSP90 receptors on APC. To support our hypothesis that
NK cells use other Hsp70-specific receptors, the expres-
sion pattern of APC receptors was tested on YT cells.
None of these receptors was found on YT cells. Apart
from this observation, several other results support the
idea that the Hsp70 receptor on NK cells differs from that
on APC: NK cells selectively interact with Hsp70, the ma-
jor stress-inducible member of the HSP70 family. Neither
the E. coli-derived Hsp70 homologue DnaK (50% homol-
ogous to Hsp70) nor the constitutively expressed, highly
homologous human Hsc70 (84% homology to Hsp70)
were able to stimulate NK cell activity (Multhoff et al.,
1999). In contrast, APCs have been found to interact with
several HSPs, including Hsc70, Hsp70, Hsp90, gp96,
and Hsp60 (Kol et al., 2000; Ohashi et al., 2000; Habich
et al., 2002). However, it is still a matter of debate as to
which receptors interact with a distinct HSP. For NK cells,
a 14-mer Hsp70 peptide derived from the C-terminal do-
main of Hsp70 could be determined as the minimal stim-
ulatory sequence (Multhoff et al., 2001). This peptide se-
quence has been found to be unique for the human
stress-inducible Hsp70 as determined by protein data-
base blast search (Altschul et al., 1997). Already two con-
servative amino acid exchanges within this peptide at po-
sitions 458 and 462 abrogate the stimulatory activity of
the peptide. To our knowledge, no HSP70 or HSP90 pep-
tide sequence has been identified that exhibits such se-
lectivity for APCs. 
Although saturability and specificity, as two attributes
of a receptor-ligand interaction, have been demonstrated
for the interaction of Hsp70 protein and Hsp70 peptide
with NK cells, and although it became obvious that APCs
use different receptors, the molecular nature of the puta-
tive Hsp70 receptor on NK cells remains elusive. Our data
provide evidence that the C-type lectin receptor CD94,
known to interact with HLA-E molecules, presenting
leader peptides of MHC class I molecules (Braud et al.,
1998; Lanier et al., 1998; Long, 1999), is involved in
Hsp70 interaction. An increased CD94 expression is ob-
served if purified NK cells are incubated either with
Hsp70 protein or the Hsp70 peptide TKD in combination
with low dose IL-2. A CD94 antibody specifically reduces
the cytolytic activity of NK cells against Hsp70-positive
tumor target cells (Multhoff et al., 1999; Multhoff et al.,
2001) and also suppresses binding of Hsp70 to YT cells.
Finally, Hsp70 binding correlates with the expression lev-
els of CD94, and CD94 is the only receptor commonly ex-
pressed on the cell surface of NK cells and the NK cell
line YT. However, CD94 alone is unlikely to be responsible
for the interaction with Hsp70 for several reasons: (i)
CD94 as a homodimer is unable to mediate cell signalling
and (ii) transiently CD94 transfected COS cells did not ex-
hibit significant Hsp70 protein or Hsp70 peptide binding
(data not shown). Although our data support the idea that
CD94 is involved in the interaction of NK cells with Hsp70
protein and Hsp70 peptide TKD, the co-receptor of CD94
that mediates signalling following contact with Hsp70
has not yet been defined.
Materials and Methods
Cell Lines
The IL-2 independent, CD7-positive, leukemic NK cell line YT
(ACC 434, DSMZ, Heidelberg, Germany) was cultivated in
RPMI-1640 medium (Gibco-BRL, Life Technologies, Rockville,
USA) supplemented with 10% heat-inactivated fetal calf serum
(FCS, BioWhittaker, Walkersville, USA), 1 mM sodium pyruvate,
2 mM L-glutamine, 1% penicillin-streptomycin (all supplements
were purchased from Life Technologies); doubling time was be-
tween 40 and 50 h at constant cell densities ranging from
0.1 – 0.8×106 cells/ml. Increasing cell densities correlate with de-
creased CD94 expression; cell densities above 0.8×106 cells/ml,
result in a significantly decreased cell viability (Yodoi et al., 1985;
Drexler and Matsuo, 2000). 
The myelogenous cell line K562 was purchased from ATCC
(CCL 243, Rockville, USA) and grown in YT cell medium. The
non-NK cell line K562 was used as a negative control in binding
studies.
Monoclonal Antibodies and Flow Cytometry
The following mouse or rat-anti-human monoclonal antibodies
(mAb), either unconjugated* or fluorescein-conjugated, were
used for the phenotypic characterization of YT cells and for
binding studies: isotype-matched control antibodies (Becton
Dickinson, Heidelberg, Germany; Coulter Immunotech, Mar-
seille, France), CD3 (IgG1, Dianova, Hamburg, Germany), CD6
(IgG1, Pharmingen, Becton Dickinson, Heidelberg, Germany),
CD7 (IgG2a, Coulter, Immunotech), CD8 (IgG1, Dianova),
CD11b* (IgG1, Coulter Immunotech), CD16 (IgG1, Becton Dick-
276 C. Gross et al.
inson), CD56 (IgG2b, Becton Dickinson), CD57 (IgM, Coulter Im-
munotech), CD91* (IgG1, Progen Biotechnik, Heidelberg, Ger-
many), CD94 (IgG1, HP-3D9, Ancell Immunology Research
Products, Bayport, USA), CD158a (IgG1, p58.1, Coulter Im-
munotech), CD158b (IgG1, p58.2, Coulter Immunotech), CD161
(IgG2a, Coulter Immunotech), NKG2A (IgG1, Z270, kindly pro-
vided by L. Moretta), W6/32* (IgG2a, Cymbus Biotechnology, Di-
anova), TLR 2 (IgG2a, eBioscience, San Diego, USA), TLR 4
(IgG2a, eBioscience), TLR 9* (IgG1, Biocarta Europe, Hamburg,
Germany), Hsp70* mAbs (IgG1, SPA810, StressGen, British
Columbia, Canada), and clone C92F3B1 (IgG1, multimmune
GmbH, Regensburg, Germany) (Welch and Suhan, 1986), glu-
tathione S-transferase (GST) rat-anti-human mAb (kindly provid-
ed by Dr. E. Kremmer, GSF – Institute for Molecular Immunology,
Munich, Germany). All antibody preparations contained 0.1%
sodium azide. 
For flow cytometry, 0.5 – 1×106 cells were incubated for 30 min
at 4°C, either with unconjugated* or fluorescence-conjugated
primary mAbs. After washing in PBS conditioned with 2% FCS,
the cells were either analyzed directly by flow cytometry or fol-
lowing incubation with a secondary FITC-rabbit anti-mouse/rat
Ig Ab (Dianova, Hamburg, Germany) for another 30 min at 4°C.
Then, the cells were analyzed on a FACSCalibur instrument
(Becton Dickinson). The percentage of positively-stained cells
was calculated as the number of specifically-stained, propidi-
um-iodide (PI)-negative, viable cells minus the number of cells
stained with an isotype-matched control antibody.
FITC-Labeling of Hsp70 Protein, Bovine Serum Albumin
(BSA), Glutathione S-Transferase (GST) and Hsp70 Peptide
TKD
Hsp70 protein (1 mg/ml; StressGen), BSA (1 mg/ml; fraction V;
Sigma, St. Louis, USA), and GST (1 mg/ml; Sigma) were incu-
bated with fluoresceine-isothiocyanate (FITC, isomer I, Sigma) in
0.1 M sodium bicarbonate (pH 9.5) overnight at 4°C. Unconju-
gated dye was removed by passing the reaction mixture over a
PD-10 desalting column (Sephadex G-25, Amersham Bio-
science, Uppsala, Sweden) equilibrated in PBS. Eluted fractions
containing FITC-labeled protein were pooled and stored at 4°C
in the dark. 
The number of dye molecules bound per molecule protein
was determined by measuring the OD at 280 nm and 495 nm. It
was calculated as 4.1 for Hsp70 protein, 4.4 FITC molecules for
BSA, and 4.5 FITC molecules for GST, respectively. Before use
the solutions of the FITC-labeled proteins were centrifuged at
100 000 g in order to remove small particles.
FITC-labeled Hsp70 peptide TKD (Multhoff et al., 2001) was
derived as a 94.3% pure, 2038.23 Da (C92H128N22O29S) FITC-γ-
Abu-TKDNNLLGRFELSG-OH lyophylized material (Bachem,
Bubendorf, Switzerland). The powder was diluted in sterile PBS
at a stock concentration of 1 mg/ml. All experiments using FITC-
labeled proteins and peptides were performed with identical
stock solution, within three months.
Binding of BSA, GST, Hsp70 Protein, Hsp70C and Hsp70
Peptide TKD to YT Cells
For binding studies, the following proteins and peptides, either
unlabeled or FITC-labeled, were used: bovine serum albumin
(BSA), glutathione S-transferase (GST), full-length recombinant
Hsp70 protein (Hsp70; SPP755, StressGen), a fusion protein,
consisting of the C-terminal substrate binding domain (aa
384 – 563) of Hsp70 and glutathione S-transferase, (Hsp70C-
GST), and Hsp70 peptide TKD. Briefly, YT cells (5×106 cells/ml),
harvested at a cell density of 0.1 – 0.8×106, were incubated for
45 min at 4°C with proteins and peptides at different concentra-
tions in a total volume of 1 ml PBS containing 2% FCS. For BSA
and Hsp70 protein the concentrations 10, 25, 50, and 100 µg/ml,
for Hsp70C-GST 10 µg/ml and for Hsp70 peptide TKD 0.2, 2.0,
4.0, and 8.0 µg/ml, were used. Binding of non-FITC-labeled pro-
teins was measured indirectly by flow cytometry, using mAbs
against Hsp70 (SPA810, StressGen) and against GST. Binding of
FITC-labeled BSA, GST, Hsp70 protein, and Hsp70 peptide TKD
was determined by direct flow cytometry, after incubation of vi-
able, non-fixed YT or K562 cells with the relevant labeled or un-
labeled proteins and peptides, at 4°C. Directly before flow cyto-
metric analysis the cells were co-stained with propidium iodide
(PI). Only PI-negative viable cells were gated and analyzed on a
FACSCalibur instrument. As negative controls, either the fluo-
rescence of untreated cells was determined (autofluorescence),
or untreated cells were stained with primary and secondary
mAbs (mAb ctrl), or cells treated with protein were incubated
with the relevant isotype-matched control Ab and secondary Ab
(isotype ctrl). Binding was determined in percent: the amount of
untreated cells (autofluorescence) or cells incubated with the
adequate negative control Abs was subtracted from the amount
of positively-stained cells that had been incubated with the dif-
ferent proteins and peptides. 
Fluorescence Microscopy
In order to visualize binding, 5×106 YT cells were incubated for
45 min at 4°C, with 50 µg/ml Hsp70-FITC or with 8.0 µg/ml TKD-
FITC, as described above. Protein and peptide uptake were
studied on non-fixed cells that were allowed to bind TKD-FITC
and Hsp70-FITC at 4°C. After two washing steps in PBS, the
cells were incubated at 37°C for 30 min. 
Following cytospin, the paraformaldehyde-fixed cells were
embedded in Fluorescent Mounting Medium (Neo-Mount, Mer-
ck, Darmstadt, Germany). The samples were analyzed for trans-
mission and fluorescence using a Zeiss Axioscop 2 scanning
microscope (Zeiss Jena, Germany) equipped with a 63× (apo-
chromat) objective. 
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Cell surface-bound heat shock protein 70 (Hsp70) ren-
ders tumor cells more sensitive to the cytolytic attack
mediated by natural killer (NK) cells. A 14-amino acid
Hsp70 sequence, termed TKD (TKDNNLLGRFELSG,
aa450–463) could be identified as the extracellular local-
ized recognition site for NK cells. Here, we show by
affinity chromatography that both, full-length Hsp70-
protein and Hsp70-peptide TKD, specifically bind a 32-
kDa protein derived from NK cell lysates. The serine
protease granzyme B was uncovered as the 32-kDa
Hsp70-interacting protein using matrix-assisted laser
desorption ionization time-of-flight mass peptide finger-
printing. Incubation of tumor cells with increasing con-
centrations of perforin-free, isolated granzyme B shows
specific binding and uptake in a dose-dependent man-
ner and results in initiation of apoptosis selectively in
tumor cells presenting Hsp70 on the cell surface. Re-
markably, Hsp70 cation channel activity was also deter-
mined selectively in purified phospholipid membranes
of Hsp70 membrane-positive but not in membrane-neg-
ative tumor cells. The physiological role of our findings
was demonstrated in primary NK cells showing elevated
cytoplasmic granzyme B levels following contact with
TKD. Furthermore, an increased lytic activity of Hsp70
membrane-positive tumor cells could be associated with
granzyme B release by NK cells. Taken together we pro-
pose a novel perforin-independent, granzyme B-medi-
ated apoptosis pathway for Hsp70 membrane-positive
tumor cells.
Elevated cytoplasmic Hsp701 levels have been found to pro-
tect tumor cells against programmed cell death (1). However,
evidence has accumulated indicating that the presence of
Hsp70 on the plasma membrane or in the extracellular milieu
is highly immunogenic and exposes target cells to immunolog-
ical attack (2). Following receptor-mediated uptake (3) and
re-presentation by antigen presenting cells, HSP-chaperoned
peptides elicit a cytotoxic, CD8 T cell response (4). Recently,
several receptors, including CD91, Toll-like receptors 2/4
(TLR2/4), and CD40 (5) have been identified to mediate the
interaction of HSP90- (gp96), HSP70- (Hsp70, Hsc70), and
HSP60-peptide complexes with antigen presenting cells (6–9).
A peptide-independent “chaperokine effect” has been described
for members of the HSP70 family. Binding of exogeneous
HSP70 to monocytes via TLR2/4 induces receptor clustering in
a CD14-dependent pathway (10) and the secretion of proin-
flammatory cytokines via the MyD88/IRAK/NF-B signal
transduction pathway (11–13). We detected Hsp70, the major-
stress inducible member of the HSP70 family, selectively in the
plasma membrane of tumor cells, but not in normal cells by cell
surface biotinylation and immunofluorescence (14). This find-
ing was confirmed most recently by proteomic profiling of tu-
mor cell membranes (15).
The amount of membrane-bound Hsp70 on tumor cells pos-
itively correlates with their sensitivity to lysis mediated by
natural killer (NK) cells. Physical (i.e. heat, irradiation) and
chemical (i.e. cytostatic drugs, alkyllysophospholipids) stress
has been found to increase Hsp70 surface expression on tumor
cells and thereby renders them better targets for NK cells
(16–18). Incubation of purified NK cells with recombinant
Hsp70 increases the cytolytic activity against Hsp70 mem-
brane-positive tumor cells (19). NK cells have been found to
interact specifically with a 14-amino acid Hsp70 sequence,
termed TKD (TKDNNLLGRFELSG, aa450–463), on the C-ter-
minal of this protein. This region (TKD) is present in the
ectoplasmic domain of viable tumor cells (20). Therefore, it was
not surprising that similar to full-length Hsp70 (19), Hsp70-
peptide TKD exhibits a comparable immunostimulatory capac-
ity to NK cells (20). Although the preceding observations indi-
cate that Hsp70-peptide functions as a tumor-selective target
recognition structure for NK cells (21), the mechanism by
which NK cells lyse Hsp70 membrane-positive tumor target
cells remained to be elucidated.
EXPERIMENTAL PROCEDURES
Cells
The NK cell line YT was cultured at low cell densities ranging
between 0.1 and 0.5  106 cells/ml in RPMI 1640 medium (Invitrogen)
containing 10% fetal calf serum (Invitrogen) supplemented with 6 mM
L-glutamine and antibiotics (100 IU/ml penicillin and 100 g/ml strep-
tomycin; Invitrogen).
The tumor sublines CX/CX and Colo/Colo were derived by cell
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sorting of CX-2 colon (Hsp70 positive: 60%) and Colo357 pancreas
(Hsp70 positive: 60%) carcinoma cell lines using the Hsp70-specific
monoclonal antibody C92F3B1 (Multimmune GmbH, Regensburg,
Germany), according to a previously described protocol (21). Hsp70
stably high expressing CX (Hsp70 positive: 80%) and Colo (Hsp70
positive: 85%) carcinoma sublines differ significantly from Hsp70 stably
low expressing CX (Hsp70 positive: 25%) and Colo (Hsp70 positive:
35%) carcinoma cells. Carcinoma sublines and the non-NK leukemic
cell line K562 were cultured in RPMI 1640 medium supplemented with
5% fetal calf serum, 6 mM L-glutamine and antibiotics. Exponentially
growing tumor cells (day 1 after feeding of the cells) were used for
granzyme B and camptothecin treatment.
All cell lines were screened regularly for mycoplasma contaminations
by an enzyme immunoassay detecting Mycoplasma arginini, Myco-
plasma hyorhinis, Achdeoplasma laidlawii, and Mycoplasma orale
(Roche Diagnostics). Only mycoplasma-free cell lines were used.
Primary NK cells were generated by CD3-depletion of peripheral
blood mononuclear cells using a standard Miltenyi biotin separation
method (Miltenyi, Bergisch Gladbach, Germany). Sorted cells were
activated by incubation of the NK cells for 3 days in supplemented
RPMI 1640 medium containing 100 IU/ml interleukin-2 (Chiron, Ratin-
gen, Germany) and 2 g/ml Hsp70-peptide TKD (TKDNNLL-
GRFELSG, aa450–463, Bachem Bubendorf, Switzerland).
Affinity Chromatography and Immunoprecipitation
Bovine serum albumin (BSA, 1 mg/ml, Sigma), lyophilized, recombi-
nant human Hsp70-protein (1 mg/ml, StressGen, British Columbia,
Canada), and Hsp70-peptide TKD (1 mg/ml, Bachem, Bubendorf,
Switzerland) were incubated with equilibrated AminoLink-agarose
beads (2 ml, Pierce) for 6 h, together with the reductant NaCNBH3,
followed by removal of uncoupled material by extensive washes with
Tris buffer and quenching non-reactive groups. Binding capacity of
BSA, Hsp70-protein, and Hsp70-peptide TKD was greater than 95%.
Cell lysates of NK cells and the leukemic non-NK cell line K562 were
loaded onto BSA, Hsp70-protein, and Hsp70-peptide TKD-conjugated
columns for 1 h at room temperature.
Columns were washed with 10 column volumes of 20 mM Tris buffer,
bound proteins were eluted with 3 M sodium chloride in 20 mM Tris
buffer, in 5 fractions (1 ml). Each fraction was subjected to a SDS-PAGE
using a 10% polyacrylamide slab gel and transferred onto polyvinyli-
dene difluoride membranes.
Western Blot Analysis
Blots were blocked with skim milk (0.1%) and incubation with mono-
clonal antibody directed against granzyme B (2C5, IgG2a, BD Bio-
sciences, Heidelberg, Germany), for 5 h at 4 °C. Blots were washed and
incubated with a secondary mouse anti-IgG horseradish peroxidase
antibody (Dianova, Hamburg, Germany), for 1 h at 4 °C. Proteins were
detected using the ECL kit (Amersham Biosciences) for 5 s.
Protein Identification by Peptide Mass Fingerprinting
A 32-kDa protein band was isolated by affinity chromatography on
immobilized Hsp70-protein or Hsp70-peptide TKD, which was excised
from Coomassie Blue-stained gels, digested with trypsin, and desalted
using reversed phase ZIP tips (Millipore, Eschborn, Germany). The
samples were embedded in 4-hydroxy--cyanocinnamic acid and the
peptide masses were determined with a Perseptive Voyager DePro
matrix-assisted laser desorption ionization-time of flight (MALDI-TOF)
mass spectrometer in reflective mode. A peaklist was compiled with the
m/z software (Proteometrics) and used for peak selection; the resulting
peptide mass fingerprint was used to search the non-redundant NCBI
protein data base using the Profound search engine (Proteometrics).
Granzyme B was identified with 100% probability and 95% confidence.
Membrane Preparation
Membrane purification was performed by Dounce homogenization
(100  106 tumor cells) in hypotonic, EDTA-free buffer containing the
protease inhibitor phenylmethylsulfonyl fluoride followed by sequential
centrifugation at 1,000  g for 5 min and at 100,000  g, at 4 °C, for 60
min. The pellet containing membranes was resuspended in 2 ml of 0.3
M NaCl in 50 mM Tris buffer, 0.5% Nonidet P-40, pH 7.6.
Cation Channel Activity Measurements
Large unilamellar liposomes were prepared from plasma membranes
derived of Hsp70 membrane-positive and membrane-negative tumors
and applied to an orifice of about 100–120 m in diameter with a Teflon
film separating two compartments. The ionic solutions containing ei-
ther symmetrical concentrations of KCl (200cis/200trans mM) or asym-
metric concentrations (200cis/50trans mM) and 5 mM K-Hepes, 7.1 mM
MgCl2, 0.5 mM CaCl2, and ATP (2 mM). The two ionic compartments
were electrically connected via agar bridges and Ag/AgCl pellet elec-
trodes to the input of a voltage clamp amplifier. Current was recorded
using patch clamp amplifier (Axopatch-1D; Axon Instruments, CA) and
data were stored on a PCM/VCR digital system (Toshiba) with a fre-
quency response in the range from direct current to 25,000 Hz. Off-line
analysis of the channel activity was carried out using the software
package Pclamp 6 and Axosope (Axon Instruments).
Flow Cytometry
Cells (0.5  106) were fixed in paraformaldehyde (1% paraformalde-
hyde in PBS) for 10 min, and permeabilized in PBS containing BSA
(0.5%), NaN3 (0.1%), and saponin (0.1%). Permeabilized cells were
incubated either with the granzyme B-phycoerythrin (PE)-conjugated
monoclonal antibody HC2-PE (IgG1; Hölzel Diagnostika, Cologne,
Germany) or with an isotype-matched IgG1 control antibody, at 4 °C for
1 h, in the dark. Following washing intracellular localized granzyme B
was analyzed on a FACSCalibur instrument (BD Biosciences).
Treatment
Stock solutions of camptothecin (4 mg/ml, Sigma, Munich, Germany)
were diluted in dimethyl sulfoxide and stored at 4 °C in the dark.
Granzyme B (Hölzel Diagnostics, Cologne, Germany) solutions were
freshly prepared directly before usage. Exponentially growing cells
(0.5–1.5  106/ml) were incubated either with camptothecin at a final
concentration of 4 g/ml or with purified, enzymatically active gran-
zyme B (10 ng/ml, 1 g/ml, 2 g/ml, 4 g/ml) (22) for 10 min, and 30 min
either at 4 or 37 °C. After washing in RPMI 1640 medium binding and
uptake was determined in non-permeabilized and permeabilized tumor
cells by flow cytometry and fluorescence microscopy on a Axioscop 25
scanning microscope (Zeiss, Jena, Germany) equipped with a 40 ob-
jective and standard filters. Images were treated by multiplicative
shading correction using the software Axiovison (Zeiss Vison, Jena,
Germany). Granzyme B was visualized in red by using the HC2-PE
antibody.
Apoptotic cell death was measured after incubation of tumor cells
with 10 ng/ml granzyme B for 4, 12, and 24 h by different apoptosis
assays, as described below.
Apoptosis Assays
Annexin V-FITC Staining—Briefly, cells were washed twice in Hepes
buffer containing 5 mM CaCl2 and incubated with annexin V-FITC
(Roche Diagnostics) for 10 min at room temperature. Annexin V-FITC
positively stained cells were measured on a FACSCalibur flow cytom-
eter (BD Biosciences).
DAPI Staining—Methanol/acetone fixed cells (0.1  106 cells/100 l)
were incubated with 0.5 g/l 4,6-diamino-2-phenylindole (DAPI) in
PBS/glycerol (3:1) for 15 min in the dark. Following washing in PBS the
cells were mounted with fluorescent mounting medium (Dako,
Glostrup, Denmark) and analyzed for fluorescence using a Zeiss model
Axioscop 2 scanning microscope (Zeiss, Jena, Germany) equipped with
a 40 objective and standard filters. Apoptosis was visualized with
DAPI staining in 50 cells, each. Images were treated by multiplicative
shading correction using the software Axiovision (Zeiss).
Cytochrome c—Cytochrome c was determined using a quantitative
immunoassay (DCDCO, R&D Systems, Wiesbaden, Germany). Briefly,
untreated, camptothecin (4 g/ml), or granzyme B (10 ng/ml)-treated
cells (1.5  106/ml) were washed in PBS and treated with lysis buffer for
1 h at room temperature. Following centrifugation at 1,000  g for 15
min, supernatants were removed and 200 l of a 1:100, 1:250, and a
1:500 dilution was used for a sandwich enzyme-linked immunosorbent
assay. Following incubation with substrate solution in the dark for 30
min the reaction was stopped. The optical density of each well was
determined on an enzyme-linked immunosorbent assay reader at 450
nm. The amount of cytochrome c was determined according to a cali-
bration curve.
51Cr Release Assay and Inhibition Assay
NK cell-mediated cytotoxicity was measured using a 12-h 51Cr radi-
oisotope assay. As target cells the colon carcinoma sublines CX and
CX were used. For blocking studies the monoclonal antibody C92F3B1
and an isotype matched control antibody (IgG1) were used at a final
concentration of 5 g/1  106 cells. Following incubation of CX and
CX target cells with the antibodies for 30 min at 4 °C, the cells were
labeled with 51Cr and the cytotoxicity assay was performed as described
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by MacDonald (23). The percentage of specific lysis was calculated as:
[(experimental release  spontaneous release)/(maximal release 
spontaneous release)]  100.
Granzyme B ELISPOT
Granzyme B release was compared in unstimulated NK cells (NK d0)
and TKD-stimulated NK cells (NK d3) after a 4-h co-incubation period
with tumor cell lines CX/CX and Colo/Colo, at different effector
to target cell ratios (E:T) ranging from 20:1 to 2:1. For detection a
granzyme B ELISPOT kit (number 552572, BD Biosciences) was used.
Briefly, 96-well ELISPOT plates (MAIPN45, Millipore) were coated
overnight at 4 °C with capture antibody, blocked with RPMI 1640
culture medium containing 10% fetal calf serum and incubated with
tumor and effector cells for 4 h at 37 °C, as specified before. After
washing in deionized water and wash buffers A and B, biotinylated
anti-granzyme B antibody was added (2 g/ml) for 2 h. After another
two washing steps granzyme B was visualized by the addition of freshly
prepared avidin-horseradish peroxidase (1 h) and substrate solution (25
min incubation period). Spots were counted automatically using
Immuno Spot Series I analyzer.
RESULTS
Granzyme B Is a Partner of Hsp70 and Hsp70-Peptide TKD—
Proteins that interact with Hsp70 were identified by affinity
chromatography on immobilized Sepharose columns coupled
either with human Hsp70-protein or a peptide derived from the
C-terminal region of Hsp70, termed TKD (TKDNNLL-
GRFELSG, aa450–463). TKD corresponds to 14-amino acids lo-
calized in the extracellular domain of Hsp70, present on Hsp70
membrane-positive tumor cells, which mediate recognition by
NK cells (20). TKD was used in the affinity column to exclude
the recognition of proteins by the substrate binding domain of
Hsp70. Recently, we showed that Hsp70-protein and TKD,
specifically bind to the NK cell line YT (24). Therefore, we
assumed that YT cells provide an ideal tool for identifying
Hsp70-interacting partners. YT cell lysates were fractionated
on immobilized Hsp70 and TKD columns. The material bound
to the columns was eluted with 3 M sodium chloride in five
fractions. As controls, YT cell lysates were administered to
carrier or BSA-conjugated columns. Moreover, lysate of a
non-NK cell line (K562) was fractionated on TKD-conjugated
affinity column. The eluted fractions were separated by SDS-
PAGE and visualized by silver staining. A dominant protein
band of apparent molecular weight of 32,000 was observed in
fractions two (F2) and three (F3) of YT cell eluates derived from
Hsp70-protein (Hsp70) or Hsp70-peptide (TKD) columns (Fig.
1A). This band was not detectable in eluates of carrier (data not
shown) or BSA-conjugated columns nor in material eluted from
the TKD affinity columns loaded with K562 cell lysates (Fig.
1A). Additionally, the 32-kDa protein band derived from F3
was excised from a SDS-PAGE stained with Coomassie Blue
and digested with trypsin (Fig. 1B). The resulting peptides
were analyzed by MALDI-TOF peptide mass fingerprinting.
Sequences of the tryptic peptides exhibited 100% homology
with granzyme B (Fig. 1B). The identity of the 32-kDa protein
FIG. 1. Identification of granzyme B as the interacting partner
for Hsp70-protein and Hsp70-peptide TKD. A, Hsp70-protein
(Hsp70), BSA, and Hsp70-peptide (TKD) columns were incubated either
with cell lysates of the NK cell line YT or the non-NK cell line K562.
Bound proteins were eluted from the columns in 5 fractions (F1–F5),
resolved on SDS-PAGE. Following silver stain, eluates of YT cells
derived from Hsp70 and TKD columns revealed a dominant 32-kDa
protein band in fractions two (F2) and three (F3). No 32-kDa protein
band was detectable in YT eluates derived from BSA columns and in
K562 eluates derived from TKD columns. The position of the 32-kDa
band is indicated with an arrowhead. B, the tryptic peptides of the
Coomassie Blue-stained 32-kDa band of fraction 3 (F3), derived from
the TKD column, correspond to human granzyme B. The probability of
identification was 100% and the estimated Z-score was 1.89 correspond-
ing to 95% confidence. C, corresponding Western blot analysis of YT
and K562 cell eluates (F3) following incubation with Hsp70-protein
(Hsp70) and Hsp70-peptide (TKD) columns. The blot was autoradio-
graphed and the localization of granzyme B was visualized by immu-
nostaining with the granzyme B specific monoclonal antibody 2C5.
Eluates of YT cells (left), but not of K562 cells (right) revealed a 32-kDa
granzyme B protein band. D, intracellular flow cytometry of permeabi-
lized YT cells (left) and K562 cells (right) using the PE-conjugated
granzyme B-specific monoclonal antibody HC2-PE (solid line), as com-
pared with an isotype-matched negative control antibody (dashed line).
Only YT cells, but not K562 cells, contain cytoplasmic granzyme B.
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band as granzyme B was further confirmed by Western blot
analysis using a specific antibody (2C5) against granzyme B.
Fractionation of YT cell lysates on Hsp70-protein (Hsp70) and
Hsp70-peptide (TKD) columns revealed the presence of gran-
zyme B protein band by Western blotting (Fig. 1C). However,
no granzyme B was detected in the eluted fraction of Hsp70
and TKD affinity columns loaded with K562 cell lysates (Fig.
1C). Also flow cytometry using a phycoerythrin-conjugated
granzyme B antibody HC2-PE showed positive staining for
cytoplasmic granzyme B in YT cells, but not in K562 cells
(Fig. 1D). In summary, these data indicate that granzyme B
interacts with full-length Hsp70-protein as well as Hsp70-
peptide TKD.
Specific Binding and Internalization of Granzyme B in
Hsp70 Membrane-positive Tumor Cells—The preceding find-
ings posed the question whether membrane-bound Hsp70
might enable specific binding and entry of granzyme B into the
cytosol. Therefore, perforin-free, purified granzyme B was co-
incubated with tumor cell sublines CX/CX and Colo/
Colo that exhibit differential Hsp70 membrane expression. A
light microscopical analysis of untreated CX and Colo cells
(control) at 4 versus 37 °C is shown in the upper row of each
panel (Fig. 2A). The corresponding immunofluorescence mi-
croscopy of the cells at 4 and 37 °C is illustrated below (control).
Initially, none of the cells showed any granzyme B staining,
neither on the cell surface nor in the cytoplasm. However, after
a 15-min incubation period of the cells with purified granzyme
B (grB) at 4 °C, a ring-shaped fluorescence, indicating a typical
cell surface staining, was detected on Hsp70 membrane-posi-
tive CX and Colo tumor sublines (Fig. 2A, left panel). A
temperature shift from 4 to 37 °C during the 30-min incubation
period resulted in uptake of granzyme B, as determined by a
cytoplasmic staining pattern in CX and Colo tumor sublines
(Fig. 2A, right panel). In contrast, the Hsp70 membrane-nega-
tive counterparts CX and Colo neither exhibited any gran-
zyme B cell surface binding at 4 °C nor uptake at 37 °C (data
not shown). Flow cytometry analysis of permeabilized cells
revealed a faint shift of the granzyme B peak to the right
selectively in Hsp70 membrane-positive CX and Colo, but
not in CX and Colo tumor sublines, if the cells were co-
incubated with 1 g/ml granzyme B for 30 min at 37 °C (Fig.
2B, upper graph). A dose-dependent increase in granzyme B
uptake, in Hsp70 membrane-positive tumor cells (CX/Colo),
was detected after co-incubation with 2 and 4 g/ml granzyme
B (Fig. 2B, lower graph). However, even at the highest concen-
tration of 4 g/ml, granzyme B was internalized much more
pronounced by Hsp70 membrane-positive as compared with
Hsp70-negative tumor cells (CX/Colo).
Potential ion channels formed by Hsp70 may play a role in
the mechanism of selective granzyme B uptake in Hsp70 mem-
brane-positive tumor cells. Indeed, a particular ion conduct-
ance pathway was observed after incorporation of vesicles de-
rived from purified phospholipids of Hsp70 membrane-positive
(CX) tumor sublines. This was not seen in vesicles obtained
from Hsp70 membrane-negative (CX) tumor cells (data not
shown). Based on these results one might speculate about an
ion channel activity facilitating uptake of granzyme B selec-
tively into Hsp70 membrane-positive tumor cells.
In Vitro Provided Granzyme B Induces Apoptosis Selectively
in Hsp70 Membrane-positive Tumor Cells—Differences in the
inducibility of apoptosis were studied by co-incubation of
Hsp70 high- (CX/Colo) and low- (CX/Colo) expressing
carcinoma cells (21) with 10 ng/ml enzymatically active gran-
zyme B (22) for 4, 12, and 24 h. The topoisomerase inhibitor
camptothecin at a final concentration of 4 g/ml served as a
positive control for apoptosis. Programmed cell death was de-
termined by using three different apoptosis assays including
annexin V-FITC, DAPI staining, and mitochondrial cyto-
chrome c release. After a 4-h incubation period, neither camp-
tothecin nor granzyme B initiated apoptosis in any of the tested
tumor cells (data not shown), indicating that our tumor carci-
noma cell lines are more resistant to apoptotic cell death, as
compared with the acute T cell leukemia cell line Jurkat. After
a 12- and 24-h incubation period with camptothecin significant
apoptosis was observed in all tumor sublines (Fig. 3A). It ap-
peared that the colon carcinoma sublines CX/CX are better
protected toward a camptothecin-mediated cell death as com-
pared with the pancreas carcinoma sublines Colo/Colo.
However, no significant differences in the inducibility of apop-
tosis by using camptothecin was observed between Hsp70
membrane-positive and Hsp70 membrane-negative tumor
cells. Interestingly, this was not the case if the tumor sublines
were incubated with granzyme B at a concentration that is
found in the serum under physiological conditions (10 ng/ml):
12 h post-treatment the amount of annexin V-FITC positive
cells was equally up-regulated in Hsp70 membrane-positive
CX/Colo tumor cells (1.3-fold); after 24 h the increase in
apoptotic cells was significant in Hsp70 membrane-positive
CX (1.8-fold) and in Colo (2.4-fold) tumor cells (Fig. 3A). In
line with these results the amount of Hsp70 membrane-posi-
tive leukemic K562 cells (25) was similarly up-regulated (1.8-
fold) following contact with granzyme B (data not shown). In
contrast, the amount of apoptotic CX and Colo tumor cells
with stably low Hsp70 membrane expression levels remained
unaltered before and after a 12- and 24-h co-incubation period
with granzyme B (Fig. 3A).
To exclude apoptosis initiated by anoikes light microscopical
analysis of untreated (control), camptothecin- (cam), and gran-
zyme B (grB)-treated CX/CX and Colo/Colo tumor cells
were performed. As shown in Fig. 3B, 24 h post-treatment with
granzyme B, neither Hsp70 membrane-positive nor -negative
tumor cell lines exhibited any signs of loss in plastic adherence.
Regarding these findings we ruled out the possibility that
anoikes might be a possible mechanism for the induction of
apoptotic cell death in Hsp70 membrane-positive tumor sub-
lines. It is important to note that all apoptosis assays were
determined within the adherent cell population following a
short term (1 min) trypsinization.
Consistent with the results derived by annexin V-FITC
staining all cell types, CX/CX-, Colo/Colo, exhibited a
positive DAPI nuclear fragmentation staining, as a typical sign
of apoptosis at a later stage, following treatment with campto-
thecin, as compared with untreated control cells (Fig. 3C).
Again, DNA fragmentation was detected only in Hsp70 mem-
brane-positive CX and Colo tumor cells, 24 h post-treat-
ment with granzyme B (grB). In line with the annexin V-FITC
staining results, no signs of DNA fragmentation were observed
in Hsp70 membrane-negative CX and Colo cells (Fig. 3C).
As an additional test for apoptotic cell death, cytochrome c
release was measured following incubation of CX and CX
cells with granzyme B and camptothecin. As summarized in
Table I, following incubation with granzyme B for 24 h, cyto-
chrome c concentration was elevated 1.8-fold (0.382 mg/ml
versus 0.690 mg/ml) in CX cells. However, no increase in
cytoplasmic cytochrome c was observed in CX cells following
treatment with granzyme B (0.452 versus 0.425 mg/ml). An
incubation with camptothecin (4 g/ml) for 24 h results in a
comparable, 1.5-fold increase in cytochrome c concentrations in
CX and CX tumor cells. In summary these results indicate
that following binding and selective uptake, via membrane-
bound Hsp70, granzyme B initiates apoptosis in a perforin-
independent manner.
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FIG. 2. Specific cell surface binding and uptake of granzyme B (grB) by Hsp70 membrane-positive tumor cells. A, comparative
binding of granzyme B (2 g/ml) to the cell surface of CX/CX and Colo/Colo tumor cells at 4 °C, and uptake into the cytosol after a
temperature shift to 37 °C for 30 min, using the PE-conjugated granzyme B-specific monoclonal antibody HC2-PE. First row, light microscopy;
second row, immunofluorescence of cells without granzyme B (control); third row, immunofluorescence of cells after addition of granzyme B, as
specified (grB). One representative fluorescence microscopy of three showing identical results is illustrated; magnification 40. B, intracellular
flow cytometry of permeabilized CX/CX (n  2) and Colo/Colo (n  4) tumor cells using granzyme B-specific monoclonal antibody HC2-PE
before (dashed line) and after (solid line) incubation of the tumor cells with 1, 2, and 4 g/ml granzyme B at 37 °C for 30 min. Only CX and Colo,
but not CX and Colo cells showed a dose-dependent shift of the granzyme B peak to the right, indicating uptake of extracellular offered
granzyme B. ctrl, control.
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FIG. 3. Isolated granzyme B (grB) induces apoptosis selectively in Hsp70 membrane-positive tumor cells. A, percentage of annexin
V-FITC positive and propidium iodide-negative CX/Colo (left) and CX/Colo (right) cells, either untreated (black bars), or following incubation
either with camptothecin (4 g/ml; light gray bars) or granzyme B (10 ng/ml; dark gray bars) for 12 and 24 h. The data represent the mean of three
to four independent experiments  S.D.; * marks granzyme B values significantly different from control (p  0.05). B, light microscopical analysis
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Granzyme B Released by TKD-activated NK Cells Mediates
Apoptosis in Hsp70 Membrane-positive Tumor Cells—The
physiological role of our findings was tested in functional as-
says using naive and Hsp70-peptide (TKD)-stimulated human
NK cells. Previously, we have shown that incubation of NK
cells with Hsp70-protein at concentrations between 10 and 50
g/ml or with equivalent TKD concentrations between 0.2 and
2.0 g/ml resulted in increased cytolytic activity against Hsp70
membrane-positive tumor target cells. Concomitantly, the ex-
pression of CD94, the killer cell inhibitory/activatory C-type
lectin receptor, was up-regulated (24). Although it was known
that Hsp70 acts as a tumor-selective recognition structure for
NK cells (21, 25), it remained unclear whether tumor cells die
by necrosis or apoptosis. To elucidate this question, NK cells
were incubated with Hsp70-peptide TKD (2 g/ml) for 3 days.
A significant increase (1.4-fold) in cytoplasmic granzyme B
levels was observed within 3 days of stimulation in CD3-neg-
ative NK cells. In contrast, granzyme B expression was not
up-regulated in CD3-positive T cells following identical treat-
ment conditions.
Killing of CX/CX and Colo/Colo tumor cells following
contact with freshly isolated, unstimulated (NK d0), or TKD-
stimulated NK cells (NK d3) was compared in a standard 12-h
51Cr release assay (Fig. 4). Because of experimental limita-
tions, the co-incubation period of NK and tumor cells in the
cytotoxicity assay could not be extended to 24 h, like in our in
vitro apoptosis assays.
Concomitant with the increase in cytoplasmic granzyme B,
the cytolytic activity of TKD-stimulated NK cells (NK d3)
against CX target cells was enhanced 1.5-fold and that of
Colo target cells 2.0-fold at effector to target (E:T) ratios
ranging between 20:1 and 2:1. In contrast, the cytolytic activity
against Hsp70 membrane-negative CX and Colo cells was
not elevated. The increased lysis of Hsp70 membrane-positive
tumor cells was decreased in both cell systems down to the
degree of lysis of Hsp70 membrane-negative tumor cells, by
Hsp70-specific monoclonal antibody, that is known to recognize
membrane-bound Hsp70-peptide TKD on viable tumor cells
(25). In contrast, the lower lysis of Hsp70 membrane-negative
tumor cells remained unaffected after incubation with Hsp70
antibody. Technically, it is not possible to quantify the absolute
amount of granzyme B that is transferred from NK cells into
tumor cells by cell-to-cell contact. However, relative values of
granzyme B release could be determined by ELISPOT analysis.
Therefore, a comparison of the cytolytic response of freshly
isolated, unstimulated (NK d0) and TKD-stimulated NK cells
(NK d3) against CX/CX and Colo/Colo tumor cells was
performed concomitantly with the definition of the granzyme B
release. Irrespectively of the tumor cell line and the E:T cell
ratio, co-incubation of tumor cells with unstimulated NK cells
(NK d0) always results in very low granzyme B release; the
number of spots was always less than 20. After a 3-day stim-
ulation period with TKD (NK d3) followed by a 4-h co-incuba-
tion time with tumor cells, granzyme B release was signifi-
cantly up-regulated. At an E:T ratio of 5:1, the number of
granzyme B spots, as determined in three independent exper-
iments, was as follows: CX, 260  20; CX, 165  6; Colo,
137  55; Colo, 66  8. Concomitantly, Hsp70 membrane-
of adherent growing CX/CX and Colo/Colo tumor cell clusters either untreated (control) or following treatment with camptothecin (cam, 4
g/ml) or granzyme B (grB, 10 ng/ml), for 24 h. Scale bar indicates 100 m. C, in parallel, either untreated (control), camptothecin (cam), or
granzyme B (grB)-treated CX/CX and Colo/Colo tumor cells (24 h) were stained with DAPI. Considerable nuclear DNA fragmentation was
observed in all tumor sublines following incubation with camptothecin (middle panel). After incubation with granzyme B only CX and Colo cells
exhibited nuclear DNA fragmentation (lower panel, left). No signs of apoptosis were observed in CX- and Colo tumor cells following incubation
with granzyme B (lower panel, right). Scale bar represents 10 m.
TABLE I
Quantitative determination of human cytochrome c in CX and
CX tumor cells either untreated (control), or following incubation
with camptothecin (4 g/ml) or granzyme B (10 ng/ml), for 24 h
The data represent the mean of four independent experiments  S.E.
Cells
Cytochrome c (mg/ml)
Control Camptothecin Granzyme B
-fold increase
CX 0.382  0.02 0.555  0.04a 0.690  0.08a
1.0 1.5 1.8
CX 0.452  0.02 0.672  0.02a 0.425  0.075
1.0 1.5 0.9
a Values significantly different from control (p  0.05).
FIG. 4. Selective kill of Hsp70 membrane-positive tumor cells,
mediated by NK cells, is blockable by Hsp70-specific mono-
clonal antibody and correlates with granzyme B secretion. Kill-
ing of CX/Colo (left panel) and CX/Colo (right panel) tumor
target cells by naive, unstimulated (NK d0), and Hsp70-peptide TKD-
stimulated NK cells (NK d3) was quantified in 12-h 51Cr release assays.
Intracellular granzyme B levels in naive NK cells (NK d0) versus
TKD-stimulated NK cells (NK d3) increased 1.4-fold; concomitantly,
lysis of CX cells was elevated 1.5-fold, that of Colo cells 2.0-fold at
different effector to target ratios. Lysis of CX and Colo tumor cells
remained unaffected. Furthermore, the increased cytolytic activity of
TKD-stimulated NK cells (NK d3 Hsp70 monoclonal antibody) against
CX and Colo cells was inhibited by Hsp70-specific antibody down to
the level of lysis of Hsp70 membrane-negative tumor cells (1.7-fold inhi-
bition, dotted line). Cytotoxicity was determined at E:T ratios ranging
from 20:1 to 2:1; spontaneous release of each target cell was below 10%.
The data represent the mean of three independent experiments  S.D.
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positive tumor target cells (CX/Colo) were lysed signifi-
cantly better as compared with their negative counterparts
(CX/Colo). These data strongly suggest that lysis of Hsp70
membrane-positive tumor cells by TKD-activated NK cells is
associated with granzyme B release. Proteases, like granzyme
B, initiate apoptosis by a intracellular mechanism (35). In Fig.
2, A and B, specific binding and a dose-dependent internaliza-
tion of in vitro provided granzyme B was detected selectively in
Hsp70 membrane-positive tumor cells. With respect to these
findings, we assumed that differences in lysis of CX/CX and
Colo/Colo tumor cells are because of a different capacity of
the tumor cells to internalize granzyme B.
DISCUSSION
Previously we have demonstrated that tumor cells, but not
normal cells, present Hsp70 on their plasma membrane (14).
Antibody mapping revealed that part of the C-terminal sub-
strate binding domain is exposed to the extracellular milieu
(26). The epitope of this antibody corresponds to a 14-amino
acid sequence, termed TKD (TKDNNLLGRFELS, aa450–463).
Thus, exposure of TKD on the cell surface sensitizes tumor cells
to the cytolytic activity of NK cells (20). Furthermore, Hsp70-
peptide TKD exhibits activatory properties on NK cells, which
is comparable with the activity observed by equivalent
amounts of full-length Hsp70 (19). Although it is obvious that
Hsp70-protein and Hsp70-peptide TKD efficiently trigger NK
cell activity, the mechanism how NK cells kill Hsp70 mem-
brane-positive tumor target cells remained unclear.
To identify molecules that are involved in the interaction of
NK cells with Hsp70-positive tumor cells, Hsp70 conjugated to
Sepharose was used as affinity bait to isolate Hsp70-binding
proteins from lysates of the human NK cell line YT (27). In the
cytoplasm, Hsp70 binds hydrophobic residues of denatured
polypeptides and co-chaperones via the substrate binding
pocket, localized in the C-terminal region of the protein, in an
ATP-dependent manner (28–31). To characterize interacting
partners specific for membrane-bound Hsp70, an affinity col-
umn with Hsp70-peptide TKD, was also used (20). A dominant
32-kDa protein band was eluted from Hsp70-protein and
Hsp70-peptide columns with lysates of NK cells. This protein
band was not detected with lysates of non-NK cells. The inten-
sity of the 32-kDa protein band was more pronounced in elu-
ates of TKD columns because at the molar level a 50–100-fold
excess Hsp70-peptide was coupled to the column, as compared
with full-length Hsp70-protein. By MALDI-TOF and Western
blot analysis the Hsp70-interacting partner could be identified
as granzyme B (Mr expected 32,000). This observation is con-
sistent with a prior report indicating binding of Hsp70 and
Hsp27 to granzyme-immobilized Sepharose columns (32).
One mechanism of NK cell-mediated killing involves the
exocytosis of cytotoxic granules containing perforin and serine
proteases (33). After internalization the protease granzyme B
cleaves procaspases into their activated form, and thereby in-
duces programmed cell death by promoting DNA fragmenta-
tion (34–36). Also gene deletion studies demonstrated that
granzyme B is critical for the induction of apoptosis (37). It is
assumed that granzyme B enters target cells either in a perforin-
dependent or perforin-independent way. Presently, the man-
nose 6-phosphate receptor is discussed to be involved in the
process of endocytosis/pinocytosis of granzyme B (38–40). Here
we provide evidence for a perforin-independent induction of
apoptosis mediated by the interaction of granzyme B with cell
surface-bound TKD. Incubation of human colon and pancreas
carcinoma sublines that differ in Hsp70 membrane expression,
with isolated, enzymatic active granzyme B, at concentrations
found in human serum under physiological conditions (41),
induces apoptosis selectively in Hsp70 membrane-positive tu-
mor cells, as determined by annexin V-FITC staining, nuclear
DNA fragmentation, and cytochrome c release. Cell viability of
Hsp70 membrane-negative tumor sublines was not affected by
granzyme B. These differences in the induction of apoptosis
were not observed with the topoisomerase inhibitor camptoth-
ecin. Therefore, we speculate that initiation of apoptosis by
granzyme B and camptothecin involves different routes. Our
results that binding of granzyme B to the extracellular exposed
region of Hsp70, defined by the Hsp70-peptide TKD, may be
critical for uptake and for the induction of apoptosis. This
observation is supported by the finding that the enhanced
cytolytic activity of NK cells against Hsp70 membrane-positive
tumor cells could be blocked by an Hsp70-specific monoclonal
antibody, which binds to TKD. It is conceivable that cell sur-
face-bound Hsp70 antibody prevents binding and internaliza-
tion of granzyme B to tumor cells and thus protects them from
apoptosis.
Earlier observations have shown that only an Hsp70 anti-
body directed against the C-terminal part TKD was able to
recognize cell surface-localized Hsp70 on viable tumor cells
(26). This suggests that the protein may be incorporated into
the lipid bilayer. This option has been supported by recent
evidence indicating interaction of HSP70s with phospholipids
of the plasma membrane (42). Moreover, an ion conductance
pathway was observed in artificial lipid bilayers after incorpo-
ration of Hsc70 (43). More recently, these proteins were found
to interact with lipids in a liposome aggregation assay (44).
Therefore, it is possible that Hsp70 is also embedded in the
plasma membrane of tumor cells. Here we report on a selective
cation channel activity in plasma membrane of Hsp70 positive
tumor cells. Based on these results, one might speculate about
channel formation, which facilitate binding and uptake of gran-
zyme B into Hsp70 membrane-positive tumor cells. In the
absence of Hsp70 in the plasma membrane, these channels
cannot be created and thus uptake of granzyme B is prohibited.
In the cytosol Hsp70 frequently cooperates with other proteins.
Therefore, we were interested to identify molecules that may be
tightly associated with Hsp70 in the plasma membrane. Un-
published data 2 of our group suggest that the silencer of death
domain, also termed Bag-4, is co-localized with Hsp70 on the
cell surface. Ongoing studies investigate the role of Hsp70 in
concert with Bag-4 in the formation of ion channels.
Keeping in mind that tumor sublines with differential Hsp70
membrane expression did not differ with respect to their intra-
cellular Hsp70 levels, neither under physiological conditions
nor following stress (21), differences in the sensitivity to gran-
zyme B-mediated apoptosis cannot be explained by differential
cleavage of Hsp70 inside the cell. Also modulations in the
expression of major histocompatibility complex class I mole-
cules, known to differentially induce killer cell inhibitory/acti-
vating receptors on NK cells, could be ruled out, because the
major histocompatibility complex class I cell surface pattern
was identical in Hsp70 membrane-positive and -negative tu-
mor sublines (21).
Apart from the observation that Hsp70 serves as an entry
port for granzyme B into Hsp70 membrane-positive tumor tar-
get cells, Hsp70-protein and TKD stimulate the production and
release of granzyme B in primary NK cells. This finding can
explain why high Hsp70 membrane expression not only predis-
poses tumor target cells to apoptotic cell death but also favors
NK cell activation. In contrast to in vitro applied granzyme B,
activated NK cells also kill Hsp70 membrane-negative tumor
cells to a certain extent. However, this weak lysis was not
2 M. Gehrmann, J. Marienhagen, H. Eichholtz-Wirth, E. Fritz, J.
Ellwart, M. Jäätellä, T. Zilch, and G. Multhoff, unpublished
observations.
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blockable with Hsp70 antibody. Together with the result that
lysis of Hsp70 membrane-positive tumor cells was reduced to
the degree of lysis observed with Hsp70 membrane-negative
tumor cells by Hsp70 antibody, we assumed that Hsp70-medi-
ated granzyme B internalization and apoptosis induction is
only one mode how activated NK cells kill tumor cells. Further-
more, in comparison to in vitro provided granzyme B, killing
mediated by NK cells engage a physical cell-to-cell contact that
is likely to result in high local granzyme B concentrations at
the tumor cells that cannot be quantified experimentally.
Therefore, our in vitro apoptosis assays were conducted with
granzyme B concentrations similar to those found in human
serum (41). These concentrations are undoubtedly different to
that secreted by NK cells and hence it would be rather surpris-
ing if they had the same efficacy. Although the absolute
amount of granzyme B transferred from NK cells into tumor
cells could not be defined, the cytotoxic response of activated
NK cells against Hsp70 membrane-positive tumor cells corre-
lated with the relative release of granzyme B into the medium,
as determined by ELISPOT analysis. Kinetical studies indicat-
ing that increasing amounts of in vitro provided granzyme B
are still selectively taken up by Hsp70 membrane-positive tu-
mor cells further support these findings.
In summary our data suggest a dual role for Hsp70-protein
and Hsp70-peptide TKD in the immune response against can-
cer. On the one hand it stimulates the production and delivery
of granzyme B by NK cells, on the other hand it facilitates
uptake of granzyme B selectively into Hsp70 membrane-posi-
tive tumor target cells. We propose the Hsp70 epitope TKD is a
naturally occurring interacting partner for granzyme B that
elucidates one part of the puzzling role of membrane-bound
Hsp70 in the natural defense mechanisms against tumor cells.
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Abstract Previously we described an involvement of the C-type lectin receptor CD94 and the neuronal adhesion
molecule CD56 in the interaction of natural killer (NK) cells with Hsp70-protein and Hsp70-peptide TKD. Therefore,
differences in the cell surface density of these NK cell–specific markers were investigated comparatively in CD94-
sorted, primary NK cells and in established NK cell lines NK-92, NKL, and YT after TKD stimulation. Initially, all NK
cell types were positive for CD94; the CD56 expression varied. After stimulation with TKD, the mean fluorescence
intensity (mfi) of CD94 and CD56 was upregulated selectively in primary NK cells but not in NK cell lines. Other cell
surface markers including natural cytotoxicity receptors remained unaffected in all cell types. CD3-enriched T cells
neither expressing CD94 nor CD56 served as a negative control. High receptor densities of CD94/CD56 were asso-
ciated with an increased cytolytic response against Hsp70 membrane–positive tumor target cells. The major histocom-
patibility complex (MHC) class I–negative, Hsp70-positive target cell line K562 was efficiently lysed by primary NK cells
and to a lower extent by NK lines NK-92 and NKL. YT and CD3-positive T cells were unable to kill K562 cells. MHC
class-I and Hsp70-positive, Cx1 tumor target cells were efficiently lysed only by CD94-sorted, TKD-stimulated NK cells
with high CD94/CD56 mfi values. Hsp70-specificity was demonstrated by antibody blocking assays, comparative
phenotyping of the tumor target cells, and by correlating the amount of membrane-bound Hsp70 with the sensitivity to
lysis. Remarkably, a 14-mer peptide (LKD), exhibiting only 1 amino acid exchange at position 1 (T to L), neither
stimulated Hsp70-reactivity nor resulted in an upregulated CD94 expression on primary NK cells. Taken together our
findings indicate that an MHC class I–independent, Hsp70 reactivity could be associated with elevated cell surface
densities of CD94 and CD56 after TKD stimulation.
INTRODUCTION
Natural killer (NK) cells are large granular lymphocytes
comprising 5% to 20% of the peripheral blood mononu-
clear cells (PBMNCs) (Trinchieri 1989). In contrast to T
cells, NK cells do neither express the multimolecular CD3
complex nor a/b and g/d T cell receptors. Almost all NK
cells are positive for the neuronal adhesion molecule
CD56, mediating homo- and heterophilic cell adhesion
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(Lanier et al 1986, 1989). With respect to the cell-surface
density of CD56, 2 distinct NK cell subsets, the CD56dim
and CD56bright could be distinguished (Cooper et al 2001).
In the early host defense, NK cells secrete immunoregu-
latory cytokines including interferon-g, interleukin (IL)–
2, IL-12, tumor necrosis factor–a and granulocyte-mac-
rophage colony–stimulating factor. NK cells also mediate
natural cytotoxicity against virus-infected cells and tu-
mor cells by release of apoptotic enzymes including gran-
zymes and perforin or by antibody-dependent cellular cy-
totoxicity through the low affinity FcgRIII receptor CD16
(Lanier et al 1988). The cytolytic activity of NK cells is
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regulated by killer cell receptors, which are known to in-
teract with self–major histocompatibility complex (MHC)
class-I or class I–like molecules (Lanier 1998a, Borrego et
al 2002). According to the missing-self theory, NK cells
preferentially recognize and kill virus-infected or trans-
formed cells with reduced, lost, or altered self-MHC
class-I molecule expression (Ljunggren and Kärre 1990).
In humans, 3 distinct killer cell receptor families have
been identified (Lanier 1998a): killer cell immunoglobulin
(Ig) receptors (KIRs), Ig-like transcripts (ILTs), and C-type
lectin receptors. The KIRs are characterized by 2 or 3 ex-
tracellular localized Ig-like domains recognizing MHC
class-I alleles including HLA-A, HLA-B, and HLA-C
(Moretta et al 1993; Wagtmann et al 1995; Pende et al
1996). Depending on their cytoplasmic domain contain-
ing an immunoreceptor tyrosine–based inhibition motif
or an immunoreceptor tyrosine–based activating motif,
NK cells mediate inhibitory and activating signals (Co-
lonna and Samaridis 1995; Biassoni et al 1996). ILTs also
belong to the Ig-like superfamily (Colonna et al 1997;
Cosman et al 1997). They are inhibitory receptors ex-
pressed predominantly on myeloid cells, dendritic cells,
and B cells (Colonna et al 1997). ILT-2, which is expressed
on some NK cells interacts directly with a broad spec-
trum of classical and nonclassical HLA molecules includ-
ing HLA-G (Navarro et al 1999). Most C-type lectin re-
ceptors are heterodimers consisting of CD94 covalently
bound to members of the NKG2 family (Lanier et al 1994;
Lazetic et al 1996). These receptors interact with nonclas-
sical HLA-E molecules, presenting leader peptides de-
rived from HLA-A, HLA-B, HLA-C, and HLA-G (Borrego
et al 1998; Braud et al 1998; Lee et al 1998). CD94/
NKG2A is an inhibitory receptor, whereas CD94/
NKG2C, CD94/NKG2E, and CD94/NKG2F are activating
receptors (Brooks et al 1997; Lanier 1998b). The activating
receptor NKG2D also belongs to the C-type lectin family,
but in contrast to other members it forms homodimers
(Wu et al 1999). NKG2D is constitutively expressed on
NK cells, g/d T cells, and CD81 T cells and interacts with
the MHC class I chain–related (MIC) antigens, MICA and
MICB, and the UL16-binding proteins, which are induced
by stress or neoplastic transformation (Bauer et al 1999;
Cosman et al 2001). Recently, a new group of activatory
receptors, termed natural cytotoxicity receptors (NCRs),
consisting of NKp30 (Pende et al 1999), NKp44 (Vitale et
al 1998; Cantoni et al 1999), and NKp46 (Pessino et al
1998) have been identified. Although NKp30 and NKp46
are constitutively expressed by almost all peripheral
blood NK cells, the ligands regulating their expression
and activatory function have not been defined yet.
By binding assays, an involvement of the C-type lectin
receptor CD94 in the interaction of NK cells with Hsp70,
the major stress-inducible member of the Hsp70 group
could be demonstrated (Gross et al 2003). Tumor cells
expressing the C terminal–localized Hsp70 sequence
‘‘TKDNNLLGRFELSG’’ (TKD, aa450–463) on their cell sur-
face are preferentially recognized and lysed by NK cells
(Multhoff et al 1999). Hsp70-protein and Hsp70-peptide
TKD, both induce proliferative and cytolytic activity in
NK cells (Multhoff et al 1999; 2001). Concomitantly, the
expression of the C-type lectin receptor CD94 and the
neuronal adhesion-molecule CD56 was found to be up-
regulated on CD3-negative NK cells (Multhoff et al 1999;
Moser et al 2002). Other NK cell–specific receptors of the
KIR family remained unaffected (Multhoff et al 1999). Be-
cause it is known that the cell surface density of CD56
(Cooper et al 2001) and CD94 (Voss et al 1998; Jacobs et
al 2001; Lian et al 2002; Gunturi et al 2003) are associated
with the cytolytic function, we aimed to study changes
in the mean fluorescence intensity (mfi) of these 2 mark-
ers in CD94-positive NK cell lines in response to Hsp70-
peptide TKD. These data were compared with the cyto-
lytic capacity against classical MHC class I–negative NK
target cells (K562) and MHC class I–positive but Hsp70-
positive (Cx1) or Hsp70-negative (Cx2) tumor target
cells.
MATERIALS AND METHODS
Tumor cell lines
The myelogenous cell line K562 was purchased from
American Type Culture Collection (CCL 243, Rockville,
MD, USA) and cultured in Roswell Park Memorial Insti-
tute-1640 medium (Gibco, Eggenstein, Germany) supple-
mented with heat-inactivated 10% fetal calf serum (FCS),
1 mM sodium pyruvate, 2 mM L-glutamine, 1% penicil-
lin-streptomycin (all supplements purchased from Life
Technologies, Rockville, MD, USA) at 378C and 5% CO2.
The colon carcinoma sublines Cx1 (Hsp70 membrane–
positive) and Cx2 (Hsp70 membrane–negative) derived
by cell sorting (Multhoff et al 1997) from Cx2 colon car-
cinoma cells (Tumorzentrum Heidelberg, Heidelberg,
Germany) differ with respect to their capacity to express
Hsp70 on the plasma membrane. Cells were kept in cul-
ture under exponential growth conditions by regular cell
passages. Every 3 days, cells were transferred after short-
term (maximum, 1 minute) trypsinization using trypsin
and ethylenediamine-tetraacetic acid solution (Gibco),
and 0.5 3 106 cells were seeded in 5 mL fresh medium
in T25 culture flasks.
In the cytotoxicity assay, K562 cells were used as a clas-
sical NK target, whereas Cx1 and Cx2 cells were ap-
plied as MHC class I–positive tumor target cells.
NK cell lines
The human NK lymphoma cell line, NK-92 (Gong et al
1994) (ACC 488, DSMZ, Heidelberg, Germany), was
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grown in RPMI-1640 medium with 20% heat-inactivated
FCS, 1 mM sodium pyruvate, 2 mM L-glutamine, 1% pen-
icillin-streptomycin, and 100 IU/mL IL-2; doubling time
was 40 to 50 hours at cell densities ranging from 0.2 to
0.6 3 106 cells/mL.
NKL cell line (Robertson et al 1996) was cultured in
RPMI-1640 medium with 10% heat-inactivated FCS, 1
mM sodium pyruvate, 2 mM L-glutamine, 1% penicil-
lin-streptomycin, and 100 IU/mL IL-2; doubling time
was 40 hours at cell densities ranging from 0.5 to 1 3
106 cells/mL.
The IL-2 independent growing NK cell line YT (Yodoi
et al 1985) (ACC 434, DSMZ) was cultivated in RPMI-
1640 medium with 10% heat-inactivated FCS, 1 mM so-
dium-pyruvate, 2 mM L-glutamine, 1% penicillin-strep-
tomycin; doubling time was 50 to 60 hours at a constant
low cell density of 0.1 3 106 cells/mL.
Cytokine-induced killer cells
PBMNCs were isolated from buffy coats of healthy hu-
man volunteers by Ficoll separation followed by mono-
cyte depletion. Peripheral blood lymphocytes were grown
in RPMI-1640 medium with 10% heat-inactivated FCS, 25
mM Hepes (Invitrogen GmbH, Karlsruhe, Germany), 2
mM L-glutamine, 1% penicillin-streptomycin, and 50 mM
2-mercaptoethanol. A quantity of 1,000 IU/mL of human
recombinant interferon-g (Imukin, Roche Diagnostics
GmbH, Mannheim, Germany) was added on day 0. After
a 24-hours incubation period, CD3 monoclonal antibody
(mAb, Ortho Biotech, Neuss, Germany), 50 ng/mL (38.1;
P. Martin, University of Washington, Seattle, WA, USA),
300 IU/mL IL-2 (Proleukin, Chiron Behring GmbH, Mar-
burg, Germany), and 100 IU/mL rIL-1b (Roche Diagnos-
tics GmbH) were added. Cells were incubated at 378C
and 5% CO2 and subcultured every 3 days in fresh me-
dium at a cell density of 0.4 3 106 cells/mL (Schmidt-
Wolf et al 1991, 1997).
CD94-positive NK cells
PBMNCs were separated by positive selection using bio-
tinylated CD94 mAb (HP3-D9, Ancell Immunology Re-
search Products, Bayport, MN, USA) and a standard Mil-
tenyi biotin separation method (Miltenyi, Bergisch Glad-
bach, Germany). Briefly, 100 3 106 cells/mL were incu-
bated with 5 mg biotin-conjugated CD94 mAb for 30
minutes at 48C. After extensive washing with bovine se-
rum albumin containing magnetic cell-sorting buffer
(MACS-buffer, Miltenyi), cells were incubated with anti-
biotin beads for 15 minutes at 48C under gentle shaking.
After washing, CD94-positive cells were separated using
a LS/VS column (Miltenyi).
Sorted cells were incubated for 4 days in RPMI-1640
medium with 10% heat-inactivated FCS, 1 mM sodium
pyruvate, 2 mM L-glutamine, 1% penicillin-streptomycin,
100 IU/mL IL-2, and 2 mg/mL Hsp70-peptide TKD
(TKDNNLLGRFELSG, purity .96%; Bachem, Bubendorf,
Switzerland) at 378C. As a control, CD94-sorted NK cells
were also incubated with the mutated peptide LKD
(LKDNNLLGRFELSG, purity .96%; Bachem) under
identical culture conditions. In long-term incubation ex-
periments CD94-sorted NK cells were cultivated in fresh
medium containing TKD (2 mg/mL) plus low-dose IL-2
(100 IU/mL) weekly for 5 weeks.
CD3-positive T cells (CD3)
CD3-positive T cells were separated by positive selection
from PBMNC using the CD3-separation kit (Miltenyi) ac-
cording to a protocol described above.
Sorted cells were incubated for 4 days in RPMI-1640
medium with 10% heat-inactivated FCS, 1 mM sodium
pyruvate, 2 mM L-glutamine, 1% penicillin-streptomycin,
100 IU/mL IL-2, and 2 mg/mL Hsp70-peptide TKD
(Bachem) at 378C.
Treatment
Exponentially growing tumor cells were either heat
shocked at a temperature of 428C for 1 hour, followed by
a recovery period of 12 hours or treated with 1 mM pac-
litaxel (Taxol-100, Bristol Arzneimittel, Munich, Germany)
for 2 hours also followed by a recovery period of 12
hours. Previously published viability assays revealed that
both treatment conditions were nonlethal for the tumor
cells (Multhoff et al 1997; Gehrmann et al 2002). After
treatment, cells were analyzed with respect to their MHC
class-I, class-II, and Hsp70 membrane expression by flow
cytometry.
Flow cytometry
The following mouse fluorescein-conjugated mAb, were
used for phenotypic characterization of effector and tar-
get cells: isotype-matched controls (Becton Dickinson,
Heidelberg, Germany), CD54 fluorescein isothiocyanate
(FITC) (Immunotech Coulter, Marseille, France), CD56
FITC (IgG2b, Becton Dickinson), CD57 phycoerythrin
(PE) (IgM, Immunotech Coulter), CD94 PE (IgG1, HP-
3D9, Ancell Immunology Research Products), CD3 FITC
and CD16/CD56 PE (Simultest, IgG1, Becton Dickinson),
NKp30 PE (IgG1, clone Z25, Beckmann Coulter, Krefeld,
Germany), NKp46 (IgG1, clone BAB281, Beckmann Coul-
ter), W6/32 PE (anti-MHC class-I, IgG2a, Cymbus Bio-
tech, Eagle Close, UK), L243 PE (MHC DR, IgG2b, Im-
munotech Coulter), 87G (HLA-G, IgG2a, kindly provided
by Dr D. Geraghty), TP25.99 (HLA-E, IgG1, kindly pro-
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vided by Dr S. Ferrone), UIC2 (MDR-1, p glycoprotein,
IgG2a, Immunotech Coulter), IMA310–0-C100 (MICA,
IgG1, Immatics Biotech, Tübingen, Germany), and cm-
Hsp70.1 FITC (Hsp70, IgG1, Multimmune GmbH, Re-
gensburg, Germany).
Briefly, 0.5 3 106 cells were incubated with fluorescein-
conjugated mAb at 48C, for 30 minutes. After washing in
phosphate-buffered saline supplemented either with 2%
(NK-92, NKL, YT, K562, Cx1, Cx2 cell lines) or 10%
(CD94-positive, CD3-positive, cytokine-induced killer
(CIK) primary cells) heat-inactivated FCS, the cells (200,
000) were analyzed on a FACS Calibur instrument (Bec-
ton Dickinson). The percentage of positively stained cells
was calculated as the number of specifically stained cells
minus the number of cells stained with an irrelevant iso-
type-matched control antibody.
Cell-mediated lympholysis assay
The cytolytic activity of primary effector cells and NK cell
lines was monitored in a standard 51Cr cytotoxicity assay
(MacDonald et al 1974). Different titrations (2:1, 1:1, 0.5:
1 or 10:1, 5:1, 2:1 or 40:1, 20:1, 10:1) of effector and 51Cr-
labeled (5 mCi of Na51CrO4, NEN-Dupont, Boston, MA,
USA) tumor target cells (3 3 103 cells per well) were in-
cubated in duplicate at a final volume of 200 mL (RPMI-
1640 medium supplemented with 10% FCS) at 378C in
96-well U-bottom plates (Greiner, Melsungen, Germany).
For antibody blocking, tumor cells (0.5 3 106 cells) were
incubated for 15 minutes with 5 mg/mL Hsp70-specific
mAb (cmHsp70.1) after labeling and then used in the cy-
totoxicity assay without further washing. After a 4-hours
incubation period, supernatants were collected and the
radioactivity was quantified on a g-counter (Canberra
Packard Instruments, Dreieich, Germany). Spontaneous
release was determined using the supernatants of target
cells that had not been coincubated with effector cells.
Maximum release was determined in the suspensions of
51Cr-labeled target cells. Specific lysis (%) was calculated
according to the following equation: (experimental re-
lease 2 spontaneous release)/(maximum release 2 spon-
taneous release) 3 100. The percentage of spontaneous
release in all experiments was always less than 20% for
each target cell line.
RESULTS AND DISCUSSION
Separation of CD94-positive NK cells and CD3-positive
T cells
We have shown previously that the C-type lectin receptor
CD94 is involved in the interaction of NK cells with
Hsp70, the major stress-inducible member of the Hsp70
family (Gross et al 2003). Tumor cells expressing the
Hsp70 epitope ‘‘TKDNNLLGRFELSG’’ on their cell sur-
face are recognized and lysed by CD3-negative, CD94-
positive NK cells (Multhoff et al 1999). Incubation of pri-
mary human NK cells with Hsp70-peptide TKD plus
low-dose IL-2 for 4 days results in an enhanced cytolytic
activity against Hsp70-positive tumor cells (Multhoff et
al 2001). Concomitantly, the percentage of CD94- and
CD56-positive cells increased. Other NK cell markers in-
cluding CD16 and KIRs (CD158a/b; CD158e1/e2;
CD158k) remained unaffected. IL-2 alone increases the
expression of CD94 and CD56 marginally, indicating that
TKD might have a synergistic effect on the upregulation
of these NK cell–specific markers (Multhoff et al 1999). In
the present study, modulations in the protein density of
CD56 and CD94 were compared in CD94-sorted, primary
NK cells, and NK cell lines before and after stimulation
with TKD. Concomitantly, the cytolytic capacity against
the classical MHC class I–negative NK target cells (K562)
and the MHC class I–positive, Hsp70 membrane–positive
(Cx1) and membrane–negative (Cx2) tumor cells was
tested.
In the first set of experiments, CD94-positive NK cells
were separated from PBMNCs of 8 healthy human vol-
unteers by magnetic activated cell sorting (MACS). As a
negative control, CD3-positive T cells were selected from
3 healthy human donors. Both positively enriched cell
populations were cultured separately in the presence of
low-dose IL-2 (100 IU/mL) and Hsp70-peptide TKD (2
mg/mL). The concentration of the supplements was iden-
tified as the optimal activating dose for human NK cells
in kinetical studies (Multhoff et al 1999). The cell surface
expression pattern of CD56, CD94, CD3, and CD16/56 in
unstimulated PBMNC is illustrated in Fig. 1A. Freshly
isolated cells were not phenotyped for CD94 and CD3
because antibody-coupled beads were still bound to the
cell surface (data not shown). On day 4, after separation
and stimulation a flow-cytometric analysis was per-
formed. One representative result of the multiparameter
flow cytometric analysis is illustrated in Fig. 1B, C. The
mean percentages of positively stained cells 6 standard
deviation of all experiments are summarized and given
on the right hand side of each individual graph. After
positive selection for CD94 and stimulation with TKD, 63
6 12% of the cells were found to be double positive for
CD94 and CD56; 22 6 9% were positive for CD94, only
(upper panel). A minor part of cells (2 to 3 6 3%) was
found to be CD94- and CD3-negative. Because CD94 sep-
aration was not complete (purity .85%), on day 4 after
stimulation, between 12% and 29% contaminating CD3-
positive T cells were detected. With respect to the NK
cell marker CD16/56 and the T cell marker CD3 this cell
population contained 54% NK cells and 16% T cells (low-
er panel). A positive selection using a CD3-specific anti-
body followed by identical stimulation with TKD re-
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Fig 1. CD94-positive NK cell and CD3-positive T cell selec-
tion. CD94-positive NK cells were selected from peripheral
blood mononuclear cells (PBMNC) derived from 8 healthy hu-
man donors using anti-CD94 biotin monoclonal antibody and
anti-biotin magnetic microbeads. The phenotype of unsepa-
rated PBMNC (A) and CD94-positive NK cells (B) after stim-
ulation with low-dose interleukin (IL)-2 (100 IU/mL) plus TKD
(2 mg/mL) for 4 days was determined by flow cytometry using
the following antibodies: CD3 fluorescein isothiocyanate
(FITC), CD16/CD56 phycoerythrin (PE), CD56 FITC and
CD94 PE. Dot-blot diagrams of 1 representative flow-cyto-
metric analysis of CD94-positive NK cells on day 4 is shown.
Mean values of the percentages of 8 experiments 6 standard
deviation are summarized on the right-hand side of each
graph. CD3-positive T cells (C) were selected from PBMNC
derived from 3 healthy human donors using anti-CD3 magnetic
microbeads. Dot-blot analysis of 1 representative flow cytom-
etry of CD3-positive cells after 4 days stimulation with low-
dose IL-2 (100 IU/mL) plus TKD (2 mg/mL) and mean values
of 3 experiments are shown.
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vealed that almost all cells (97%) were CD3-positive T
cells; no CD16/56-positive NK cells (3%) were found. The
percentage of CD94/CD56–positive cells was only 7%.
After long-term stimulation, the CD94/CD56–positive
phenotype remained stable. Cells were incubated in fresh
medium supplemented with TKD plus low-dose IL-2
once a week. Figure 2 shows representative dot-blot pro-
files of the CD94/CD56 staining of CD94-enriched NK
cells on days 14, 21, 28, and 35. Although the percentages
of CD94/CD56–positive cells remained constant, the mfi
decreased during long-term culture (data not shown).
The number of CD3-positive T cells did not increase; in-
dicating that even repeated stimulation rounds with IL-2
plus TKD does not favor T cell growth. From these re-
sults, we conclude that it is possible to keep CD94/CD56–
positive NK cells in culture for several weeks.
A comparison of the protein density, as determined by
the mfi, of unstimulated and TKD-stimulated CD94-sort-
ed NK cells and NK cell lines NK-92, NKL, and YT re-
vealed that a significant increase in CD94 and CD56 ex-
pression was detected only with primary NK cells, within
4 days of stimulation (Table 1).
Comparative phenotypic characterization of the cell-
surface markers CD94 and CD56 on primary NK, CIK,
and T cells and on NK cell lines NK-92, NKL, and YT
In addition to the CD94 and CD56 expression, differences
in the expression pattern of newly defined NCRs, NKp30
and NKp46 were tested in CD94-enriched NK cells, CD3-
enriched T cells, and in NK cell lines NK-92, NKL, and
YT after treatment with IL-2 plus TKD. In contrast to pri-
mary human NK cells, neither NK cell lines nor T cells
showed any difference in their CD94, CD56, or NCR ex-
pression pattern after TKD stimulation. The percentages
of positively stained cells and mfi values of all markers
derived from 3 to 8 independent experiments after stim-
ulation are summarized in Table 2. After cell sorting and
TKD stimulation, 85% of the primary NK cells were pos-
itive for the C-type lectin receptor CD94; 63% of these
cells also expressed the neuronal adhesion molecule
CD56. NKp30 and NKp46 was found on 58% and 75% of
the CD94-sorted cells, respectively, and on the NK lines
NK-92 (29% and 62%) and NKL (78% and 77%) at vari-
able percentages. These markers did not differ before and
after stimulation with TKD. YT cells were negative for
NKp30 (0%) but strongly positive for NKp46 (98%). CD3-
sorted T cells were negative for all tested markers. Both
NK cell lines, NK-92 and NKL, were found to express
CD94 (99%). However, coexpression of CD56 was deter-
mined only on NK-92 cells (99%). In contrast, only a small
subpopulation of 15% of the NKL cells did express CD56.
As shown previously, the percentage of CD94-positive
cells varied on YT cells between 13% and 52%, depending
on the number of cells in culture; a negative correlation
was consistently found with increasing cell densities
(Gross et al 2003). With the culture conditions tested here,
37% to 54% of the YT cells were positive for CD94; CD56
was almost not detectable. CIK cells were also analyzed
with respect to their CD94 and CD56 expression pattern.
Because CIK cells are a heterogeneous cell population
consisting of a mixture of T and NK cells, the percentages
for CD94 and CD56 varied from 18% to 54% and from
29% to 67%, respectively. Because of this high variability,
standard deviations were not provided for CIK cells.
With respect to the mfi, again striking differences were
found between primary NK cells and NK cell lines. Only
primary NK cells reacted on TKD stimulation with a sig-
nificantly upregulated mfi of CD94 from 156 to 416, and
of CD56 from 114 to 393, between day 0 and day 4 (Table
1). The expression of NCRs remained unaffected by TKD
stimulation (data not shown). In all other cell types, the
mfi values of the tested markers remained unaltered. In
comparison with NK cell lines, primary NK cells showed
the highest expression levels of the cell surface markers
CD94 and CD56 on day 4. The CD94 mfi values on CIK
cells, NK-92, and NKL cells were 57, 170, and 193, re-
spectively. Very low CD94 mfi levels were detectable in
YT cells. With respect to CD56, the mfi values of CIK and
NK-92 cells was 181 and 72, respectively; NKL cells
showed low mfi values of 4. Positive mfi values for CD56
were not found in YT cells and CD3-positive T cells, lack-
ing CD56 molecules on their cell surface. Significant mfi
values of NKp30 and NKp46 were only found in CD94-
sorted NK cells, after stimulation with TKD.
In summary, although the percentages of CD94-posi-
tive cells were comparably high in primary NK cells and
NK cell lines NK-92 and NKL, striking differences were
recorded with respect to the cell surface density of this
receptor. Furthermore, only primary NK cells reacted
with a significant upregulation in the cell surface density
of CD94 after stimulation with TKD. All other tested
markers remained unaltered. Similar results were seen
for the neuronal adhesion molecule CD56. To distinguish
the different NK cell types on the basis of their CD94/
CD56 receptor density, the mfi values were marked in
Figure 3 with 1 and 2 symbols as follows: mfi . 300,
111; mfi 150–300, 11; mfi 10–150, 1; mfi , 10, 2.
Association of the cell surface intensity of CD94/CD56
with Hsp70 reactivity
The cytolytic response of the different effector cells, pre-
stimulated with TKD, was tested in a 4-hours cytotoxicity
assay using the myeloid cell line K562 and the colon car-
cinoma sublines Cx1 and Cx2 as target cells. A pheno-
typic characterization of the tumor cell lines is summa-
rized in Table 3. Only Cx1 and Cx2 colon carcinoma
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Fig 2. CD94 and CD56 expression pattern on CD94-sorted, primary natural (NK) cells after long-term (5 weeks) stimulation with TKD.
CD94-positive NK cells were cultured in medium containing low-dose interleukin (IL)-2 (100 IU/mL) plus TKD (2 mg/mL). Medium was
completely renewed once a week. Cell density was kept at 2 3 106 cells/mL. Phenotypic characterization was performed by flow cytometry
on days 14, 21, 28, and 35 using fluorescence-conjugated CD56 fluorescein isothiocyanate and CD94 phycoerythrin antibodies. The data
represent 1 representative profile of 3 independent experiments.
Table 1 Comparative analysis of the mean fluorescence intensity
(mfi) of unstimulated and interleukin (IL)-2 (100 IU/mL) plus TKD (2
mg/mL) stimulated CD94-positive, primary natural killer (NK) cells
and NK cell lines NK-92, NKL, and YT
Mean fluorescence intensity (mfi)
Unstimulated IL-2 plus TKD
CD94-positive NK cells
CD94
CD56
156 6 42
114 6 62
416 6 176**
393 6 264**
NK-92
CD94
CD56
175 6 13
76 6 19
173 6 12
72 6 22
NKL
CD94
CD56
148 6 10
0 6 0
152 6 10
0 6 0
YT
CD94
CD56
8 6 1
0 6 0
7 6 2
0 6 0
Cells were stained with the following antibodies: CD94 phyco-
erythrin, CD56 fluorescein isothiocyanate. Mean values from 8 in-
dependent experiments are summarized 6 standard deviation.
** Significantly different from control (P , 0.05).
cells were found to be positive for MHC class-I mole-
cules; the classical NK target cell line K562 was MHC
class I–negative. With respect to the missing-self theory
(Ljunggren and Kärre 1990), K562 cells are lysed because
of a deficient MHC class-I expression associated with a
lack of inhibitory signals for KIRs. On the other hand
about 50% of the K562 cells do express Hsp70 on their
cell surface and thus provide a recognition signal for the
activating form of the C-type lectin receptor CD94. There-
fore, we assumed that recognition of K562 cells is medi-
ated by at least 2 receptor mechanisms: inactivating of
inhibitory KIRs due to the missing MHC class-I expres-
sion and activating of the C-type lectin receptor due to
the Hsp70 membrane expression. Because it is known
that Cx1 and Cx2 exhibit an identical MHC class-I and
class-II expression pattern but differ significantly with re-
spect to their Hsp70 membrane expression (Multhoff et
al 1997), an involvement of KIR could be ruled out for
the Hsp70 reactivity. In addition to MHC class-I, class-II,
and Hsp70, the expression of several adhesion molecules
including CD54 (intracellular adhesion molecule
(ICAM)), CD106 (vascular adhesion molecule (VCAM)),
CD57 and CD56 (neuronal adhesion molecule (NCAM))
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Table 2 Comparative phenotypic characterization of CD94-positive, primary natural killer (NK) cells, CD3-positive T cells, cytokine-induced
killer cells, and NK cell lines NK-92, NKL, YT stimulated with low dose interleukin-2 plus TKD for 4 days
Positively stained cells (%)
CD94 (n 5 8) CIK (n 5 3) NK-92 (n 5 6) NKL (n 5 3) YT (n 5 6) CD3 (n 5 3)
CD94
CD56
NKp30
NKp46
85 6 7a
63 6 12
58 6 14
75 6 8
18–54b
29–63b
not tested
not tested
99 6 0
99 6 1
29 6 8
62 6 16
99 6 0
15 6 3
78 6 9
77 6 2
37–54b
3 6 1
0 6 0
98 6 1
7 6 2
3 6 1
0 6 0
0 6 0
Mean fluorescence intensity (mfi)
CD94a CIK NK-92 NKL YT CD3
CD94
CD56
NKp30
NKp46
416 6 176a
393 6 264
182 6 75
502 6 223
57 6 25
181 6 48
not tested
not tested
173 6 12
72 6 22
8 6 1
8 6 1
154 6 10
4 6 1
12 6 3
10 6 1
7 6 1
0 6 0
0 6 0
44 6 7
0 6 0
0 6 0
0 6 0
0 6 0
Cells were stained with the following fluorescein-conjugated antibodies: CD3 fluorescein isothiocyanate, CD16/56 phycoerythris (PE), CD56
FITC, CD94 PE, NKp30 PE, and NKp46 PE.
a mfi of CD94/CD56-positive cells.
b Heterogeneous cell population, a range or a median value is provided.
Fig 3. Comparative cytolytic activity of CD94-positive, primary natural killer (NK) cells, NK-92, NKL, YT cell lines and CD3-positive, primary
T cells. K562, Hsp70 membrane–positive Cx1 and negative Cx2 cells were used as target cells in a 4-hours 51Cr cytotoxicity assay. The
spontaneous release for each target cell was less than 20%. It is important to note that effector to target cell ratios ranged from 10:1 to 2:1
in case of CD94-positive, primary NK cells and from 40:1 to 10:1 in case of NK cell lines. Mean values of 3 independent experiments are
shown.
were determined on the target cell lines. K562, Cx1 and
Cx2 tumor cells were strongly positive for CD54. With
respect to the adhesion molecules CD106, CD57, and
CD56, only Cx1 and Cx2 tumor cells showed a com-
parable but weak expression; K562 cells were negative for
these markers. Also, the multidrug resistance gene prod-
uct MDR-1 was comparably expressed on Cx1 and Cx2
tumor cells but not on K562 cells. With respect to the
expression of the stress-inducible MHC-related molecule
MICA, only K562 cells were found to be positive. HLA-E
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Table 3 Phenotypic characterization of K562, Hsp70-positive Cx1
and Hsp70-negative Cx2 target cells. Cells were stained with fluo-
rescein isothiocyanate or phycoerythrin-conjugated antibodies
Antibody
clone Specificity
Positively stained cells (%)
K562 Cx1 Cx2
W6/32
L243 B8.12.2
cmHsp70.1
ICAM
VCAM
NC1
MHC I
HLA DR
Hsp70
CD54 (ICAM)
CD106 (VCAM)
CD57 (HNK1)
0 6 0
0 6 0
42 6 8
99 6 0
not tested
0.2 6 0.1
99 6 1
8 6 3
93 6 3
69 6 6
9 6 3
12 6 4
99 6 1
6 6 2
18 6 6
54 6 5
10 6 3
14 6 3
NCAM 16.2
UIC2
AMO1
87G
TP25.99
CD56 (NCAM)
MDR-1 p-gp
MICA
HLA-E
HLA G
0 6 0
1 6 0
89 6 4.5
0 6 0
0 6 0
19 6 7
68 6 8
3.5 6 0.5
6 6 2
2 6 3
17 6 4
64 6 7
5 6 0
5 6 2
3 6 2
Mean values of at least 3 different experiments are shown.
Fig 5. Increased Hsp70 membrane expression after treatment with
paclitaxel (P) increases lysis of Cx2 tumor target cells. Cx1 and
Cx2 cells were either heat shocked at the nonlethal temperature of
428C for 1 hour (hs) or incubated with a nonlethal dose of paclitaxel
(1 mM) for 1 hour. The major histocompatibility complex class I, class
II, and Hsp70 phenotype of the tumor target cells before and after
treatment are summarized in Table 4. Cx2 tumor cells exhibited an
upregulated Hsp70 expression after P treatment that correlates with
an increased sensitivity to lysis. Nonlethal heat shock neither in-
creases Hsp70 membrane expression nor lysis of Cx2 cells. The
spontaneous release for each target cell was less than 20%. Effector
to target cell ratios were 10:1, 5:1, and 2:1.
Fig 4. Hsp70-specific antibody inhibits the increased lysis of Cx1
tumor cells. After labeling, Cx1 and Cx2 tumor target cells were
incubated for 15 minutes with Hsp70-specific monoclonal antibody
(cmHsp70.1, 5 mg/mL) and used as targets for CD94-sorted natural
killer cells. Lysis of Cx2 cells remained unaffected after antibody
treatment (data not shown). The spontaneous release for each tar-
get cell was less than 20%. Effector to target cell ratios were 10:1,
5:1, and 2:1.
and HLA-G, as nonclassical MHC molecules mediating
interaction with C-type lectin receptors (Borrego et al
1998), were not found on any of the tested tumor cell
lines. A comparison of K562 and Cx1 and Cx2 cell lines
revealed differences in the MHC class-I, MDR-1, and
MICA expression. In contrast, Cx1 and Cx2 tumor sub-
lines exhibited identity in all tested markers with 1 ex-
ception, the Hsp70 membrane expression.
The cytolytic response, mediated by different NK cell
types was tested against all 3 target cell lines K562, Cx1
and Cx2 cells. It is important to note that the effector to
target cell ratios (E:T) ranged from 10:1 to 2:1 in the case
of CD94-positive, primary NK cells and was 4-times high-
er (40:1 to 10:1) in all other effector cell lines. K562 cells
were lysed by CD94-positive NK cells, NK-92, and NKL
cells. At a defined E:T ratio of 10:1, CD94-positive cells
showed the strongest cytolytic activity against K562 cells
with 71%. In contrast only half of the K562 cells were
killed by NK-92 cells at this E:T ratio. K562 cells were
also killed by NKL cells but to a much lesser extent as
compared with primary NK cells. YT cells and primary
T cells did not lyse K562 cells at all. The MHC I-positive
and Hsp70-positive Cx1 and Cx2 tumor cell lines were
only lysed by CD94-positive, primary NK cells; however,
with respect to the differential Hsp70 membrane expres-
sion, lysis of Cx2 cells was significantly weaker com-
pared with that of Cx1 cells. Apart from primary NK
cells, the NK cell lines were unable to kill Cx1 and Cx2
target cells. This might be because of the inhibitory signal
mediated by the MHC class-I expression. Only CIK cells
exhibited a weak but indistinguishable lysis of Cx1 and
Cx2 cells, at an E:T ratio 4-times higher than that of pri-
mary NK cells (data not shown).
Because Cx1 and Cx2 tumor cells differ only with re-
spect to the Hsp70 membrane expression, we speculated
that differences in lysis mediated by TKD-stimulated
CD94-positive primary NK cells is due to Hsp70 that ap-
pears to function as an activating signal. CD94 has been
found to be involved in the interaction of NK cells with
Hsp70 protein (Gross et al 2003). Although all NK cell
lines were positive for CD94, they showed different cy-
totoxicity against Hsp70-positive tumor target cells.
Therefore, we suggest that the differences in cell kill
might be associated with the cell surface density of CD94.
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Table 4 Phenotypic characterization of viable Hsp70-positive Cx1 and Hsp70-negative Cx2 target cells either untreated, after nonlethal
heat shock (hs, 428C for 1 h, 378C for 12 h), or treatment with the nonlethal concentration of paclitaxel (P, 1 mM for 2 h, 378C for 12 h;
Gehrmann et al 2002)
Antibody Specificity
Positively stained cells (%)
Cx1 Cx2 Cx1hs Cx2hs Cx1P Cx2P
W6/32
L243
cmHsp70.1
MHC I
HLA DR
Hsp70
98 6 1
7 6 3
89 6 6
97 6 1
5 6 2
21 6 5
98 6 2
4 6 3
85 6 3
99 6 1
5 6 2
19 6 4
98 6 2
3 6 3
87 6 8
99 6 1
5 6 4
79 6 4
Cells were stained with fluorescein isothiocyanate or phycoerythrin-conjugated antibodies. Mean values of at least 3 different experiments
are shown. Untreated and treated cells were used as target cells for CD94-sorted natural killer cells in cytotoxicity assays.
Fig 6. Comparative cytolytic activity of CD94 high (111) and CD94 low (11) expressing natural killer (NK) cells. Peripheral blood mono-
nuclear cells were separated in CD94 high (111) and CD94 low (11) expressing NK cells by flow cytometry cell sorting. Both subpopulations
were stimulated with low dose interleukin-2 (100 IU/mL) and TKD (2 mg/mL) for 4 days and used as effector cells in a 4-hours 51Cr cytotoxicity
assay. Major histocompatibility complex class I- and Hsp70-positive tumor cells were used as target cells. The spontaneous release for each
target cell was less than 20%. Effector to target cell ratios were only 2:1, 1:1, and 0.5:1.
Cells with high (111, mfi . 300) expression levels of
this receptor showed an increased kill of Hsp70-positive
tumor cells. NK cells with moderate (11, mfi 150–300)
or low (1, mfi , 10) expression levels in this marker did
not show any Hsp70-specific kill, indicating an essential
role of the protein density of CD94 for Hsp70 reactivity.
Study of Michaelsson (2002) revealed that HLA-E, pre-
senting leader peptides from Hsp60, results in increased
sensitivity to lysis mediated by NK cells due to a loss of
recognition by CD94/NKG2A inhibitory receptors. Be-
cause Cx1 and Cx2 tumor cells both exhibited a com-
parable but very low HLA-E surface expression pattern
and K562 cells completely lack expression of HLA-E, an
involvement of HLA-E in the recognition by CD94-posi-
tive, primary NK cells was excluded. Similar to CD94,
CD56 was upregulated in CD94-sorted, primary NK cells
after stimulation with TKD. Because CD56 mediates hom-
ophilic cell adhesion, we speculated about a role of CD56
in the cytolytic response against Hsp70-positive tumor
target cells. However, Cx1 and Cx2 cells revealed iden-
tical CD56 expression levels (Multhoff et al 1997), where-
as K562 cells lack CD56 expression (Table 3). In contrast
to this finding, Cx1 and K562 cells, but not Cx2 cells,
were lysed by primary TKD-stimulated NK cells. There-
fore, the involvement of CD56 in the cytolytic mechanism
of Hsp70-positive tumor target cells remained to be elu-
cidated. Concomitant with the finding that stimulation of
NK cell lines NK-92, NKL, and YT with TKD did not
increase the cell surface expression of CD94 and CD56,
the cytolytic activity against Hsp70 membrane–positive
tumor cells was also not enhanced.
To prove that indeed Hsp70 provides the target struc-
ture for CD94-sorted, TKD-stimulated NK cells, antibody
blocking studies were performed. As illustrated in Figure
4, the increased lysis of Cx1 tumor cells could be re-
duced to the degree of Cx2 cell lysis by Hsp70-specific
antibody. In contrast, lysis of Cx2 cells remained unaf-
fected after antibody incubation (data not shown). These
findings were further supported by the fact that a pacli-
taxel-induced increase in membrane-bound Hsp70, es-
pecially on Cx2 cells, correlated with an increased sen-
sitivity toward lysis mediated by NK cells (Fig. 5). The
Hsp70 phenotype together with the MHC class-I and II
expression in Cx1 and Cx2 tumor cells before and after
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Fig 7. The 14-mer Hsp70-peptide TKD, but not the 14-mer LKD,
exhibiting 1 amino acid exchange at position 1 (T to L), stimulates
Hsp70 reactivity concomitant with an increase in the mean fluores-
cence intensity of CD94 on natural killer cells. Lysis of Cx1 tumor
cells was significantly enhanced as compared with that of Cx2 cells.
The spontaneous release for each target cell was less than 20%.
Effector to target cell ratios were 10:1, 5:1, and 2:1.
nonlethal heat shock (428C) or treatment with a nonlethal
concentration of paclitaxel (1 mM) are summarized in Ta-
ble 4. Heat was unable to induce an increased membrane
expression of Hsp70 and thus lysis of Cx2 cells remained
unaltered (Fig. 5, left graph). However, after paclitaxel
treatment (Fig. 5, right graph), Hsp70 expression was sig-
nificantly upregulated in Cx2 tumor cells. Concomitantly
the percentage-specific lysis drastically increased. Be-
cause upregulation of membrane-bound Hsp70 in Cx1
cells was only marginal, no upregulated cytotoxicity of
Cx1 cells was observed (data not shown). In summary,
these findings clearly indicate that Hsp70 provides the
target structure for TKD-stimulated, CD94-positive pri-
mary NK cells.
In an effort to further elucidate the role of CD94 in the
cytolytic activity, more detailed additional cell-sorting ex-
periments were performed. As demonstrated in Figure 6,
primary NK cells consist of 2 subgroups that differ with
respect to their CD94 mfi cell surface expression pattern.
By cell sorting through CD94, 2 subpopulations with
CD94 high (111, mfi .300), and CD94 intermediate
(11, mfi 150–300) mfi were generated. Both subpopula-
tions were incubated separately with low-dose IL-2 and
TKD for 4 days. A representative flow cytometric profile
of both populations is illustrated in the middle panel of
Figure 6. The CD94 high population was also strongly
positive for CD56, whereas the CD94 intermediate pop-
ulation was weakly positive for CD56. Both subpopula-
tions were tested as effector cells in a 4-hours cytotoxicity
assay using MHC class-I and Hsp70-positive tumor cells
as targets. As illustrated in Figure 6, the CD94 high pop-
ulation showed an increased killing activity of Hsp70-
positive tumor cells compared with the CD94 interme-
diate population.
Finally, the role of the 14 amino acid peptide TKD, as
a naturally occurring sequence of the Hsp70-protein, in
the stimulation of the NK cell activity and CD94 expres-
sion was analyzed in comparison with a mutated 14-mer
peptide that exhibits 1 amino acid sequence exchange at
position 1 (T-L). Both peptides were tested under identi-
cal conditions (2 mg/mL for 4 days) with respect to their
immunostimulatory efficacy on CD94-sorted, primary
NK cells. Interestingly, only TKD but not LKD in com-
bination with low-dose IL-2 (100 IU/mL) was able to in-
duce Hsp70 reactivity toward Cx1 tumor cells. Further-
more, an increase in CD94 mfi was also only observed
with TKD-stimulated NK cells (Fig. 7). Taken together,
these findings support our hypothesis that indeed the mfi
of the CD94 expression is a relevant marker for the Hsp70
reactivity.
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The Cell Surface-Localized Heat Shock Protein 70 Epitope
TKD Induces Migration and Cytolytic Activity Selectively in
Human NK Cells1
Robert Gastpar,2* Catharina Gross,2* Lydia Rossbacher,* Joachim Ellwart,† Julia Riegger,*
and Gabriele Multhoff 3*
Profiling of surface-bound proteins uncovers a tumor-selective heat shock protein 70 (Hsp70) membrane expression that provides a
target structure for human NK cells. Hsp70 peptide TKD (TKDNNLLGRFELSG; aa 450–463) was found to enhance the cytolytic
activity of NK cells. In this study, we demonstrate that TKD-activated CD3CD56CD94 NK cells are selectively attracted by Hsp70
membrane-positive tumor cells, and supernatants derived thereof. Hsp70 membrane-negative tumors failed to attract these NK cells.
The capacity to migrate was associated with a substantial lytic activity against Hsp70-positive tumor cells. Because NK cell migration
was independent of cell-to-cell contact, the involvement of a soluble factor was assumed. Interestingly, synthetic Hsp70 protein and
Hsp70 peptide TKD, mimicking surface-bound Hsp70, initiates migration of NK cells in a concentration-dependent (1–5g/ml), highly
selective, and chemokine-independent manner. In summary, our results indicate that Hsp70 peptide TKD not only stimulates cytolysis
but also chemotaxis in CD3CD56CD94 NK cells. The Journal of Immunology, 2004, 172: 972–980.
U nlike T and B cells, NK cells express neither clonallyrestricted, genetically diverse TCRs nor Abs. The inter-action with target cells depends on an interplay between
germline-encoded inhibitory receptors, with specificity for certain
MHC class I alleles, and activating receptors whose ligands are
less well characterized (1–3). Classical and nonclassical MHC
class I molecules were characterized as interacting partners for
killer cell Ig-like receptors, Ig-like transcripts, and C-type lectin
receptors. According to the missing-self theory, target cells lacking
MHC class I expression are susceptible to NK cell-mediated cy-
totoxicity, because they fail to provide the ligand for inhibitory
receptors (1, 2, 4). We identified a heat shock protein 70 (Hsp70)4
epitope (TKDNNLLGRFELSG; aa 450–463) on tumor cells as a
recognition site for NK cells. To examine the role of membrane-
bound Hsp70 in more detail, we investigated the ability of tumor
cells with differential Hsp70 membrane expression pattern to at-
tract effector cells. NK cells circulate in the peripheral blood or
reside in the spleen and liver but are also present in thymus, bone
marrow, and lymph nodes. Following viral and bacterial infec-
tions, NK cells accumulate in extrahematic organs (5–7). In addi-
tion, NK cells efficiently infiltrate murine tumors, especially those
lacking host MHC class I molecules due to defects in transporter-
associated Ag processing or 2-microglobulin genes (8, 9). In
vitro, NK cell migration is inducible by several chemokines and
cytokines including macrophage-inflammatory protein-1, IFN--
inducible protein 10, TNF-, and IL-2 (10–17). Chemokine
knockout mice showed severe defects in the migration of NK cells
into solid tumors (11). Apart from chemokines, less is known
about additional stimuli, for the recruitment of NK cells. There-
fore, in the present study we intended to identify tumor cell-de-
rived factors involved in NK cell migration.
Several groups reported on a plasma membrane localization of
molecular chaperones on tumor cells (18–20). We detected Hsp70,
the major stress-inducible member of the HSP70 group on a num-
ber of different tumor cells, but not on normal tissues (21). By cell
sorting via Hsp70-specific Ab, we generated colon carcinoma sub-
lines with a stable high and low Hsp70 cell surface expression.
Apart from Hsp70, the sublines exhibited an identical expression
pattern of other cell surface markers, including MHC and adhesion
molecules (22). The Hsp70 epitope exposed to the extracellular
milieu could be identified as the amino acid sequence TKDNNLL-
GRFELSG (TKD; aa 450–463), which is part of the C-terminal
domain of Hsp70 (23, 24). We identified NK cells as being rele-
vant effector cells for the recognition of membrane-bound Hsp70
on tumor cells (21, 22, 25–27). Incubation of NK cells with Hsp70
peptide TKD results in an up-regulated CD94 expression that is
associated with an enhanced lytic activity against Hsp70 mem-
brane-positive tumor target cells (24). Binding studies revealed a
firm interaction of Hsp70 and Hsp70 peptide TKD to CD94-pos-
itive NK cells (28). In this study, we studied the migratory capacity
of Hsp70-activated NK cells toward Hsp70 membrane-positive
and -negative tumor cells and supernatants derived thereof. In an
effort to identify a tumor-derived soluble factor, different Hsp70-
related peptides, including TKD, were tested as potential attract-
ants for Hsp70-reactive effector cells.
Materials and Methods
Peptides and proteins
The following 14-mer peptides TKDNNLLGRFELSG (TKD; aa
450–463), TKDNNLLGKFELTG (Hsc70 14-mer; aa 450–463), and
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AADNKSLGQFNLDG (DnaK 14-mer; aa 447–460) were produced by
F-moc synthesis (fluorenylmethoxycarbonyl/t-butyl-based solid-phase pep-
tide chemistry method; Bachem, Bubendorf, Switzerland), as previously
described (24). The purity of each peptide was 96%.
Human rHsp70 protein was purchased from Stressgen (SPP-75; Victo-
ria, British Columbia, Canada).
Cell culture
The adherent growing human pancreatic carcinoma cell line Colo357 was
separated into two sublines, Colo and Colo, by FACS according to their
Hsp70 plasma membrane expression using an Hsp70FITC Ab specific for
the epitope presented to the surface (clone cmHsp70.1; multimmune, Re-
gensburg, Germany). The resulting sublines exhibit either high (Colo) or
low (Colo) Hsp70 plasma membrane expression. Similarly, the human
colon carcinoma cell line CX2 was separated into sublines with stable high
(CX) and stable low (CX) Hsp70 plasma membrane expression, as pre-
viously described (22). The cell lines were maintained mycoplasma free in
RPMI 1640 medium containing 10% heat-inactivated FCS (Life Technol-
ogies, Eggenstein, Germany) supplemented with 100 IU/ml penicillin, 100
g/ml streptomycin, 2 mM L-glutamine, and 1 mM sodium pyruvate, and
were harvested by treatment with trypsin/EDTA (all cell culture reagents
were purchased from Life Technologies).
Supernatants were collected from tumor cells cultured for 48 h in a
humidified atmosphere, at 37°C and 5% CO2. Then, supernatants were
centrifuged at 300  g to remove cell debris, and filtered through a 0.2-m
filter (Costar, Corning, NY).
Selection of CD94-positive and CD94-negative cells
CD94-positive and -negative cells were selected from PBMC derived from
healthy human donors using CD94-biotin Ab (HP3-D9; Ancell Immunol-
ogy Research Products, Bayport, MN) and anti-biotin magnetic microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, 1  108 cells/ml
were incubated with 5 g of biotin-conjugated CD94 Ab for 30 min at 4°C.
After extensive washing with MACS buffer (PBS, 0.5% BSA, and 2 mM
EDTA), cells were incubated with anti-biotin magnetic microbeads for 15
min at 4°C. Afterward, cells were washed and separated using a LS/VS
column (Miltenyi Biotec).
PBL, CD94-positive, and CD94-negative cells were incubated for 4
days in RPMI 1640 medium (Life Technologies) supplemented with heat-
inactivated FCS (10%) plus 100 IU/ml IL-2 and 2 g/ml Hsp70 peptide
TKD at 37°C, in a humidified atmosphere containing 5% CO2.
Migration assay
Migration assays were performed in a Transwell cell culture system
(Costar; Corning) in triplicate. The upper and lower compartments were
separated by a tissue culture polycarbonate membrane (polyvinyl-pyrroli-
done free; Nucleopore, Pleasanton, CA), 6.5 mm in diameter, with a pore
size of 5 m. Tumor target cells (CX, CX, Colo, Colo), cell culture
supernatants, and peptides were placed in a total volume of 600 l of RPMI
1640 medium containing 10% FCS in the lower compartment. Then, 2 
106 PBL or CD94-positively sorted cells stimulated with TKD were la-
beled with sodium [51Cr]chromate (100 Ci; NEN-DuPont, Boston, MA)
for 2 h. After extensive washing, labeled cells were counted, and 0.2  106
cells were resuspended in 100 l of RPMI 1640 medium supplemented
with 10% FCS and carefully added to the upper compartment. rIL-15 (10
ng/ml; Immunex, Seattle, WA) served as a positive control for chemotaxis
(29). After a 4-h incubation period in a humidified incubator at 37°C and
5% CO2, the cell suspension in the lower compartment was harvested, and
radioactivity was measured on a gamma counter (Packard Instruments,
Meriden, CT). The number of migrated cells was determined according to
the following equation: % specific migration  (experimental value 
spontaneous value)/(maximum value  spontaneous value)  100.
Flow cytometry
Directly conjugated Abs (CD3FITC, CD16/56PE, CD56FITC (BD Bio-
sciences, Heidelberg, Germany); NKG2APE (Immunotech Coulter, Mar-
seille, France); CD94PE (Ancell); CD94FITC (BD PharMingen, San Diego,
CA)) were added to cell suspensions (1  105 cells), incubated for 20 min
on ice, washed, and analyzed on a FACSCalibur instrument (BD Bio-
sciences). The percentage of single- or double-positively stained cells was
defined as the number of specifically stained cells minus the number of
cells stained with an isotype-matched control Ab.
Cytotolysis assay
CX, CX and Colo, Colo tumor target cells (3  103) were incubated
for 1 h with sodium [51Cr]chromate (100 Ci; NEN-DuPont), extensively
washed, and plated with effector cells at indicated E:T ratio. After a 4-h
incubation period at 37°C and 5% CO2, supernatants were harvested, and
radioactivity was determined by gamma counting. The percentage of spe-
cific lysis was calculated according to the following equation: % specific
lysis  (experimental release  spontaneous release)/(maximum release 
spontaneous release)  100. The spontaneous release was 15% for each
target cell.
Results
TKD-stimulated PBL selectively infiltrate Hsp70-positive tumor
cell clusters
Previously, we reported that incubation with Hsp70 peptide TKD
and low-dose IL-2 increases the cytolytic activity of NK cells
against tumor target cells expressing Hsp70 on their cell surface
(24). The role of membrane-bound Hsp70 as a target structure for
NK cells has been demonstrated using HLA-identical colon car-
cinoma sublines CX and CX that differ profoundly with respect
to their capacity to express Hsp70 on the plasma membrane (22).
To obtain further insight into the interaction of TKD-stimulated
effector cells and Hsp70-positive tumor target cells, a long-term
coincubation experiment was set up. TKD-stimulated PBL were
added to exponentially growing tumor cell subpopulations. After a
24-h incubation period, the morphology of cocultures and controls,
omitting PBL, was analyzed by light microscopy (Fig. 1). The
inserts represent a 2.5-fold higher magnification of a selected cell
cluster. When cultivated in the absence of TKD-stimulated PBL,
both Hsp70-positive CX and Hsp70-negative CX cells showed
a similar morphology, forming adherent spheroidal cell clusters
(control). In contrast, the morphology of CX cells cocultured
with TKD-stimulated PBL (PBL) differed significantly from that
of CX cells, indicating that activated PBL were attracted by
Hsp70-positive CX tumor cells. Almost all CX cell clusters
were infiltrated by effector cells, whereas Hsp70-negative CX
cell clusters remained unaffected. In addition, a significantly re-
duced viability was observed in CX cells compared with CX
cells after coincubation with TKD-activated PBL (data not shown).
These findings are in line with results from cytotoxicity assays
showing that Hsp70-positive target cells are more susceptible to
lysis mediated by TKD-stimulated effector cells, as compared with
Hsp70-negative target cells (22, 25).
FIGURE 1. Infiltration of Hsp70-positive tumor cell clusters by TKD-
activated PBL. Hsp70 membrane-positive CX and -negative CX cells
(0.1  106 cells/well) were seeded in 96-well flat-bottom plates and grown
for 48 h. Tumor cells were coincubated with either medium or TKD-stim-
ulated PBL for another 24 h. Light-microscopic analysis is shown of tumor
cells only (control; upper row) or tumor cells coincubated with TKD-ac-
tivated PBL (PBL; lower row) at a magnification of 5 on a Zeiss
(Oberkochen, Germany) Axiovert 25 microscope; small insets show a 2.5-
fold magnification of one representative cell cluster. The scale bar in the
lower right panel indicates 100 m.
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TKD-stimulated PBL migrate to Hsp70 membrane-positive
tumor cells and supernatants derived thereof
The increased sensitivity of Hsp70-positive tumor target cells me-
diated by TKD-stimulated NK cells has been demonstrated by us-
ing HLA-identical colon carcinoma sublines CX and CX with
differential Hsp70 membrane expression. In this study, an addi-
tional tumor model system was established using the human pan-
creatic carcinoma cell line Colo357. Initially, Colo357 cells ex-
press Hsp70 on 50% of the cells. Identical with the CXCX
cell separation, Hsp70 high (Colo)- and low (Colo)-expressing
sublines were generated by cell sorting via an Hsp70 mAb (22).
Fig. 2A illustrates the percentages of Hsp70 positively stained cells
in CX (90%) and CX (20%), and in Colo (73%) and Colo
(34%) sublines after cell sorting. The migratory capacity of TKD-
activated PBL was tested toward these different tumor sublines and
against supernatants derived thereof. The cell density of the effec-
tor and tumor cells in the lower compartment, the pore size and
pore distribution, and the coincubation time were optimized in
kinetic studies (data not shown). In a first set of experiments, CX,
CX and Colo, Colo cells, with differential Hsp70 membrane
expression pattern, were cultured in the lower compartment for
48 h. Then, TKD-activated PBL were added carefully to the upper
compartment and after a 4-h coincubation period, specific migra-
tion was measured. As depicted in Fig. 2B, migration of TKD-
activated PBL, derived from five independent healthy human vol-
unteers, toward Hsp70 plasma membrane-positive CX (11%) and
Colo (10%) was higher as compared with target cells with low
Hsp70 membrane expression (CX, 5%; Colo, 6%). Differences
in migration toward CX, CX cells was more pronounced as
compared with Colo, Colo tumor cells. This finding is due to
the fact that differences in the Hsp70 cell membrane expression in
the positive and negative sublines was also weaker in the Colo cell
system. Migration to 10 ng/ml of the cytokine IL-15, serving as a
positive control, was 15% (data not shown). This is in line with
previously published data (29).
It has been shown that coincubation of IL-2-activated NK cells
and K562 target cells results in effector-target cell conjugates that
trigger chemokine secretion and chemoattraction of additional NK
cells (30). To rule out chemoattraction induced by direct cell-to-
cell contact, cell-free supernatants derived from 2-day tumor cell
cultures, were used. Interestingly, the migration assay toward su-
pernatants of Hsp70 membrane-positive CX and Colo cells re-
sulted in significant migration (12%), whereas that toward CX
and Colo cells did not induce migration (3 and 6%, respectively)
(Fig. 2C). This suggests that migration of TKD-activated PBL
might be induced by a soluble factor that is secreted equally well
by Hsp70 membrane-positive CX and Colo tumor cells. Recent
data provide evidence for a tumor-specific release of members of
the HSP70 family (31), indicating that the soluble factor released
by CX and Colo tumor cells might be Hsp70 or an HSP-related
protein.
It is also important to note that incubation of PBL with low dose
IL-2 plus Hsp70 peptide TKD is a prerequisite for the induction of
the migratory capacity, because unstimulated PBL or PBL cultured
with IL-2 alone did not migrate toward Hsp70 membrane-positive
and -negative tumor target cells, or supernatants derived thereof
(data not shown).
CD3CD56CD94 NK cells exhibit migratory and cytolytic
activity against Hsp70 membrane-positive tumor cells
According to the preceding findings, we were interested in the
phenotype and functional properties of both the migrated and non-
migrated cell populations. Therefore, after a 4-h migration assay
toward supernatants of Hsp70 membrane-positive tumor cells,
nonmigrated cells from the upper compartment and migrated cells
from the lower compartment were collected and immunopheno-
typed. The initial population (PBL) consisted of 34% CD3 T
cells, 11% CD3CD16/56 NKT cells, and 29% CD3CD16/56
NK cells (Fig. 3A). The nonmigrated cells showed no significant
differences in the percentage of CD3 T cells (36%), and
CD3CD16/56 NKT cells (7%). However, the CD3CD16/56
FIGURE 2. TKD-activated PBL migrate toward Hsp70-positive target
cells and supernatants (SN) derived thereof. A, Phenotypic characterization
of the Hsp70 membrane expression on human colon carcinoma cell sub-
lines CX and CX and human pancreatic carcinoma cell sublines Colo
and Colo. The sublines were generated by FACS using Hsp70FITC Ab
(clone cmHsp70.1), which recognizes the Hsp70 surface epitope. The data
represent the mean percentage (SEM) of Hsp70-positively stained cells
of at least eight independent experiments. B, Migration of TKD-activated
PBL to CX, CX and Colo, Colo tumor cells. Migration was tested in
a Transwell system with two compartments separated by a polycarbonate
membrane with a pore size of 5 m. In the lower compartment, CX, CX
or Colo, Colo cells (0.2  106 cells per well) were grown for 48 h in 600
l of RPMI 1640 medium containing 10% FCS. PBL, stimulated with
TKD (2 g/ml) plus low-dose IL-2 (100 IU/ml) for 4 days, were harvested,
labeled with sodium [51Cr]chromate (100 Ci), and transferred into the
upper chamber of the Transwell system. Following a 4-h coincubation
period, radioactivity was determined in PBL that migrated to the lower
chamber. Specific migration was calculated as described in Materials and
Methods. Results are shown as the mean  SEM of at least five indepen-
dent experiments. Statistically significant (Student’s t test), , p  0.05. C,
In the next set of experiments, 600 l of cell-free culture supernatant (SN)
of CXCX and ColoColo tumor cells cultured for 48 h were admin-
istered in the lower compartment. Following a 4-h coincubation period
with PBL, radioactivity was determined in the migrated cells of the lower
chamber. Specific migration was calculated as described in Materials and
Methods. Results are shown as the mean  SEM of at least five indepen-
dent experiments. Statistically significant (Student’s t test), , p  0.05; ,
p  0.005.
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NK cell subpopulation shrank from 29 to 17%. In contrast, a sig-
nificant increase in the percentage of CD3CD16/56 NK cells
was observed (from 29 to 61%) within the migrated cell popula-
tion, whereas the amount of CD3 T cells was found to be reduced
by half (from 34 to 18%). These results suggest that predominantly
CD3CD16/56 NK cells were attracted by supernatants derived
from Hsp70 membrane-positive tumor cells.
Recently, we demonstrated an increase in cell surface density of
the C-type lectin receptor CD94 after TKD stimulation, selectively
on NK cells (28, 32). Furthermore, the enhanced lysis of tumor
target cells with Hsp70 plasma membrane expression by TKD-
stimulated NK cells was blockable in the presence of CD94 Ab
(32). This suggests an involvement of CD94 in the interaction of
NK cells with Hsp70-expressing tumor cells. Therefore, the role of
CD94 was studied in more detail with respect to the migratory
capacity. Compared with the original population, the percentage of
CD56CD94 cells was markedly reduced in the nonmigrated cell
population (from 28 to 18%). Concomitantly, a drastic increase of
CD56CD94 cells was found in the migrated cell population
(from 28 to 59%; Fig. 3A). The results of five independent migra-
tion assays confirmed this finding; the amount of CD56CD94
cells was always twice as high in the migrated cell population if
FIGURE 3. NK cells migrate and exhibit lytic activity against Hsp70-positive tumor target cells. A 4-h migration assay was performed using TKD-
stimulated PBL against supernatants of Hsp70-positive CX tumor cells to determine the phenotype and the lytic activity of nonmigrated and migrated cells
in comparison with the initial PBL population. A, Nonmigrated PBL (middle panel), and migrated cells (right panel) were harvested and analyzed by
multiparameter flow cytometry using CD3FITC, CD16/56PE, CD56FITC, and CD94PE Abs, and a double staining was performed with CD94FITC and
NKG2APE Abs. The phenotype of each cell population was compared with the initial PBL population (left panel) that had been stimulated with TKD for
4 days. Numbers in the dot plot diagrams indicate percentage of positively stained cells for each quadrant. Data of one representative result of five
independent experiments is shown. Increase in CD56CD94 cells was always doubled in the migrated cell population if compared with the initial PBL
population. B, Concomitantly, the cytolytic activity of the three effector cell populations (initial PBL, nonmigrated PBL, and migrated PBL) was tested in
a standard 4-h chromium release assay. Specific lysis of the effector cells was assessed against CX and Colo tumor target cells with high Hsp70 surface
expression (F) and CX and Colo tumor target cells with low Hsp70 surface expression (E). E:T ratios ranged from 1:1 to 20:1. Data represent the mean
values of four independent experiments.
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compared with the initial PBL and three to four times higher if
compared with the nonmigrated cell population. No significant
changes were observed in the CD56CD94 (7 vs 8 vs 10%) and
in the CD56CD94 cell population (4 vs 2 vs 6%), indicating
that predominantly CD56CD94 NK cells were attracted by cell
culture supernatants of CX cells. Multiparameter staining using
CD94FITC- and NKG2APE-specific Abs revealed that the migrated
cells were double positive for CD94 and NKG2A.
To correlate phenotype and function, cytolysis assays were per-
formed using nonmigrated and migrated cells as effectors. The
initial cell population (PBL) exhibited only a moderately increased
lytic activity against Hsp70-positive CX and Colo tumor cells
at an E:T ratio of 20:1 (Fig. 3B, left graph). Nonmigrated cells
consisting predominantly of T cells showed a very weak lytic ac-
tivity against all four tumor sublines (Fig. 3B, middle graph). In-
terestingly, the migrated cell population showed a very strong lytic
activity against Hsp70-positive tumor target cells (CX and
Colo) and a weaker activity against Hsp70-negative tumor target
cells (CX and Colo) (Fig. 3B, right graph). Because this effect
is associated with an increase in the percentage of
CD3CD56CD94 NK cells, we speculate that these effector
cells might be responsible for migration and lytic activity.
To further confirm this hypothesis, functional tests were per-
formed using MACS-sorted effector cell populations. Fig. 4 illus-
trates the phenotypic characterization of CD3-sorted PBL that had
been stimulated with TKD for 4 days, directly after cell separation.
The cytolytic activity of both cell populations was tested against
Hsp70-positive tumor target cells (CX, Colo, and K562). K562
cells are susceptible to NK cell-mediated lysis due to a missing
MHC class I expression that might trigger inhibitory NK cell re-
ceptors, and due to the Hsp70 membrane expression as a trigger for
CD94 (our unpublished observation). The CD3 T cell population
(93  10% CD3CD16/56) showed no lytic activity (Fig. 4A). In
contrast, the CD3 cell population consisting of 44  22%
CD3CD16/56 NK cells lysed Hsp70-positive tumor target cells
to a significant extent (Fig. 4A). Regarding these findings, CD3 T
cells were excluded as mediators of the cytolytic response against
Hsp70-positive tumor target cells.
Preceding migration assays indicated that the phenotype of the
migrated cells might be CD3CD56CD94. To analyze the role
of CD94 in more detail, TKD-stimulated PBL derived from three
independent donors were separated by MACS using a CD94 Ab.
The CD94-depleted population (4  2% CD56CD94) showed
a negligible lysis of Hsp70-positive tumor target cells (Fig. 4B),
whereas the CD94-enriched population (58  9% CD56CD94)
showed a strong lytic activity against CX, Colo, and K562
cells. Compared with the CD3 separation, following CD94 enrich-
ment, the cytolytic activity was slightly increased. The CD94-en-
riched cell population consists of CD3CD16/56 NK cells,
CD3CD16/56 NKT cells, and CD3CD16/56 T cells. To de-
fine which subpopulation is responsible for the Hsp70-mediated
cytotoxicity, CD94 cells were further separated into a
CD94CD3 (79  19% CD56CD94) and a CD94CD3 cell
subpopulation (70  7% CD56CD94). A strong lytic activity
against Hsp70-positive CX cells was mediated by the
CD94CD3 population (Fig. 4C). Due to the fact that the CD3
T cell population still contains 28  8% CD56CD94 NK cells,
a weak cytolytic activity was also seen in this population. In con-
trast to Hsp70-positive tumors, lysis of Hsp70-negative counter-
parts (CX, Colo) was 10%.
Taken together, these results support our migration data show-
ing that CD3CD56CD94 NK cells are responsible for the mi-
gratory and lytic activity against Hsp70 membrane-positive tumor
cells.
Hsp70 protein and Hsp70 peptide TKD stimulate migration in
CD3CD56CD94 NK cells
Earlier, we have shown that not only Hsp70-positive tumor cells
but also supernatants derived thereof were able to induce NK cell
migration. Because supernatants of Hsp70 membrane-negative tu-
mor cells were unable to induce migration, attraction appeared to
be associated with Hsp70 membrane expression. Therefore, we
speculate about a soluble factor that might be released by Hsp70
membrane-positive tumor cells.
The Hsp70 epitope recognized by NK cells is identical with the
14-aa peptide TKD, residing in the C-terminal domain (24). There-
fore, in addition to full-length Hsp70 protein, the cell surface-
localized peptide TKD, mimicking the NK cell recognition site in
a soluble form, was tested in migration assays. As shown in Fig.
5A, maximal migratory capacity of NK cells was detected if 10
g/ml Hsp70 protein diluted in fresh medium was subjected to the
lower compartment. A comparable migration of NK cells was in-
duced by 1 g/ml TKD peptide. In summary, these data indicate
that Hsp70 protein and Hsp70 peptide TKD both exhibited similar
chemotactic activity, which is comparable with that of superna-
tants derived from Hsp70 membrane-positive tumor cells.
In our previous experiments, the chemotactic factor was placed
in the lower compartment, and the effector cells were placed in the
upper compartment. To rule out chemokinesis or random cell mo-
bility, the following experiments were performed. One criteria for
directed chemotaxis is migration along a positive gradient. If the
chemoattractant is equally distributed (no gradient), or in case of a
negative gradient, active migration should therefore be inhibited.
Fig. 5B demonstrates that migration of CD94-positive cells in re-
sponse to 1 g/ml TKD was observed only in a positive TKD-
gradient (16%). In the presence of equal TKD concentrations in the
upper and lower compartments, migration was inhibited (5%; ki-
nesis I). Similar results were seen in a negative gradient (3%;
kinesis II). These results demonstrate that migration in response to
TKD was rather chemotaxis than chemokinesis or random cell
mobility.
To determine whether TKD-related peptides also stimulate CD94-
positive NK cells to migrate, two peptides derived from members
of the HSP70 group (Hsc70450–463 and DnaK447–460) were used at
concentrations ranging from 0.1 to 10 g/ml (Fig. 5C). Interestingly,
TKD-activated CD94-positive NK cells were selectively attracted by
TKD, whereas no migration was induced by HSP70 peptides derived
from Hsc70 and DnaK. Because Hsc70450–463 (TKDNNLLGKF
ELTG) and DnaK447–460 (AADNKSLGQFNLDG) differ from TKD
(TKDNNLLGRFELSG) by 2- and 7-aa exchanges (indicated by bold
type and underlining), respectively, the induction of migration me-
diated by TKD has to be considered to be specific. Furthermore,
the migratory response to TKD was concentration dependent,
showing an optimal concentration range between 1 and 5 g/ml.
Concentrations 5 g/ml resulted in a reduced migratory activity
of NK cells. In contrast to CD94-positive NK cells, CD94-negative
T cells showed no migration toward the HSP70 peptides at any
concentration. Taken together, these findings demonstrate a con-
centration-dependent, specific attraction of CD94-positive NK
cells by Hsp70 peptide TKD.
Discussion
NK cells circulate in the blood vessel system but also reside in
solid tissues. Mobilization, recruitment, and migration of NK cells
and cytotoxicity are induced in response to a variety of inflamma-
tory stimuli (7, 12, 14–16). Several mouse tumors, including B16
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FIGURE 4. Hsp70-positive tumor target cells are lysed selectively by CD3CD56CD94 NK Cells, but not by CD3 T cells. A, Separation of PBL
of three independent donors in a CD3-negative (CD3; upper dot plot) and CD3-positive (CD3; lower dot plot) subpopulation by MACS using CD3 Ab.
Separated cells were stimulated for 4 days with TKD (2 g/ml) plus IL-2 (100 IU/ml) and phenotyped using CD3FITC and CD16/56PE Abs. The dot plot diagrams
of one representative separation is illustrated. Numbers in the dot plot diagram represent the mean percentage values of positively stained cells of three experiments.
Concomitantly, the cytolytic activity of both effector cell populations (CD3, f; CD3, ) was tested in a standard 4-h chromium release assay. Specific lysis
of effectors was assessed against Hsp70 membrane-positive CX, Colo, and K562 tumor target cells. E:T ratios ranged from 1:1 to 10:1. The mean  SEM from
three independent separations is shown. B, Separation of PBL of three independent donors in CD94-positive (CD94; upper dot plot) and CD94-negative (CD94;
lower dot plot) subpopulation by MACS using CD94 Ab. TKD-stimulated subpopulations were phenotyped using CD56FITC and CD94PE Abs. Concomitantly,
the cytolytic activity of both effector cell populations (CD94, ; CD94, ) was tested against Hsp70 membrane-positive CX, Colo, and K562 tumor target
cells. C, The CD94-positive subpopulations were further separated in a CD3-negative (CD94CD3; upper dot plot) and CD3-positive (CD94CD3; lower dot
plot) cell population by MACS using CD94 and CD3 Ab. TKD-stimulated effector cells were phenotyped separately using CD56FITC and CD94PE Abs.
Concomitantly, the cytolytic activity of both effector cell populations (CD94CD3, Œ; CD94CD3, ‚) was tested against Hsp70 membrane-positive CX
tumor target cells. Due to low cell numbers, cytolytic activity against K562 cells could not be tested.
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melanoma, MCA 102 sarcoma, lung carcinoma, MADB106 mam-
mary carcinoma, and RMA-S lymphomas have been found to be
infiltrated with NK cells (11, 33–36). In these models, attraction
could be associated with chemokines, a large family of small pro-
teins involved in lymphocyte trafficking, and cytokines (37, 38).
In the present study, we record on a cytokine- and chemokine-
independent stimulus inducing selective migration of NK cells.
Incubation of PBL with Hsp70 peptide TKD enhances the cyto-
lytic activity against Hsp70-positive tumor target cells. Coincuba-
tion and migration assays revealed infiltration of TKD-stimulated
PBL selectively into Hsp70 membrane-positive, but not into
Hsp70 membrane-negative tumor cell clusters. Therefore, we hy-
pothesized that predominantly Hsp70-positive tumor cells possess
chemotactic properties. To answer the question whether cell-to-
cell contact or a soluble factor is responsible for migration, in
additions to cells, supernatants of Hsp70 membrane-positive and
-negative tumor cells were tested with respect to their capacity to
induce migration. Our results indicate that a soluble factor is se-
creted by Hsp70 membrane-positive tumor cells. Recent data dem-
onstrate Hsp70 can be released by tumor cells expressing Hsp70
on their cell surface (31, 39). Although the molecular nature of the
chemotactic factor secreted by Hsp70 membrane-positive tumor
cells remained elusive, we could demonstrate that NK cells were
attracted by Hsp70 protein and TKD peptide in a tumor cell-free
setting. Due to the fact that migration was found only toward a
positive gradient, chemokinesis or random cell mobility appears to
be unlikely.
A comparative phenotypic characterization of the migrated and
nonmigrated cell population revealed that predominantly
CD3CD56CD94 NK cells but not CD3-positive T cells mi-
grated toward supernatants of Hsp70 membrane-positive tumor
cells. The C-type lectin receptor CD94 is covalently linked to
members of the NKG2 family (40). CD94/NKG2A, an inhibitory,
and CD94/NKG2C, an activating receptor, are recognizing
HLA-E. It appeared that cell surface homeostasis of the inhibitory
receptor is independent of functional signaling (41). CD94 Ab
blocking (32), and binding studies (28) indicate that, apart from
HLA-E, presenting leader peptides of HLA-A, -B, and -C mole-
cules, Hsp70 and Hsp70 peptide TKD provide an additional pos-
itive ligand for an activating CD94 receptor. This finding is further
supported by the fact that, although CX and CX tumor sublines
are lacking HLA-E cell surface expression (42), Hsp70 membrane-
positive tumor cells are lysed significantly better by CD94, mi-
grated NK cells as compared with their Hsp70 membrane-negative
counterparts. Cell sorting via CD3 and CD94 further confirmed
these findings. Although, in addition to CD94, the expression of
NKG2A was comparably up-regulated in the migrating cell pop-
ulation, these NK cells showed a strong cytolytic activity against
Hsp70 membrane-positive target cells. Because, irrespective of the
NK cell activity (inhibitory/activatory), NKG2A was always co-
expressed with CD94 (data not shown), the specificity of this Ab
for inhibitory NK cells is doubtful. Additional experiments will
elucidate the molecular nature of the coreceptor for NK cells with
Hsp70 reactivity.
Interestingly, migration of CD94-positive NK cells toward
Hsp70 peptide TKD appears to be highly selective, because closely
related HSP70 peptides with 2- or 7-aa exchanges were unable to
stimulate migration. This observation is in line with our previous
findings, that the stimulation of the cytolytic activity of NK cells
is also restricted to TKD and Hsp70 protein, the major stress-
inducible member of the HSP70 family. Other members of this
group, including the constitutively expressed Hsc70 (84% homol-
ogy to Hsp70) or the E. coli-derived Hsp70 homolog DnaK (50%
homology to Hsp70), failed to stimulate cytotoxicity (32). Further-
more, protein database BLAST search revealed that the 14-mer
sequence TKD is a highly variable region within the Hsp70 se-
quence and thus is not found in any other protein sequence regis-
tered so far (43). In this study, the uniqueness of this sequence has
been demonstrated with respect to its migratory function. How-
ever, TKD stimulation was found to be a prerequisite to generate
sensitivity for the chemotactic signal. No migration was observed
if the effector cells were not prestimulated with TKD plus
low-dose IL-2.
The role of chemokines in the migration of TKD-activated
CD3CD56CD94 NK cells could be ruled out for several rea-
sons. No differences in the expression pattern of chemokine re-
ceptors was found following stimulation of NK cells with TKD
FIGURE 5. TKD induces migration selectively in CD94-positive NK
cells. A, Migration of CD94-positive NK cells is inducible by human re-
combinant Hsp70 and TKD. CD94-positive NK cells were derived from
MACS. Following stimulation with TKD (2 g/ml) plus IL-2 (100 IU/ml)
for 4 days, migration toward medium supplemented with Hsp70 (F) or
TKD (E) was tested at concentrations ranging from 0.1 to 10 g/ml. Re-
sults are shown as the mean  SEM of three independent experiments.
Statistically significant differences (Student’s t test), , p  0.05; , p 
0.005. B, TKD induces chemotaxis but not chemokinesis. Migration of
CD94 NK cells, stimulated with TKD (2 g/ml) plus IL-2 (100 IU/ml)
for 4 days, was tested in a positive gradient (migration; 1 g/ml TKD in the
lower compartment), equal gradient (kinesis I; equal concentrations of 1
g/ml TKD in the upper and lower compartments), or a negative gradient
(kinesis II; 1 g/ml TKD only in the upper compartment). Results are
shown as the mean  SEM of three independent experiments. Statistically
significant differences between chemotaxis and chemokinesis (Student’s t
test), , p  0.005. C, Migration of CD94-positive NK cells to TKD is
concentration dependent and highly specific. TKD-activated CD94-posi-
tive NK cells were tested for their capacity to migrate toward TKD at
concentrations ranging from 0.1 to 10 g/ml TKD (left panel; F). Two
closely related peptides derived from Hsc70 (aa 450–463; E) and DnaK
(aa 447–460; Œ) were included as controls. All peptides were diluted in
RPMI 1640 medium containing 10% FCS. Identical experiments were per-
formed with the CD94-depleted T cell subpopulation (CD94; right
panel). Results are shown as the mean  SEM of five independent exper-
iments. Statistically significant differences compared with initial values
(Student’s t test), , p  0.05; , p  0.005.
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(data not shown). Differences in the chemokine secretion pattern
correlating with Hsp70 membrane expression was also unlikely,
because NK cell attraction was also possible with TKD peptide in
a tumor cell-free setting. Because Hsp70 membrane-positive and
-negative tumor sublines were generated by cell sorting of one
parental tumor cell line, both sublines exhibited an identical ex-
pression of MHC and adhesion molecules (22).
Adoptive transfer of TKD-stimulated NK cells in tumor-bearing
mice revealed that predominantly Hsp70-positive tumors were
eliminated (44–46). In this report, we show directed migration of
NK cells to Hsp70-positive tumor cells, and supernatants derived
thereof, and to TKD peptide. Therefore, it was speculated that
killing of Hsp70-positive tumors in vivo might be related to an
enhanced migratory capacity of CD94-positive NK cells.
It is known that IL-2-activated NK cells can induce regression
of established lung and liver tumors (47–50). However, the anti-
tumor effect is often limited, because primary tumors and metas-
tases are not efficiently infiltrated by NK cells. The prestimulation
of CD94-positive NK cells with TKD in combination with low-
dose IL-2 results in cytolytic active effector cells with the ability to
migrate toward Hsp70-positive tumors that have to be defeated.
Therefore, our findings might have further clinical implications
with respect to the development of an NK cell-based cellular
immunotherapy.
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